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“The important thing is not to stop questioning.  
Curiosity has its own reason for existence.  
One cannot help but be in awe when he contemplates  
the mysteries of eternity, of life, of the marvelous structure of reality.  
It is enough if one tries merely to comprehend a little of this 
 mystery each day.” 
-Albert Einstein-   
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Estrogens 
Estrogens are the primary female sex hormones and are responsible for development and 
maturation of the female reproductive organs (both during foetal life and at puberty), the 
regulation of the reproductive functions, the endometrial menstrual cycle, the regulation of 
endometrial receptivity and the establishment and maintenance of pregnancy. Next to their 
role on the female reproductive function, they also play a regulatory role in a variety of 
physiological processes of different organs and tissues in health and disease (Figure 1) [1-6]. 
The actions of estrogens are not limited to women. Estrogens can be synthesised inside the 
human body (endogenous) or they can be derived from exogenous origins like food 
micronutrients, food additives, drugs and environmental pollutants [7]. 
Figure 1. Pleiotropic effect of estrogens in the human body.   
P = progesterone 
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Endogenous estrogens 
Steroids are compounds derived from cholesterol that consist of three phenolic rings (A-C) and 
one cyclopentane ring (D, Figure 2). Carbons in the steroid structure are bound to different 
hydrogen or methyl groups and are numbered as indicated in Figure 2. C17 presents a side chain 
that is typical of the different steroid classes (androgens, progestogens and estrogens).  
 
Figure 2. Structures of the endogenous estrogens, estradiol, estrone and estriol with carbon numbering and steroid 
ring numbering. 
 
Estrogens are C18 steroids with an aromatic phenol group in the A-ring [8]. The most potent of 
three endogenous estrogens is 17-estradiol (E2). E2 is produced predominantly during the 
reproductive years, primarily by the ovaries in women and in smaller amounts by the testes in 
males, and secreted into the blood circulation. The less potent estriol (E3) is the dominant 
estrogen during pregnancy and secreted mainly by the placenta. After menopause, when the 
ovaries have ceased their actions, E2 levels decrease and estrone (E1) becomes the main 
estrogenic compound with the highest circulating levels among all estrogens (Table 1; [9, 10]). 
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Table 1. Circulating steroid levels and their precursors  
               Steroid Pre-menopausal women 
Post-menopausal 
women 
Men 
Pr
og
es
to
ge
ns
 Progesterone 
(P) 
0-80 nM (depending on 
phase of menstrual cycle) 
0-0.04 nM 0-0.4 nM 
Pregnenolone 
(P5) 
1-15 nM 1-15 nM 1-15 nM 
An
dr
og
en
s 
Dehydroepiandrosterone 
(DHEA) 
3-30 nM 2-20 nM 10-25 nM 
Dehydroepiandrosterone- 
sulfate (DHEA-S) 
1103-8103 nM 1103-6103 nM 2103-10103 nM 
Androstenedione 
(A4) 
3.1-5.9 nM 3.1-5.9 nM 3.1-5.9 nM 
Androstenediol 
(A5) 
0.8-1.1 nM 0.8-1.1 nM 2.6-3.7 nM 
Testosterone 
(T) 
0.2-2 nM 0.2-1 nM 5-25 nM 
Dihydrotestosterone 
(DHT) 
0.08-1.3 nM 0.03-1.65 0.85-3.5 nM 
Es
tr
og
en
s 
Estrone 
(E1) 
0.015-0.5 nM 0.01-0.12 nM 0.033-0.1 nM 
Estrone-sulfate 
(E1-S) 
2-5 nM 510-3-2010-3 nM 2-4 nM 
Estradiol 
 (E2) 
0.005-1.0 nM (depending on 
phase of menstrual cycle) 
0.005-0.08 nM 0.02-0.04 nM 
Exogenous estrogens 
Several compounds present in food, food additives, drugs or other compounds in the 
environment can have estrogenic actions. These exogenous sources of estrogens are called 
environmental estrogens (or xenoestrogens) and are small synthetic or naturally occurring 
molecules that mimic endogenous estrogens. Flavonoids are an example of naturally occurring 
agents with estrogenic activity produced by plants, and therefore called phyto-estrogens [8]. 
An important example of inorganic agents with estrogenic action are the metallo-estrogens 
such as metals and metalloids (these include cadmium, chromium, cobalt, copper, nickel, lead, 
mercury, tin, arsenite, selenite and vanadate). These are compounds found, among others, in 
cigarette smoke. The environmental estrogens are recognized as endocrine disruptors and may 
contribute to the development of hormone-dependent cancers including lung, breast and 
endometrial cancer in subjects exposed to these environmental estrogen [7, 11-13]. 
14
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Estrogen Receptors 
Estrogenic effects are mediated by two classical estrogen receptors, estrogen receptor alpha 
(ER) and beta (ER), and the membrane G-protein-coupled estrogen receptor 1 (GPER). 
Despite the fact that ER and ER are highly homologous, they are encoded by different genes, 
ESR1 located at chromosome 6 and ESR2 located at chromosome 14. The two receptors share 
homology with the members of a large superfamily of nuclear receptors that bind other 
steroids. Nuclear receptors function as ligand-activated transcription factors [14] and share 
similar evolutionary conserved structural and functional features [15]. ER and ER are 
structurally organised in a non-conserved NH2-terminal domain (A/B domain) containing a 
ligand-independent activation function domain (AF-1) which is involved in interaction with co-
activators and transcriptional activity of target genes, a highly-conserved DNA-binding domain 
(DBD; C domain), a hinge domain (D domain) containing a nuclear localization signal (NLS) 
which is required for nuclear translocation, a ligand binding domain (LBD) containing a ligand-
dependent AF-2, and a COOH-terminal (E/F domain) (Figure 3).  
 
Figure 3. Schematic overview of ER, ER and their isoforms, they share high homology in the distinct domains.  
AF-1 = activation function domain 1; DBD = DNA-binding domain; NLS = nuclear localization signal; LDB = ligand 
binding domain; AF-2 = activation function domain 2. 
 
Both ESR1 and ESR2 undergo alternative splicing which results in distinct receptor variants. The 
most widely described variants of ER are the truncated ER-∆3, ER-46 and ER-36 kDa. 
ER-∆3 differs from the wild-type full-length ER (66 kDa) by the absence of exon 3, and is 
therefore missing part of the DNA-binding domain. ER-46 is lacking the NH2-terminal domain 
including the AF-1, whereas ER-36 also lacks the AF-2 domain, but retains the DNA-binding 
domain and a partial dimerization-domain and the ligand-binding domain. The last 138 amino 
acids of ER-36 are replaced for a novel 22 amino acid sequence [15, 16]. Both ER-36 and 
ER-46 isoforms can form a heterodimer with the wild-type ER, and as dimers, they can 
repress the genomic estrogen signalling activity of ER [17]. ER-36 expression is associated 
15
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with cell growth, proliferation and differentiation through non-genomic estrogen signalling in 
hormone responsive cancers including breast and uterine cancer [18, 19]. 
Regarding ER, besides the 60 kDa wild-type protein form, currently four other variants are 
described, namely ER2, ER3, ER4 and ER5 and all have novel COOH-terminal domains. 
These isoforms are not fully characterized yet, but several experiments show that the 
receptors are unable to bind estrogens and are likely to differentially modulate estrogens 
action by forming heterodimers with the wild-type receptors [15, 16]. 
GPER belongs to the seven-transmembrane G protein-coupled receptor family, it is not a 
member of the nuclear receptor superfamily and differs structurally from ER and ER. GPER 
is intracellularly located in the endoplasmic reticulum and the cell membrane and mediates 
rapid non-genomic actions [20-22]. 
 
Estrogen signalling 
Estrogen signalling is regulated by different mechanisms (Figure 4) [23, 24]. First, the classical 
genomic activation via its receptors, which are bound in an inactive state to heat-shock 
proteins (HSP). The ER/HSP complex is dissociated upon ligand binding when estrogen diffuses 
through the cell membrane, and followed by receptor dimerization. The dimer translocates 
from the cytoplasm to the nucleus, to bind directly to specific DNA regions containing typical 
motifs called estrogen response elements (ERE). Those EREs were believed to locate 
predominantly in the promoter regions of target genes, however recent investigations show 
that the majority of EREs is located distant from the promoter regions like in enhancers 
(currently referred to as cistrome, the set of cis-acting targets of a trans-acting factor on a 
genome-wide scale). Recruitment of transcriptional co-activators, such as steroid receptor co-
activator (SRC) and nuclear receptor co-activator (NCOA) [24] and co-repressors, like NCoR 
(nuclear receptor co-repressor) [25] and SMRT (silencing mediator of RAR and TR) [26] result 
in modification of transcription of the target gene in response to estrogen. 
Beside this classic genomic action, ERs can activate the intracellular signalling via non-classic 
genomic actions.  In this case, ERs interact indirectly with the DNA via other transcription factor 
complexes, like c-Fos/c-Jun or SP-1, to regulate transcription of the target genes. In these 
cases, targeted genes lack a canonical ERE in their binding region. Another mechanism through 
which ERs can regulate gene function is by a ligand-independent mechanism. In this less 
understood mechanism, growth factors are thought to activate kinases and thereby 
phosphorylate ERs, phosphorylated ERs form dimers and subsequent DNA-binding in the 
target gene will modulate transcription of the target gene. In a final, more rapid non-genomic 
pathway, estrogen exerts it effects in a manner of seconds or minutes by activation of kinases 
and phosphatases that modulate ion channels or increase nitric oxide levels. This results in a 
rapid physiologic response without gene transcriptional regulation. This signalling pathway is 
less well understood, and is thought to involve membrane bound ERs, including truncated 
isoforms of the classical ERs and GPER. [15].  
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E2 binds to ER and ER with equal affinity, but the two receptors activate distinct and tissue 
specific actions. All estrogen receptors are distributed differentially and at distinct intracellular 
locations among different tissues in the body, the effects mediated depend on the relative 
expression and actions of ER vs. ER vs. GPER. Activated nuclear receptors are able to form 
dimers, and since they are co-expressed in many cell-types, both homodimers ER () or ER 
() and heterodimers ER may be formed [27]. ER predominates in the uterus, mammary 
glands, pituitary gland, skeletal muscle, adipose tissue and the bone, while ER plays a more 
dominant role in the ovary, prostate, lung, cardiovascular and central nervous system [1, 28] 
(Figure 1). Frequent reported actions of ER include cell proliferation and differentiation, while 
ER shows anti-proliferative effects [17]. 
 
 
Figure 4. Estrogen and ERs signalling.  
I.    Ligand-dependent activation and direct binding from ER-dimers to the ERE.  
II.   Ligand-dependent activation and indirect DNA-binding of ERs via transcription factor complexes.  
III.  Membrane bound receptors are activated by phosphates and kinases to activate rapid non-genomic signalling. 
VI. Ligand-independent activation of ERs by growth factors, to induce gene transcription. 
 
Synthesis of estrogens 
The two main pathways of estrogen synthesis and its precursors are the systemic production 
by endocrine glands and the local metabolism in peripheral tissues. 
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Endocrine glands (endocrinology) 
The biologically active sex steroid hormones estrogen, progesterone and testosterone control 
a wide variety of developmental and physiological processes from foetal life to adulthood. 
Classical endocrine glands like the adrenals, ovaries and testes are responsible for sex steroid 
synthesis. These sex steroids are secreted in the blood circulation and distributed to all tissues 
throughout the body. The biosynthesis of sex steroid hormones is controlled by the 
hypothalamus-pituitary-gonadal (HPG) axis (Figure 3). The hypothalamus releases 
gonadotropin releasing hormone (GnRH) and stimulates the anterior pituitary gland to release 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) into the blood circulation. LH 
binds to its receptor on target cells (Leydig cells of the testes and theca cells of the ovaries) 
and increases the expression of steroidogenic acute regulatory protein (StAR). StAR facilitates 
the transfer of cholesterol into the mitochondria, followed by conversion of cholesterol into 
pregnenolone (P5) by the P450 side chain cleavage enzyme (P450scc) [29, 30]. P5 can be 
converted into either the active steroid hormone progesterone (P) by 3-hydroxysteroid 
dehydrogenase (3-HSD), or into the intermediate dehydroepiandrosterone (DHEA) via 
cytochrome P450 17 (CYP17). DHEA may be further converted by 3-HSD 2 into 
androstenedione (A4) and subsequently via 17-HSD 5 (or in the testis by 17-HSD 3, this will 
be disregarded in this thesis) to either testosterone (T) or via aromatase to estrone. Finally, 
testosterone and estrone can be converted to estradiol by aromatase and 17-HSD 1, 
respectively. These active hormones are secreted into the blood circulation and distributed to 
all tissues of the body [4, 10, 31]. 
 
Peripheral synthesis (intracrinology)   
Besides the production and secretion of sex hormones by endocrine glands, these compounds 
are also synthesized in peripheral tissues from circulating precursors of adrenal and gonadal 
origin [31]. The enzymes responsible for steroid synthesis in the endocrine glands are 
divergently expressed in several peripheral tissues. The term intracrinology refers to the ability 
of peripheral tissues to use inactive precursors to locally synthesize steroid hormones 
according to the specific needs of the tissues (Figure 5).  
The locally produced sex steroids exert their actions in the same cells in which they are 
produced, and are intracellularly inactivated before being released as a biological inactive 
compound into the circulation. This intracellular inactivation of these locally produced sex 
steroids prevents a systemic effect of these sex steroids into other tissues [32, 33]. Therefore, 
the levels of the circulating sex steroids are different from those found in peripheral tissues. 
The best studied sex steroid metabolizing enzymes involved in the intracrine transformation 
of gonadal and adrenal DHEA and DHEAS into biological active sex hormones are STS, SULT1E1 
(together the sulfatase pathway), aromatase, 17-HSD 1 and 17-HSD 2 and will be discussed 
briefly below. 
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Depending on the expression levels of the steroidogenic and metabolizing enzymes present in 
a tissue, estrogens can be formed from adrenal DHEA and DHEAS via the conversion to 
androgens [32, 34, 35]. Ovarian CYP17A1 in humans does not possess the lyase activity towards 
P [10], hence estrogens cannot be formed from progesterone. However, nothing is known 
about the catalytic activity of peripheral CYP17A1. Normally, peripheral tissues produce sex 
steroids using precursors available in the circulation, and for a very limited number of tissues, 
the complete pathway to produce steroids from cholesterol is demonstrated.  
 
 
Figure 5. Schematic demonstration of endocrinology and intracrinology. 
The HPG-axis is responsible for the production of sex steroids which are secreted into the circulation as active 
hormones and distributed to all tissues of the body via the circulation (full arrow). Intracrinology is represented 
by the local formation of sex steroids in peripheral tissues via adrenal DHEA (or E2, T), were hormones act in the 
cell and are inactivated before release to the blood circulation (dashed arrow).  
GnRH = gonadotropin releasing hormone (GnRH), LH = luteinizing hormone, FSH = follicle stimulating hormone, 
DHEA = dehydroepiandrosterone, E2 = estradiol, T = testosterone. 
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Sulfatase pathway 
Steroid sulfatase (STS) and estrogen sulfotransferase (SULT1E1) are involved in hydrolysis and 
conjugation, respectively, of estrogens (both E1 and E2) with a sulphate moiety. E1 conjugated 
with a sulfate-group (E1-sulfate) is the estrogenic compound with the highest blood circulating 
levels due to its high water-solubility and long half-life [9, 36]. E1-sulfate is completely inactive 
and is not able to pass the cell membrane. STS, encoded by the STS gene located in the X 
chromosome, is a membrane-associated microsomal enzyme localized on the endoplasmic 
reticulum [9]. The molecular weight is 65.5 KDa and this enzyme converts E1-sulfate to free 
intracellular E1. SULT1E1, a 35.1 KDa protein whose gene localises in chromosome 4, catalyses 
the reverse reaction. Therefore, the sulphatase pathway has the role to recruit steroids from 
the circulation into the cells. 
 
Aromatase pathway 
Another extra-ovarian source of estrogens is represented by the aromatization of the 
androgens androstenedione (A4) and testosterone (T) to E1 and E2, respectively, catalysed by 
the enzyme CYP19A1 aromatase [10, 37, 38]. The CYP19A1 gene is localised on chromosome 
15. Different tissue specific promoters lead to the generation of distinct tissue specific 
transcripts [39]. The encoded protein is 503 amino-acid long with a molecular weight of 57.9 
KDa. 
 
17-HSDs 
A final reaction in the estrogen synthesis is the redox balance between E1 and E2. The enzymes 
17-beta-hydroxysteroid dehydrogenases (17β-HSDs) control this final step in the formation of 
all androgens and estrogens. These enzymes are divided into reductive and oxidative enzymes. 
The first group catalyses the reduction of E1 into E2 and A into T. Reductive enzymes include 
17β-HSD 1, 5, 7 and 12. The second group, oxidative enzymes, convert E2 back to E1 (and T to 
A) and include 17β-HSD 2, 4, 8, 14 [35, 37, 40, 41]. 
Although several oxidative and reductive 17β-HSDs are postulated to use estrogens as 
substrate, recent studies have contrasted this contention. The catalytic activity of these 
enzymes was typically determined using cell-free extracts or using recombinant proteins, with 
frequently non-physiological enzymes, substrates and co-factor levels. In addition, the cell 
compartmentation and the tissue specific expression further contribute to substrate specificity 
of each enzyme and were not considered. Recent animal studies and human investigations 
tend to indicate that 17β-HSD 1 and 2 are involved in estrogen metabolism in vivo, although a 
potential role for 17β-HSD types 7 and 12 to convert E1 into E2 is not fully excluded [42]. 
Additional 17β-HSDs can metabolise androgens and other steroids. Type 6 17β-HSD uses 5α-
reduced androgens with 17-hydroxyl oxidative activity (converting androsterone to 
androstanedione) and 3-hydroxyl oxidative activity (converting 3αDIOL to the most potent 
20
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androgen dihydrotestosterone -DHT). Type 14 17β-HSD is thought to have 17β-hydroxyl 
oxidative action on various steroids and type 7 is involved in cholesterol metabolism, whereas 
there is apparently little or no in vivo role for the types 8, 9, 10, 11 and 12 17β-HSDs on steroid 
metabolism.  
Therefore, in conclusion, 17β-HSD 1 and 2 are central in the estrogen metabolism, whereas 
the contribution of other 17β-HSDs is dispensable in vivo [10, 37, 38]. 
Beside this central metabolic network connecting DHEA, androgens and estrogens, peripheral 
tissues also express additional enzymes that are involved in steroid synthesis and metabolism. 
 
3-HSDs 
Type 1 3β-HSD is the peripheral counterpart of ovarian 3β-HSD 2 with the same catalytic 
activity on androstenes (DHEA) and pregnenes (P5). Also, 3β-HSD 2, initially considered 
restricted to endocrine tissues, is detected peripherally in recent reports [43-45]. Peripheral 
3β-HSDs covert the most abundant serum steroid, DHEA, to A4, which can be further 
metabolised to all other androgens and estrogens. In addition, 3β-HSDs convert 
androstanediol (A5) and the isomer 17α-A5 to T. These represent alternative and minor paths 
in the steroid metabolism, present in peripheral tissues only but that can be of relevance to 
fine-tune the steroid signalling as discussed later (Chapter 2 and general discussion, Chapter 
7) 
 
AKR1Cs 
Soluble cytoplasmic aldo-ketoreductases (AKR) have broad substrate specificity with non-
stereo-selective 3α/3β-HSD, 17- and 20-ketosteroid reductase activities. Four AKRs are 
specifically involved in steroid metabolism: AKR1C1, 1C2, 1C4 and AKR1C3, also called 17β-HSD 
5 (as previously discussed) [46, 47]. AKRs metabolise androgens and progestogens and due to 
their wide distribution, they contribute to make intracrine networks flexible and intricate [48, 
49]. 
 
SRD5As 
Steroid 5α-reductases convert 3-keto Δ4 androstene and pregnene to 5α-reduced steroids 
(androstanes and pregnanes). The role of SRDAs is well characterised in prostate, where these 
enzymes covert into the most potent androgen (DHT). However, SRD5A1 and 3 are widely 
expressed in several other tissues, where they are important in progesterone and androgen 
metabolism [50]. Contrarily to types 1 and 3, type 2 SRD5A has restricted tissue distribution.  
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Endometrium and estrogens 
Endometrial steroid actions are mediated by hormone-receptors via the classical mechanisms, 
although non-genomic and rapid signallings are also present [51-54]. Estrogens and 
progesterone contribute to reproductive functions and pregnancy maintenance. They control 
the menstrual cycle during the woman’s reproductive life, thus synchronizing the ovarian and 
menstrual cycles necessary for embryo implantation [4]. Finally, estrogen overexposure 
unopposed by progesterone or progestins, is also associated with gynaecological diseases 
including endometrial cancer. 
 
The menstrual cycle 
The 28-day-long menstrual cycle in humans is characterized by the proliferative phase (ovarian 
follicular phase) in which estrogen level increases and induces epithelial cell proliferation (days 
5-12). After ovulation (days 12-14), during the secretory phase (ovarian luteal phase; days 15-
28) the corpus luteum secretes progesterone, which induces stroma cell decidualisation. In the 
absence of pregnancy, menstruation (days 1-5) takes place [4, 51]. 
 
Reproductive biology 
Under estrogen and progesterone control, the endometrium reaches its receptive status 
(window of implantation, WOI) during the mid-luteal phase, supporting blastocyst 
implantation and pregnancy maintenance [55]. 
From animal studies, we know that estrogen is essential to activate blastocyst adhesion and 
activates neovascularization, a prerequisite for embryo nidation and nutrient supply [56, 57]. 
The WOI is characterized by high E2 plasma levels. ERα and PR expression shows specific and 
varying cytosolic and nuclear patterns [58] and ERα and PR expression decreases after 
ovulation and in preimplantation stages [59, 60]. Both estrogen deficiency as well as sustained 
estrogen signalling has deleterious effects on endometrial receptivity [61-63].  
Available human data also indicate that steroid stimulation retards or shortens the luteal phase 
and therefore affects the WOI. The consequential asynchrony between ovarian and menstrual 
cycles by steroid stimulation, can be compensated by administration of progesterone or hCG 
during the luteal phase [64]. 
 
Endometrial cancer 
Endometrial cancer (EC) arises from the inner layer of the uterus, the endometrium. It is the 
most common gynaecological malignancy in the Western world with an incidence rate of 26 
new diagnosed cases per 100.000 women per year, and 4.6 per 100.000 related deaths in the 
period 2011 to 2015. The risk of developing EC during a woman’s lifetime is 2.9%, based on 
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data of the period 2013 to 2015 [65]. The majority of EC is diagnosed in postmenopausal 
women and becomes frequently symptomatic during early disease development and therefore 
diagnosed at an early stage. 
Approximately 80% of diagnosed cases are estrogen-dependent type-1 endometrioid ECs 
developed through endometrium hyperplasia with atypia, which is characterised by low-grade 
histology, hormone receptor expression (ER and PR) and a good prognosis. Known risk factors 
for developing type-1 EC are endogenous and exogenous estrogen exposure unopposed by 
progesterone or progestins associated with obesity, early menarche, nulliparity, late 
menopause, diabetes, old age and use of tamoxifen. Although patients diagnosed with EC type-
1 have a good prognosis, 20-30% of these patients develop locoregional recurrent disease 
and/or distant metastases for which poor treatment opportunities exist with consequently 
poor survival rates [66-69]. 
Type-2 ECs are defined as non-endometrioid ECs, usually serous papillary-, clear cell-, or 
squamous carcinomas, which are considered as not hormone-dependent and are associated 
with a higher risk of metastases and poor prognosis [68, 70]. 
 
Endometrial cancer treatment 
Standard treatment for early stage type-1 EC is hysterectomy with bilateral salpingo-
oophorectomy. In young patients who are still in their reproductive years with a wish to 
become pregnant, fertility preservation treatment using progestogens might be an option. In 
patients with early stage and high risk disease (like type-2 EC), besides hysterectomy with 
bilateral salpingo-oophorectomy, the pelvic lymph nodes are dissected as part of surgical 
staging. After surgery, depending on the final histological results, adjuvant radiotherapy and/or 
chemotherapy can be prescribed.  
In patients with advanced stage disease, treatment can include surgery, chemotherapy, 
radiotherapy, and hormone therapy [68, 71, 72]. 
 
Hormone therapy 
In case of advanced or recurrent disease, radiotherapy (for local recurrence/metastasis) or 
chemotherapy can be prescribed. These treatment options however, have important 
debilitating side-effects and overall poor efficacy leading to compromised Quality of Life (QoL). 
Endocrine drugs are also prescribed for these cases. The first line choice is usually a 
progestogen, and second line treatment can be an aromatase inhibitor or tamoxifen. Similar 
to chemotherapy, endocrine drugs have limited therapeutic efficacy and tumours may quickly 
become insensitive [73, 74]. 
Although in both the fertility preservation and the metastatic settings endocrine drugs show 
limited therapeutic efficacy, it is currently believed that their real potential is underestimated 
and their performance could be improved by, among others, giving the treatment to 
preselected responsive patients [75]. 
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Intracrinology from a broader perspective 
As mentioned previously, sex hormones play an important regulatory role in health and disease 
in a broad range of also non-endocrine organs. In the second part of this thesis, the role of 
estrogen signalling will be explored in chronic obstructive pulmonary disease (COPD).  
 
Lung and sex hormones 
Sex hormones play an important role in lung development and homeostasis. Androgens, 
progestogens and estrogens are present and exert genomic and non-genomic actions via their 
hormone receptors. All classical hormone receptors, AR, PRs and ERs (with ER as predominant 
form) and membrane GPER are present [22, 76]. Currently there is little data on receptor splice 
variants in the lung, but the presence of receptor variants is confirmed in publications on 
several lung diseases [77-81]. 
Human and animal studies support a promoting role for estrogens and an inhibitory role for 
androgens in lung development and maturation. Testosterone (secreted by the foetal testes) 
inhibits the production of surfactants, which starts later in male than in female neonatal lungs 
[82]. However, androgens and AR also support the developing lung during branching 
morphogenesis [83]. Besides the promoting role for ERs on lung maturation, ERs are also 
important for alveolar formation [84]. The impact of the sex steroids and their receptors at 
birth results in a smaller female lung with fewer respiratory bronchioles than males but the 
lungs mature faster due to the earlier surfactant production.  
Sex hormones remain active in the lung throughout lifetime and modulate lung function in 
both a beneficial or detrimental way [6, 80, 85]. Gender differences in lung disease are well 
documented and believed to be associated predominantly to sex steroids. For instance, the 
prevalence of asthma during childhood is more common in boys than girls and becomes 
predominant in women in adulthood. In 20% of asthmatic women, exacerbations occur during 
pregnancies and up to 40% of women experience premenstrual worsening of the disease [86, 
87]. Also, differences in the incidence, morbidity and mortality between men and women in 
smoking-induced lung disease have been observed. The awareness of a role for sex hormones 
in the development and progression of lung disease is present, though, the contribution of 
intracrine synthesis is poorly studied and therefore less understood.  
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Gender differences in COPD: estrogen as a key player? 
Chronic obstructive pulmonary disease (COPD) is one of the gender predisposed respiratory 
disorders, with high morbidity and mortality rates. COPD is defined as a common, preventable 
and treatable disease, characterized by persistent respiratory symptoms and airflow limitation, 
which are associated with airway and/or alveolar abnormalities [88]. Noxious gasses, usually 
cigarette smoke, are the primary cause of COPD, but other known risk factors including 
exposure to inhaled environmental pollutants and genetic predisposition have been identified. 
A mixture of chronic bronchitis, small airways disease and emphysema are the major 
pathological conditions of COPD and cause poorly reversible and progressive airway 
obstruction associated with structural changes resulting in shortness of breath, cough, mucus 
and/or sputum production. Chronic bronchitis is characterized by an enhanced chronic 
inflammatory response, thickening of the airway walls and increased mucus production and is 
more prevalent in the female sex. Small airways disease includes the narrowing, by fibrosis, 
and the destruction of the small airways [89]. Emphysema, which affects more males than 
females, is characterized by the destruction of alveolar walls due to excessive lung 
inflammation.  
The inflammatory response in COPD involves both innate and adaptive immune systems and 
is characterized by accumulation of neutrophils, macrophages, T-lymphocytes and B-
lymphocytes. The inflammation is associated with the peripheral airways, the lung 
parenchyma, and low-grade systemic inflammation [90-92]. 
Besides smoking cessation, there are currently no therapies available to reduce disease 
progression. Therefore, the treatment is primarily based on the reduction of disease symptoms 
and the prevention of exacerbations. Stable disease is treated with inhaled long-acting 
bronchodilators. Corticosteroids can be used in patients who have co-existing features of 
asthma and more reversible airway obstruction, but most COPD patients are insensitive to 
corticosteroid therapy [91, 93]. Better understanding of the mechanisms causing COPD are a 
necessity in order to develop therapies to reduce disease activity and progression.  
 
In 2016, worldwide 251 million people suffered from COPD and caused over three million 
deaths [94]. In the Netherlands, for the year 2017, COPD was diagnosed in 589.400 people of 
which 300.400 men and 297.900 women [95]. Formerly, the incidence and mortality by COPD 
was greater among men than women, but is currently almost equal in both sexes. The 
increased use of tobacco in women only partly explains this new trend. Several studies suggest 
that women are biologically more susceptibile to the effects of tobacco smoke after the 
consumption of the same number of cigarettes [96-98]. Women develop COPD at a younger 
age, after less pack-years and with faster decline in lung function and more severe disease 
progression than men. Women are also more likely to get hospitalized and die of COPD 
compared with males [99, 100]. 
The cause of this increased susceptibility in females to develop COPD is largely unknown, but 
may be in part explained by the greater dose received after the same level of tobacco exposure 
due to the relatively smaller airways for the same lung volume [101, 102]. Also, estrogens are 
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thought to play an important pro-proliferative role in the inflammatory response triggered by 
cigarette smoke, and this may also contribute to the female gender susceptibility. 
Investigating the complex relationship between estrogens and cigarette smoke induced 
pulmonary disease requires the use of experimental mouse models wherein several aspects of 
the disease can be studied. By means of the smoking mouse model, important hallmarks of the 
pathogenesis of COPD including chronic lung inflammation, impaired lung function, 
emphysema, mucus hypersecretion and small-airway remodelling can be explored. 
Several studies using the smoking-mouse model, suggested an increased level of small-airway 
remodelling in female mice compared with ovariectomised mice and male smoke-exposed 
mice [103]. Using young female mice, Tam et al. showed that small-airway remodelling was 
associated with activation of Transforming Growth Factor-1, increased oxidative stress and 
downregulation of antioxidant genes [103]. These effects were diminished by ovariectomy and 
the selective estrogen modulator, tamoxifen. On the other hand, Glassberg et al. showed in 
aging female mice that estradiol-deficiency increases the risk of smoke-induced lung disease 
and that this effect could be prevented by estradiol replacement [104]. Even though there is 
still controversy, our knowledge of estrogen signalling in the lung is slowly improving and 
should be used to consider the possibility of developing novel therapy options in either a sex-
specific way, or the possibility that sex hormones could be used as targeted therapy in both 
men and women. 
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Aims and thesis outline  
This thesis starts with a thorough exploration of the relevance of estrogen signalling and the 
contribution of intracrinology in different human tissues. In chapter 2 we review the concepts 
of the intracrine regulation of estrogens, and to a lesser extent of progestogens and androgens, 
in endometrium and related pathological conditions (including endometrial cancer -EC-) and 
the lungs. 
 
In previous studies of our team it was demonstrated that the enzyme 17-hydroxysteroid 
dehydrogenase 1 (17β-HSD 1)  is highly expressed in endometrioid EC cells. It locally converts 
the circulating abundant low-active-estrone into the highly-active-estradiol, which 
consequently supports tumour growth [105]. In addition, we have shown that 17β-HSD 1 may 
have prognostic significance [38]. In chapter 3, we further explore the potential clinical utility 
of 17β-HSD 1 in-vitro, in-ovo (chorioallantoic membrane assay - CAM), and ex-vivo in EC 
biopsies.  
To further verify the clinical validity of the proof-of-concept obtained with the CAM-model, in 
chapter 4 the development of an orthotopic xenograft mouse model of EC that exhibits the 
most relevant features of the human disease, regarding metastatic spread and estrogen 
dependency is described.  
 
The lungs are not considered classically estrogen sensitive tissues, but both estrogens and 
intracrinology seem to play also a pivotal role in this organ. We used COPD as a model to study 
estrogen signalling and intracrinology. In chapter 5 we investigate the cigarette smoke-induced 
lung inflammation in female estrogen receptor-α deficient mice. In chapter 6, we further map 
the intracrine network in lungs and in the condition of COPD.  
 
In chapter 7, the implications of the research in this thesis are discussed and recommendations 
for future research are pointed out.  
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Abstract 
Our understanding of the intracrine (or local) regulation of estrogen and other steroid 
synthesis and degradation expanded in the last decades, also thanks to recent technological 
advances in chromatography mass-spectrometry. Estrogen responsive tissues and organs are 
not passive receivers of the pool of steroids present in the blood but they can actively modify 
the intra-tissue steroid concentrations. This allows fine-tuning the exposure of responsive 
tissues and organs to estrogens and other steroids in order to best respond to the physiological 
needs of each specific organ. Deviations in such intracrine control can lead to unbalanced 
steroid hormone exposure and disturbances. 
Through a systematic bibliographic search on the expression of the intracrine enzymes in 
various tissues, this review gives an up-to-date view of the intracrine estrogen metabolisms, 
and to a lesser extent that of progestogens and androgens, in the lower female genital tract, 
including the physiological control of endometrial functions, receptivity, menopausal status 
and related pathological conditions. An overview of the intracrine regulation in the lungs is 
given. Current therapeutic approaches aimed at interfering with these metabolisms and future 
perspectives are discussed. 
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Introduction 
The term ‘intracrinology’, coined in 1988 by prof Labrie, refers to the ability of peripheral 
tissues to use blood precursors and generate steroids [1]. Several studies have been published 
but several controversies still exist and relate to the following technical and biological aspects: 
a. some intracrine enzymes in peripheral tissues have low expression (300-50.000-times lower 
than in endocrine glands [2, 3], close to the detection limit of standard methods like western 
blotting and immunohistochemistry -IHC); b. the technology to robustly quantify steroids 
(liquid-/gas-chromatography tandem mass-spectrometry -LC-MS or GC-MS), became available 
during the last 5-10 years only [4]; c. intracrine pathways are highly complex. 
This review summarises our knowledge of intracrinology in peripheral tissues like the 
endometrium and lungs, with special attention to the metabolism of estrogens. Drug 
development and potential therapeutic approaches are discussed. In this review, the enzymes 
involved in steroid deactivation/clearance ([5, 6]; with the exclusion of steroid 
sulphotransferases) and those involved in the transport of conjugated steroids through the 
plasma membrane [7] are not described. Studies on serum/tissue steroid levels are reported 
and discussed only if based on gold standard GC/LC-MS. 
 
From ovarian estrogen synthesis to intracrinology 
Local steroid metabolism is possible because those enzymes responsible for steroid synthesis 
in classical glands (ovaries, adrenals, testes) are expressed in peripheral tissues, where 
additional and alternative routes for metabolising steroids are present and make intracrine 
networks intricate and flexible (Figures 1 and 2, Tables I and II). In particular, several componds 
generated through these pathways, although not being estrogens, can have estrogenic action, 
because they are able to bind and activate the estrogen receptors. The biologic activity of the 
various compounds is given in Table I, and in Figure 2, by the color codes. 
Figure 1. Steroid structure 
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A: structure of the C21 steroid progesterone (P, used as an example), with carbon numbering and steroid ring 
numbering. In the storied graphics in Figures 1B and 2, the H groups and the relative bonds will be omitted (with 
the exclusion of the H in 5α-reduced steroids - androstanes and pregnanes). Methyl groups will be indicated by 
the bonds only without the CH3 group. 
B: structures of C21 pregnene (Δ4 and Δ5, i.e. double bond between C4 and C5 or between C5 and C6, respectively), 
pregnane (5α-reduced steroid), C19 androstene (Δ4, Δ5) and androstane and C18 (A-ring)-aromatic estrogens. 
Chemical structures were designed with the aid of Sketcher V2.4 [8], available online at PubChem 
(www.ncbi.nlm.nih.gov; pubchem.ncbi.nlm.nih.gov) [9].

Table I. Major steroidal compounds 
1. Abbreviation (used here) 
2. Common name 
3. Chemical name 
 Blood concentration ** (nM) Biologic 
activity *** 
Entries * 
1. none 
2. none 
3. 5α-pregnan-20-ol-3-one (1) 
PR
EG
N
AN
ES
 
n.d.  
CAS:516-59-6 
HMDB:60408 
CB:0504265 
ChEBI:81469 
1. none 
2. allopregnandiol (4 isomers) 
3   a. 5α-pregnane-3α,20α-diol ^ 
     b. 5α-pregnane-3β,20β-diol 
     c. 5α-pregnane-3β,20β-diol 
     d. 5α-pregnane-3β,20α-diol 
3a. M S: 28-49(10) 
3a. F: 0.2-0.7(10); S: 13-20(10) 
3a. GABAA+ 
 
 
a.CAS:566-58-5 
b.CAS:516-53-0 
c.CAS:516-53-0 
d.CAS:516-53-0 
1. 5αDHP  
2. allopregnanedione 
3. 5α-pregnane-3,20-dione 
F: 0.2-1.1(5,10)  
 
PR+ 
GABAA+ 
CAS:566-65-4 
HMDB:0003759 
ChEBI:28952 
1. none 
2. none 
3. 5α-pregnan-17α-ol-3,20-dione 
n.d.  
CAS:570-59-2 
CB:4441841 
 
1. none 
2. none 
3. 5α-pregnan-3,17α-diol-20-one (2)^ 
n.d.  CAS:6890-65-9 
CB:7269033 
1. THP (isomer 1/4) 
2. allopregnanolone (3) 
3. 3α-hydoxy-5α-pregnan-20-one 
All: 0.2-10(6) 
M: 0.1-0.2(10); S: 3.6-10(10) 
F: 0.1-0.2(10); S: 4.0-6.7(10) 
GABAA+ 
CAS:516-54-1 
HMDB:0001449 
PC:262961 
1. THP (isomer 2/4) 
2. pregnanolone (3) 
3. 3α-hydroxy-5β-pregnan-20-one 
M S: 8.6-18(10) 
F: 0.06-0.1(10); S: 5.5-10(10) GABAA+ 
CAS:128-20-1 
HMDB:0062782 
CHEBI:1712   
PC:31402 
1. THP (isomer 3/4) 
2. isopregnanolone (3) 
3. 3β-hydoxy-5α-pregnan-20-one 
M S: 7.8-10(10) 
F: 0.08-0.2(10); S: 3.7-7.1(10) 
GABAA- 
(THP-S) 
CAS:516-55-2 
HMDB:0001455 
PC:92787 
1. THP (isomer 4/4) 
2. epipregnanolone (3) 
3. 3β-hydoxy-5β-pregnan-20-one 
All: 0.3-3(6) 
M S: 0.4-0.6(10) 
F: 0.02-0.04(10); S: 1.5-2.5(10) 
GABAA- 
(THP-S) 
CAS:128-21-2 
HMDB:0001471 
PC:228491 
1. 3αDHP 
2. 3α-dihydroprogesterone 
3. 4-pregnen-3α-ol-20-one  
 
n.d. GABAA+ 
CAS:25680-68-6 
PC:121951 
1. 3βDHP(4) 
2. 3β-dihydroprogesterone 
3. 4-pregnen-3β-ol-20-one  
n.d.  PC:121951 
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1. P 
2. progesterone 
3. 4-pregnene-3,20-dione 
M: 0-0.4 (6) 
Fpre: 0-80(6) 
Fpost: 0-0.4(6)   
PR+ HMDB:01830 
 
1. 17OHP 
2. 17α-hydroxyprogesterone 
3. 17-hydroxypregn-4-en-3,20-dione 
M: 0.61-7.0(6) 
F: 0.21-2.3(6) 
 
PR+ 
 
CAS:68-96-2 
HMDB:0000374 
CHEBI:17252 
PC:6238 
1. 20αDHP 
2. 20α-dihydroprogesterone 
3. 20α-hydroxypreg-4-en-3-one 
PR
EG
N
EN
ES
 
Fpre: 0.8-11.7(6) PR+ 
CAS:145-14-2 
HMDB:0003069 
PC:8956 
1. 17OHP5 
2. 17-hydroxypregnenolone 
3. 5-Pregnen-3β,17α-diol-20-one 
M: 1.0-12 (6)  
F: 0-6.0(6)  
CAS:387-79-1 
HMDB:0000363 
CHEBI:28750 
PC:3032570 
1. P5 
2. pregnenolone 
3. pregn-5-en-3β-ol-20-one 
M: 1-15(6); S: 200-1000(6) 
Fpre: 1.0-15(6); S: 100-1000(6)   
Fpost: 1.0-15(6); S: 10-500(6) 
GABAA- (P5-
S) 
CAS:145-13-1 
HMDB:0000253 
CHEBI:16581 
PC:8955 
1. none 
2. androstanedione 
3. 5α-androstane-3,17-dione 
AN
DR
O
ST
AN
ES
 
M: 0.3(7)  
HMDB:0000899 
CHEBI:22542 
 
1. AN 
2. androsterone 
3. 3α-hydroxy-5α-androstan-17-one 
All: 0.5-0.9(7) 
M: 0.4-4.0(6,10); S: 617-1080(10) 
F: 0.3-0.6(10); S: 359-1070(10) 
AR+ weak 
GABAA+ 
HMDB:0000031 
1. 5βAN 
2. etiocholanolone 
3. 3α-hydroxy-5β-androstan-17-one 
M: 0.09-0.2(10); S: 32-70(10) 
F: 0.1-0.4 (10); S: 34-88(10) 
GABAA+ 
CAS:53-42-9 
HMDB:00490 
CHEBI:28195 
PC:5880 
1. 3αDIOL 
2. androstanediol 
3. 5α-androstane-3α,17β-diol 
M: 0.4-0.5(9,10); S: 35-121(10) 
F: 0.03-0.06 (10); S: 2.4-4.8(10) 
ERβ+ weak 
GABAA+ 
HMDB:0000495 
1. 3βDIOL 
2. 3β-androstanediol 
3. 5α-androstane-3β,17β-diol 
All: 0.15(7) 
M S: 34-103(10) 
F S: 8.7-18(10) 
ERβ+ HMDB:0000493 
1. EPI 
2. epiandrosterone 
3. 3β-hydroxy-17-oxo-5α-androstane 
M: 0.3-0.7(9,10); S: 211-532(10) 
F: 0.3-0.7(10); S: 172-350(10) AR+ 
weak 
CAS:481-29-8 
HMDB:0000365 
CHEBI:541975 
PC:441302 
1. DHT 
2. dihydrotestosterone 
3. 17β-hydroxy-5α-androstan-3-one 
M: 0/85-3.5 (50-100)(6) 
Fpre: 0.08-1.3(6) 
Fpost: 0.03-1.65(6) 
AR+ 
HMDB:0002961 
CHEBI:16330 
PC:10635 
1. EpiT(8) 
2. epitestosterone 
3. 17α-hydroxy-4-androsten-3-one 
AN
DR
O
ST
EN
ES
 
M: 1.3-2.9(7) AR+ weak (9) 
CAS:481-30-1 
HMDB:0000628 
CHEBI:42534  
CB:10204 
1. A5 
2. androstenediol 
3. androst-5-ene-3β,17β-diol 
M: 2.6-3.7(9,10); S: 243-494(10) 
F: 0.8-1.1(10,11); S: 85-302(10) 
AR+ weak 
CAS 521-17-5  
HMDB:0003818 
CHEBI:2710 
PC:10634 
1. 17αA5 
2. 17α-androstenediol 
3. androst-5-ene-3β,17α-diol 
n.d. 
AR+ weak 
GABAA- 
CAS:521-17-5 
HMDB:0003818 
CHEBI:2710 
PC:10634 
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1. Δ4-A5 
2. 4-androstenediol 
3. androst-4-ene-3β,17β-diol 
n.d.  
CAS:1156-92-9 
HMDB:0005849 
PC:12476620 
1. DHEA 
2. dehydroepiandrosterone 
3. (3β)-3-hydroxyandrost-5-en-17-one 
M: 10-25(6); S: 2K-10K(6) 
Fpre: 3.0-30(6); S: 1K-8K(6) 
Fpost: 2.0-20(6); S: 1K-6K(6) 
GABAA- 
(DHEA & 
DHEA-S) 
HMDB:0000077 
1. A4 
2. androstenedione 
3. 4-Androstene-3,17-dione 
   
   
   
  A
N
DR
O
ST
EN
ES
 
All: 3.1-5.9(7) AR+ 
CAS:63-05-8 
HMDB:0000053 
CHEBI:16422 
1. T 
2. testosterone 
3. 17β-hydroxyandrost-4-ene-3-one 
M: 5-25(6) 
Fpre: 0.2-2.0(6) 
Fpost: 0.2-1.0(6) 
AR+ 
CAS:55-22-0 
HMDB:0000234 
CHEBI:17347 
1. E2 
2. 17β-estradiol 
3. (17β)-estra-1,3,5(10)-triene-3,17-diol 
ES
TR
O
G
EN
S 
M: 0.02-0.04(6)  
Fpre: 0.005-1.0(6) 
Fpost: 0.005-0.08(6) 
ER+ 
CAS:50-28-2 
HMDB:0000151 
CHEBI:16469 
1. E1 
2. estrone 
3. 3-hydroxy-1,3,5(10)-estratrien-17-one 
M: 0.033-0.1(6); S: 2.0-4.0(6) 
Fpre: 0.015-0.5; S: 2.0-5.0(6) 
Fpost: 0.01-0.12; S: 5-20(X10-3) (6) 
ER+ 
CAS:53-16-7 
HMDB:0000145 
CHEBI:17263 
 
List of the steroids discussed in the present review with the major features. Nomenclature of these compounds 
is variable and aliases are given as Supplemental materials.  
 
* CAS: Chemical Abstracts Service, a division of the American Chemical Society (www.cas.org. Accessed on date: 
February 2018); HMDB: Human Metabolome Data Base (www.hmdb.ca. Accessed on date: February 2018) [10]; 
CB: Chemical Book (www.chemicalbook.com. Accessed on date: February 2018); ChEBI (www.ebi.ac.uk/chebi. 
Accessed on date: February 2018) [11]; PC: PubChem (www.ncbi.nlm.nih.gov; pubchem.ncbi.nlm.nih.gov. 
Accessed on date: February 2018) [9]. 
** M: male subjects; F: female subjects; Fpre: female premenopausal subjects; Fpost: female postmenopausal 
subjects; -S: sulphated compounds. 
*** PR, ER, AR: compound activates the indicated steroid receptor; GABAA allosteric positive (+) or negative (-) 
modulator. ^ This isomer is shown in Figure 2. n.d.: not determined. 
References and sources. (1): 20β-/5β-isomers exist (CB8678436, Chemical Book - www.chemicalbook.com. 
Accessed on date: February 2018); (2): Isomer 5α-pregnan-3β,17α-diol-20-one exists (CB:0291774, Chemical 
Book - www.chemicalbook.com. Accessed on date: February 2018); (3): In general, 5α-reduced and 3α-
hydroxysteroids are positive allosteric modulator of GABAA, whereas 3α- and 3β-sulphated hydroxysteroids and 
5β-reduced steroids are negative allosteric modulator of GABAA. The 3β-hydroxy isomers of THP are inactive [12, 
13]; (4): This compound is GABAA receptor inactive; (5): [14]; (6): [15]; (7): Data extracted from the Human 
Metabolome Data Base - HMDB (www.hmdb.ca. Accessed on date: February 2018) [10]; (8): This compound is 
strong inhibitor of SRD5As. (9): [16]; (10): [17].
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Intracrine regulation of estrogen 
 

1. P 
2. progesterone 
3. 4-pregnene-3,20-dione 
M: 0-0.4 (6) 
Fpre: 0-80(6) 
Fpost: 0-0.4(6)   
PR+ HMDB:01830 
 
1. 17OHP 
2. 17α-hydroxyprogesterone 
3. 17-hydroxypregn-4-en-3,20-dione 
M: 0.61-7.0(6) 
F: 0.21-2.3(6) 
 
PR+ 
 
CAS:68-96-2 
HMDB:0000374 
CHEBI:17252 
PC:6238 
1. 20αDHP 
2. 20α-dihydroprogesterone 
3. 20α-hydroxypreg-4-en-3-one 
PR
EG
N
EN
ES
 
Fpre: 0.8-11.7(6) PR+ 
CAS:145-14-2 
HMDB:0003069 
PC:8956 
1. 17OHP5 
2. 17-hydroxypregnenolone 
3. 5-Pregnen-3β,17α-diol-20-one 
M: 1.0-12 (6)  
F: 0-6.0(6)  
CAS:387-79-1 
HMDB:0000363 
CHEBI:28750 
PC:3032570 
1. P5 
2. pregnenolone 
3. pregn-5-en-3β-ol-20-one 
M: 1-15(6); S: 200-1000(6) 
Fpre: 1.0-15(6); S: 100-1000(6)   
Fpost: 1.0-15(6); S: 10-500(6) 
GABAA- (P5-
S) 
CAS:145-13-1 
HMDB:0000253 
CHEBI:16581 
PC:8955 
1. none 
2. androstanedione 
3. 5α-androstane-3,17-dione 
AN
DR
O
ST
AN
ES
 
M: 0.3(7)  
HMDB:0000899 
CHEBI:22542 
 
1. AN 
2. androsterone 
3. 3α-hydroxy-5α-andr stan-17-one 
All: 0.5-0.9(7) 
M: 0.4-4.0(6,10); S: 617-1080(10) 
F: 0.3-0.6(10); S: 359-1070(10) 
AR+ weak 
GABAA+ 
HMDB:0000031 
1. 5βAN 
2. etiocholanolone 
3. 3α-hydroxy-5β-androstan-17-one 
M: 0.09-0.2(10); S: 32-70(10) 
F: 0.1-0.4 (10); S: 34-88(10) 
GABAA+ 
CAS:53-42-9 
HMDB:00490 
CHEBI:28195 
PC:5880 
1. 3αDIOL 
2. androstanediol 
3. 5α-androstane-3α,17β-diol 
M: 0.4-0. (9,10); S: 35-121(10) 
F: 0.03-0.06 (10); S: 2.4-4.8(10) 
ERβ+ weak 
GABAA+ 
HMDB:0000495 
1. 3βDIOL 
2. 3β-androstanediol 
3. 5α-androstane-3β,17β-diol 
All: 0.15(7) 
M S: 34-103(10) 
F S: 8.7-18(10) 
ERβ+ HMDB:0000493 
1. EPI 
2. epiandrosterone 
3. 3β-hydroxy-17-oxo-5α-androstane 
M: 0.3-0.7(9,10); S: 211-532(10) 
F: 0.3-0.7(10); S: 172-350(10) AR+ 
weak 
CAS:481-29-8 
HMDB:0000365 
CHEBI:541975 
PC:441302 
1. DHT 
2. dihydrotestosterone 
3. 17β-hydroxy-5α-androstan-3-one 
M: 0/85-3.5 (50-100)(6) 
Fpre: 0.08-1.3(6) 
Fpost: 0.03-1.65(6) 
AR+ 
HMDB:0002961 
CHEBI:16330 
PC:10635 
1. EpiT(8) 
2. epitestosterone 
3. 17α-hyd oxy-4-androsten-3-one 
AN
DR
O
ST
EN
ES
 
M: 1.3-2.9(7) AR+ weak (9) 
CAS:481-30-1 
HMDB:0000628 
CHEBI:42534  
CB:10204 
1. A5 
2. androstenediol 
3. androst-5-ene-3β,17β-diol 
M: 2.6-3.7(9,10); S: 243-494(10) 
F: 0.8-1.1(10,11); S: 85-302(10) 
AR+ weak 
CAS 521-17-5  
HMDB:0003818 
CHEBI:2710 
PC:10634 
1. 17αA5 
2. 17α-androst nediol 
3. androst-5-ene-3β,17α-diol 
n.d. 
AR+ weak 
GABAA- 
CAS:521-17-5 
HMDB:0003818 
CHEBI:2710 
PC:10634 
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Chapter 2 

1. Δ4-A5 
2. 4-androstenediol 
3. androst-4-ene-3β,17β-diol 
n.d.  
CAS:1156-92-9 
HMDB:0005849 
PC:12476620 
1. DHEA 
2. dehydroepiandrosterone 
3. (3β)-3-hydroxyandrost-5-en-17-one 
M: 10-25(6); S: 2K-10K(6) 
Fpre: 3.0-30(6); S: 1K-8K(6) 
Fpost: 2.0-20(6); S: 1K-6K(6) 
GABAA- 
(DHEA & 
DHEA-S) 
HMDB:0000077 
1. A4 
2. androstenedione 
3. 4-Androstene-3,17-dione 
   
   
   
  A
N
DR
O
ST
EN
ES
 
All: 3.1-5.9(7) AR+ 
CAS:63-05-8 
HMDB:0000053 
CHEBI:16422 
1. T 
2. testosterone 
3. 17β-hydroxyandrost-4-ene-3-one 
M: 5-25(6) 
Fpre: 0.2-2.0(6) 
Fpost: 0.2-1.0(6) 
AR+ 
CAS:55-22-0 
HMDB:0000234 
CHEBI:17347 
1. E2 
2. 17β-estradiol 
3. (17β)-estra-1,3,5(10)-triene-3,17-diol 
ES
TR
O
G
EN
S 
M: 0.02-0.04(6)  
Fpre: 0.005-1.0(6) 
Fpost: 0.005-0.08(6) 
ER+ 
CAS:50-28-2 
HMDB:0000151 
CHEBI:16469 
1. E1 
2. estrone 
3. 3-hydroxy-1,3,5(10)-estratrien-17-one 
M: 0.033-0.1(6); S: 2.0-4.0(6) 
Fpre: 0.015-0.5; S: 2.0-5.0(6) 
Fpost: 0.01-0.12; S: 5-20(X10-3) (6) 
ER+ 
CAS:53-16-7 
HMDB:0000145 
CHEBI:17263 
 
List of the steroids discussed in the present review with the major features. Nomenclature of these compounds 
is variable and aliases are given as Supplemental materials.  
 
* CAS: Chemical Abstracts Service, a division of the American Chemical Society (www.cas.org. Accessed on date: 
February 2018); HMDB: Human Metabolome Data Base (www.hmdb.ca. Accessed on date: February 2018) [10]; 
CB: Chemical Book (www.chemicalbook.com. Accessed on date: February 2018); ChEBI (www.ebi.ac.uk/chebi. 
Accessed on date: F bruary 2018) [11]; PC: PubChem (www.ncbi.nlm.nih.gov; pubchem.ncbi.nlm.nih.gov. 
Accessed on date: Februa y 2018) [9]. 
** M: male subjects; F: female subjects; Fpre: female premenopausal subj cts; Fpost: female postmenopausal 
subjects; -S: sulphated compounds. 
*** PR, ER, AR: compound activates the indicated steroid receptor; GABAA allosteric positive (+) or negative (-) 
modulator. ^ This isomer is shown in Figure 2. n.d.: not determined. 
References and sources. (1): 20β-/5β-isomers exist (CB8678436, Chemical Book - www.chemicalbook.com. 
Accessed on date: February 2018); (2): Isomer 5α-pregnan-3β,17α-diol-20-one exists (CB:0291774, Chemical 
Book - www.chemicalbook.com. Accessed on date: February 2018); (3): In general, 5α-reduced and 3α-
hydroxysteroids are positive allosteric modulator of GABAA, whereas 3α- and 3β-sulphated hydroxysteroids and 
5β-reduced steroids are negative allosteric modulator of GABAA. The 3β-hydroxy isomers of THP are inactive [12, 
13]; (4): This compound is GABAA receptor inactive; (5): [14]; (6): [15]; (7): Data extracted from the Human 
Metabolome Data Base - HMDB (www.hmdb.ca. Accessed on date: February 2018) [10]; (8): This compound is 
strong inhibitor of SRD5As. (9): [16]; (10): [17].
41
In
tr
ac
rin
e 
re
gu
la
tio
n 
of
 e
st
ro
ge
n 
 
1.
 1
7β
H
SD
4
 
2 .
 3
29
5 
3 .
 H
SD
17
B4
  
DB
P;
 M
FE
-2
; M
PF
-
2;
 P
RL
TS
1;
 S
DR
8C
1 
Ch
r: 
5q
23
.1
 
G
en
e:
 1
84
  
m
RN
A:
 2
.9
 
E x
on
s:
 2
8 
aa
: 7
36
 
D a
lto
n:
 7
96
86
   
L:
 P
er
ox
iso
m
e 
m
ito
ch
on
 
1.
 1
7β
-h
yd
ro
xy
st
er
oi
d 
de
hy
dr
og
en
as
e 
ty
pe
 4
 
2.
 s
ho
rt
 c
ha
in
 d
eh
yd
ro
ge
na
se
/r
ed
uc
ta
se
 su
pe
rf
am
ily
 
3 .
 fa
tt
y 
ac
id
 β
-o
xi
da
tio
n 
(s
te
ro
id
s i
n 
pi
gs
) 
4 .
 (e
st
ab
lis
he
d)
 v
er
y 
lo
ng
 c
ha
in
 b
ra
nc
he
d 
fa
tt
y 
ac
id
s,
 b
ile
 a
ci
ds
 
   
 (p
os
tu
la
te
d)
 A
5
DH
EA
(1
) ; 
E2

E1
(1
4)
 
5 .
 u
bi
qu
ito
us
 (l
iv
er
, h
ea
rt
, p
ro
st
at
e,
 te
st
is
, l
un
g,
 s
ke
le
ta
l m
us
cl
e,
 k
id
ne
y,
 p
an
cr
ea
s,
 th
ym
us
, o
va
ry
, i
nt
es
tin
e,
 
pl
ac
en
ta
, b
ra
in
, s
pl
ee
n,
 c
ol
on
, l
ym
ph
oc
yt
es
)(1
4)
 
6.
 N
AD
/N
AD
H
 
1.
 1
7β
H
SD
6
 
2 .
 8
63
0 
3 .
 H
SD
17
B6
 
H
SE
; R
O
DH
; 
SD
R9
C6
 
Ch
r: 
12
q1
3 
G
en
e:
 2
4.
5 
m
RN
A:
 1
.6
 
E x
on
s:
 8
 
aa
: 3
17
 
D a
lto
n:
 3
59
66
   
L :
 E
nd
Re
t 
m
ic
ro
so
m
es
 
1.
 1
7β
-h
yd
ro
xy
st
er
oi
d 
de
hy
dr
og
en
as
e 
ty
pe
 6
 
2.
 sh
or
t c
ha
in
 d
eh
yd
ro
ge
na
se
/r
ed
uc
ta
se
 su
pe
rf
am
ily
 
3 .
 3
α
-3
β
-e
p
im
er
as
e;
 1
7β
-h
yd
ro
xy
l o
xi
d
at
io
n
 (
5
α
-r
ed
uc
ed
 st
er
oi
ds
); 
re
tin
oi
ds
  
4 .
 (e
st
ab
lis
he
d)
 3
α
D
IO
L
DH
T(
10
) ; 
AN

an
dr
os
ta
ne
di
on
e(
5)
;  
  A
N

EP
I 
( p
os
tu
la
te
d)
 3
α
D
IO
L
AN
(5
) ; 
E2

E1
(5
)   
5.
 se
le
ct
iv
el
y 
di
st
rib
ut
ed
 (l
iv
er
, t
es
tis
, l
un
g,
 s
pl
ee
n,
 b
ra
in
, o
va
ry
, k
id
ne
y,
 a
dr
en
al
, p
ro
st
at
e)
(1
4)
 
6.
 N
AD
/N
AD
P 
1.
 1
7β
H
SD
7
 
2 .
 5
14
78
 
3 .
 H
SD
17
B7
 
PR
AP
; S
DR
37
C1
 
Ch
r: 
1q
23
 
G
en
e:
 2
2.
1 
  
m
RN
A:
 1
.5
 
Ex
on
s:
 9
 
aa
: 3
41
 
D a
lto
n:
 3
82
06
   
L :
 E
nd
Re
t 
1.
 1
7β
-h
yd
ro
xy
st
er
oi
d 
de
hy
dr
og
en
as
e 
ty
pe
 7
 
2 .
 sh
or
t c
ha
in
 d
eh
yd
ro
ge
na
se
/r
ed
uc
ta
se
 su
pe
rf
am
ily
 
3 .
 3
-k
et
os
te
ro
id
 re
du
ct
as
e 
of
 s
te
ro
ls
 
4 .
 (e
st
ab
lis
he
d)
 S
te
ro
ls/
ch
ol
es
te
ro
l b
io
sy
nt
he
sis
; D
H
T
3β
D
IO
L(
1)
 
5 .
 w
id
el
y 
di
st
rib
ut
ed
 (o
va
ry
, u
te
ru
s,
 p
la
ce
nt
a,
 li
ve
r, 
br
ea
st
, t
es
tis
, n
eu
ro
na
l t
is
su
e,
 a
dr
en
al
 g
la
nd
, s
m
al
l 
in
te
st
in
e,
 p
ro
st
at
e,
 a
di
po
se
 ti
ss
ue
 lu
ng
, a
nd
 th
ym
us
)(1
4,
18
)  
6.
  N
AD
P/
N
AD
PH
 
1.
 1
7β
H
SD
8
 
2 .
 7
92
3 
3 .
 H
SD
17
B8
 
KE
6;
 F
AB
G
; H
KE
6;
 
FA
BG
L;
 R
IN
G
2;
 H
2-
KE
6;
 (m
or
e^
^)
  
Ch
r: 
6p
21
.3
 
G
en
e:
 2
.2
   
m
RN
A:
 1
.0
 
E x
on
s:
 9
 
aa
: 2
61
 
D a
lto
n:
 2
69
74
 
L :
 m
ito
ch
on
 
1.
 1
7β
-h
yd
ro
xy
st
er
oi
d 
de
hy
dr
og
en
as
e 
ty
pe
 8
 
2.
 sh
or
t c
ha
in
 d
eh
yd
ro
ge
na
se
/r
ed
uc
ta
se
 su
pe
rf
am
ily
 
3 .
 fa
tt
y 
ac
id
 e
lo
n
ga
ti
o
n
; s
te
ro
id
 1
7β
H
SD
 a
ct
io
n
 (
ro
d
en
ts
).
  
4 .
 (e
st
ab
lis
he
d)
 fa
tt
y 
ac
id
s  
   
   
   
(p
os
tu
la
te
d)
 E
2
E1
 
5 .
 w
id
el
y 
di
st
rib
ut
ed
 (p
ro
st
at
e,
 p
la
ce
nt
a,
 k
id
ne
y,
 b
ra
in
, c
er
eb
el
lu
m
, h
ea
rt
, l
un
g,
 s
m
al
l i
nt
es
tin
e,
 o
va
ry
, t
es
tis
, 
ad
re
na
l, 
st
om
ac
h,
 li
ve
r, 
ad
re
na
ls)
(1
4-
19
)   
6.
 N
AD
/N
AD
P 
1.
 1
7β
H
SD
9
 
2 .
 5
95
9 
3 .
 H
SD
17
B9
  
RD
H
5;
 (m
or
e^
^)
 
Ch
r: 
12
q2
3 
G
en
e:
 4
.4
   
m
RN
A:
 1
.4
 
Ex
on
s:
 4
 
aa
: 3
18
 
Da
lto
n:
 3
49
79
  
L :
 E
nd
Re
t 
1.
 1
7β
-h
yd
ro
xy
st
er
oi
d 
de
hy
dr
og
en
as
e 
ty
pe
 9
 
2 .
 sh
or
t c
ha
in
 d
eh
yd
ro
ge
na
se
/r
ed
uc
ta
se
 su
pe
rf
am
ily
 
3 .
 re
tin
oi
d 
m
et
ab
ol
ism
 (s
te
ro
id
 m
et
ab
ol
ism
 in
 ro
de
nt
s)
  
4.
 (e
st
ab
lis
he
d)
 re
tin
oi
ds
   
   
 (p
os
tu
la
te
d)
 A
N

3α
D
IO
L(
1)
; a
nd
ro
st
an
ed
io
ne

DH
T(
1)
 
 
 
 
 
Intracrine regulation of estrogen 
 

1. P 
2. progesterone 
3. 4-pregnene-3,20-dione 
M: 0-0.4 (6) 
Fpre: 0-80(6) 
Fpost: 0-0.4(6)   
PR+ HMDB:01830 
 
1. 17OHP 
2. 17α-hydroxyprogesterone 
3. 17-hydroxypregn-4-en-3,20-dione 
M: 0.61-7.0(6) 
F: 0.21-2.3(6) 
 
PR+ 
 
CAS:68-96-2 
HMDB:0000374 
CHEBI:17252 
PC:6238 
1. 20αDHP 
2. 20α-dihydroprogesterone 
3. 20α-hydroxypreg-4-en-3-one 
PR
EG
N
EN
ES
 
Fpre: 0.8-11.7(6) PR+ 
CAS:145-14-2 
HMDB:0003069 
PC:8956 
1. 17OHP5 
2. 17-hydroxypregnenolone 
3. 5-Pregnen-3β,17α-diol-20-one 
M: 1.0-12 (6)  
F: 0-6.0(6)  
CAS:387-79-1 
HMDB:0000363 
CHEBI:28750 
PC:3032570 
1. P5 
2. pregnenolone 
3. pregn-5-en-3β-ol-20-one 
M: 1-15(6); S: 200-1000(6) 
Fpre: 1.0-15(6); S: 100-1000(6)   
Fpost: 1.0-15(6); S: 10-500(6) 
GABAA- (P5-
S) 
CAS:145-13-1 
HMDB:0000253 
CHEBI:16581 
PC:8955 
1. none 
2. androstanedione 
3. 5α-androstane-3,17-dione 
AN
DR
O
ST
AN
ES
 
M: 0.3(7)  
HMDB:0000899 
CHEBI:22542 
 
1. AN 
2. androst rone 
3. 3α-hydroxy-5α-androstan-17-one 
All: 0.5-0.9(7) 
M: 0.4-4.0(6,10); S: 617-1080(10)
F: 0.3-0.6(10); S: 359-1070(10) 
AR+ weak 
GABAA+ 
HMDB:0000031 
1. 5βAN 
2. etiocholanolone 
3. 3α-hydroxy-5β-androstan-17-one 
M: 0.09-0.2(10); S: 32-70(10) 
F: 0.1-0.4 (10); S: 34-88(10) 
GABAA+ 
CAS:53-42-9 
HMDB:00490 
CHEBI:28195 
PC:5880 
1. 3αDIOL 
2. androstanediol 
3. 5α-androstane-3α,17β-diol 
M: 0.4-0.5(9,10); S: 35-121(10) 
F: 0.03-0.06 (10); S: 2.4-4.8(10) 
ERβ+ weak 
GABAA+ 
HMDB:0000495 
1. 3βDIOL 
2. 3β-andr stanediol 
3. 5α-androstane-3β,17β-diol 
All: 0.15(7) 
M S: 34-103(10) 
F S: 8.7-18(10) 
ERβ+ HMDB:0000493 
1. EPI 
2. epiandrosterone 
3. 3β-hydroxy-17-oxo-5α-androstane 
M: 0.3-0.7(9,10); S: 211-532(10) 
F: 0.3-0.7(10); S: 172-350(10) AR+ 
weak 
CAS:481-29-8 
HMDB:0000365 
CHEBI:541975 
PC:441302 
1. DHT 
2. dihydrotestosterone 
3. 17β-hydroxy-5α-androstan-3-one 
M: 0/85-3.5 (50-100)(6) 
Fpre: 0.08-1.3(6) 
Fpost: 0.03-1.65(6) 
AR+ 
HMDB:0002961 
CHEBI:16330 
PC:10635 
1. EpiT(8) 
2. epitestosterone 
3. 17α-hydroxy-4-androsten-3-one 
AN
DR
O
ST
EN
ES
 
M: 1.3-2.9(7) AR+ weak (9) 
CAS:481-30-1 
HMDB:0000628 
CHEBI:42534  
CB:10204 
1. A5 
2. androstenediol 
3. androst-5-ene-3β,17β-diol 
M: 2.6-3.7(9,10); S: 243-494(10) 
F: 0.8-1.1(10,11); S: 85-302(10) 
AR+ weak 
CAS 521-17-5  
HMDB:0003818 
CHEBI:2710 
PC:10634 
1. 17αA5 
2. 17α-androstenediol 
3. androst-5-ene-3β,17α-diol 
n.d. 
AR+ weak 
GABAA- 
CAS:521-17-5 
HMDB:0003818 
CHEBI:2710 
PC:10634 
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Chapter 2 

1. Δ4-A5 
2. 4-androstenediol 
3. androst-4-ene-3β,17β-diol 
n.d.  
CAS:1156-92-9 
HMDB:0005849 
PC:12476620 
1. DHEA 
2. dehydroepiandrosterone 
3. (3β)-3-hydroxyandrost-5-en-17-one 
M: 10-25(6); S: 2K-10K(6) 
Fpre: 3.0-30(6); S: 1K-8K(6) 
Fpost: 2.0-20(6); S: 1K-6K(6) 
GABAA- 
(DHEA & 
DHEA-S) 
HMDB:0000077 
1. A4 
2. androstenedione 
3. 4-Androstene-3,17-dione 
   
   
   
  A
N
DR
O
ST
EN
ES
 
All: 3.1-5.9(7) AR+ 
CAS:63-05-8 
HMDB:0000053 
CHEBI:16422 
1. T 
2. testosterone 
3. 17β-hydroxyandrost-4-ene-3-one 
M: 5-25(6) 
Fpre: 0.2-2.0(6) 
Fpost: 0.2-1.0(6) 
AR+ 
CAS:55-22-0 
HMDB:0000234 
CHEBI:17347 
1. E2 
2. 17β-estradiol 
3. (17β)-estra-1,3,5(10)-triene-3,17-diol 
ES
TR
O
G
EN
S 
M: 0.02-0.04(6)  
Fpre: 0.005-1.0(6) 
Fpost: 0.005-0.08(6) 
ER+ 
CAS:50-28-2 
HMDB:0000151 
CHEBI:16469 
1. E1 
2. estrone 
3. 3-hydroxy-1,3,5(10)-estratrien-17-one 
M: 0.033-0.1(6); S: 2.0-4.0(6) 
Fpre: 0.015-0.5; S: 2.0-5.0(6) 
Fpost: 0.01-0.12; S: 5-20(X10-3) (6) 
ER+ 
CAS:53-16-7 
HMDB:0000145 
CHEBI:17263 
 
List of the steroids discussed in the present review with the major features. Nomenclature of these compounds 
is variable and aliases are given as Supplemental materials.  
 
* CAS: Chemical Abstracts Service, a division of the American Chemical Society (www.cas.org. Accessed on date: 
February 2018); HMDB: Human Metabolome Data Base (www.hmdb.ca. Accessed on date: February 2018) [10]; 
CB: Chemic l Book (www.chemicalbook.com. Acce sed on date: February 2018); ChEBI (www.ebi.ac.uk/chebi. 
Accessed on date: February 2018) [11]; PC: PubChem (www.ncbi.nlm.nih.gov; pubchem.ncbi.nlm.nih.gov. 
Accessed on date: February 2018) [9]. 
** M: male subjects; F: female subjects; Fpre: f male premenopausal subjects; Fpost: female postmenopausal 
subjects; -S: sulphated compounds. 
*** PR, ER, AR: compound activates the indicated steroid receptor; GABAA allosteric positive (+) or negative (-) 
modulator. ^ This isomer is shown in Figure 2. n.d.: not determined. 
References and sources. (1): 20β-/5β-isomers exist (CB8678436, Chemical Book - www.chemicalbook.com. 
Accessed on date: February 2018); (2): Isomer 5α-pregnan-3β,17α-diol-20-one exists (CB:0291774, Chemical 
Book - www.chemicalbook.com. Accessed on date: February 2018); (3): In general, 5α-reduced and 3α-
hydroxysteroids are positive allosteric modulator of GABAA, whereas 3α- and 3β-sulphated hydroxysteroids and 
5β-reduced steroids are negative allosteric modulator of GABAA. The 3β-hydroxy isomers of THP are inactive [12, 
13]; (4): This compound is GABAA receptor inactive; (5): [14]; (6): [15]; (7): Data extracted from the Human 
Metabolome Data Base - HMDB (www.hmdb.ca. Accessed on date: February 2018) [10]; (8): This compound is 
strong inhibitor of SRD5As. (9): [16]; (10): [17].
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Intracrine regulation of estrogen 
 

1. P 
2. progesterone 
3. 4-pregnene-3,20-dione 
M: 0-0.4 (6) 
Fpre: 0-80(6) 
Fpost: 0-0.4(6)   
PR+ HMDB:01830 
 
1. 17OHP 
2. 17α-hydroxyprogesterone 
3. 17-hydroxypregn-4-en-3,20-dione 
M: 0.61-7.0(6) 
F: 0.21-2.3(6) 
 
PR+ 
 
CAS:68-96-2 
HMDB:0000374 
CHEBI:17252 
PC:6238 
1. 20αDHP 
2. 20α-dihydroprogesterone 
3. 20α-hydroxypreg-4-en-3-one 
PR
EG
N
EN
ES
 
Fpre: 0.8-11.7(6) PR+ 
CAS:145-14-2 
HMDB:0003069 
PC:8956 
1. 17OHP5 
2. 17-hydroxypregnenolone 
3. 5-Pregnen-3β,17α-diol-20-one 
M: 1.0-12 (6)  
F: 0-6.0(6)  
CAS:387-79-1 
HMDB:0000363 
CHEBI:28750 
PC:3032570 
1. P5 
2. pregnenolone 
3. pregn-5-en-3β-ol-20-one 
M: 1-15(6); S: 200-1000(6) 
Fpre: 1.0-15(6); S: 100-1000(6)   
Fpost: 1.0-15(6); S: 10-500(6) 
GABAA- (P5-
S) 
CAS:145-13-1 
HMDB:0000253 
CHEBI:16581 
PC:8955 
1. none 
2. androstanedione 
3. 5α-androstane-3,17-dione 
AN
DR
O
ST
AN
ES
 
M: 0.3(7)  
HMDB:0000899 
CHEBI:22542 
 
1. AN 
2. androst rone 
3. 3α-hydroxy-5α-androstan-17-one 
All: 0.5-0.9(7) 
M: 0.4-4.0(6,10); S: 617-1080(10) 
F: 0.3-0.6(10); S: 359-1070(10) 
AR+ weak 
GABAA+ 
HMDB:0000031 
1. 5βAN 
2. etiocholanolone 
3. 3α-hydroxy-5β-androstan-17-one 
M: 0.09-0.2(10); S: 32-70(10) 
F: 0.1-0.4 (10); S: 34-88(10) 
GABAA+ 
CAS:53-42-9 
HMDB:00490 
CHEBI:28195 
PC:5880 
1. 3αDIOL 
2. androstanediol 
3. 5α-androstane-3α,17β-diol 
M: 0.4-0.5(9,10); S: 35-121(10) 
F: 0.03-0.06 (10); S: 2.4-4.8(10) 
ERβ+ weak 
GABAA+ 
HMDB:0000495 
1. 3βDIOL 
2. 3β-andr stanediol 
3. 5α-androstane-3β,17β-diol 
All: 0.15(7) 
M S: 34-103(10) 
F S: 8.7-18(10) 
ERβ+ HMDB:0000493 
1. EPI 
2. epiandrosterone 
3. 3β-hydroxy-17-oxo-5α-androstane 
M: 0.3-0.7(9,10); S: 211-532(10) 
F: 0.3-0.7(10); S: 172-350(10) AR+ 
weak 
CAS:481-29-8 
HMDB:0000365 
CHEBI:541975 
PC:441302 
1. DHT 
2. dihydrotestosterone 
3. 17β-hydroxy-5α-androstan-3-one 
M: 0/85-3.5 (50-100)(6) 
Fpre: 0.08-1.3(6) 
Fpost: 0.03-1.65(6) 
AR+ 
HMDB:0002961 
CHEBI:16330 
PC:10635 
1. EpiT(8) 
2. epitestosterone 
3. 17α-hydroxy-4-androsten-3-one 
AN
DR
O
ST
EN
ES
 
M: 1.3-2.9(7) AR+ weak (9) 
CAS:481-30-1 
HMDB:0000628 
CHEBI:42534  
CB:10204 
1. A5 
2. androstenediol 
3. androst-5-ene-3β,17β-diol 
M: 2.6-3.7(9,10); S: 243-494(10) 
F: 0.8-1.1(10,11); S: 85-302(10) 
AR+ weak 
CAS 521-17-5  
HMDB:0003818 
CHEBI:2710 
PC:10634 
1. 17αA5 
2. 17α-androstenediol 
3. androst-5-ene-3β,17α-diol 
n.d. 
AR+ weak 
GABAA- 
CAS:521-17-5 
HMDB:0003818 
CHEBI:2710 
PC:10634 
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Chapter 2 

1. Δ4-A5 
2. 4-androstenediol 
3. androst-4-ene-3β,17β-diol 
n.d.  
CAS:1156-92-9 
HMDB:0005849 
PC:12476620 
1. DHEA 
2. dehydroepiandrosterone 
3. (3β)-3-hydroxyandrost-5-en-17-one 
M: 10-25(6); S: 2K-10K(6) 
Fpre: 3.0-30(6); S: 1K-8K(6) 
Fpost: 2.0-20(6); S: 1K-6K(6) 
GABAA- 
(DHEA & 
DHEA-S) 
HMDB:0000077 
1. A4 
2. androstenedione 
3. 4-Androstene-3,17-dione 
   
   
   
  A
N
DR
O
ST
EN
ES
 
All: 3.1-5.9(7) AR+ 
CAS:63-05-8 
HMDB:0000053 
CHEBI:16422 
1. T 
2. testosterone 
3. 17β-hydroxyandrost-4-ene-3-one 
M: 5-25(6) 
Fpre: 0.2-2.0(6) 
Fpost: 0.2-1.0(6) 
AR+ 
CAS:55-22-0 
HMDB:0000234 
CHEBI:17347 
1. E2 
2. 17β-estradiol 
3. (17β)-estra-1,3,5(10)-triene-3,17-diol 
ES
TR
O
G
EN
S 
M: 0.02-0.04(6)  
Fpre: 0.005-1.0(6) 
Fpost: 0.005-0.08(6) 
ER+ 
CAS:50-28-2 
HMDB:0000151 
CHEBI:16469 
1. E1 
2. estrone 
3. 3-hydroxy-1,3,5(10)-estratrien-17-one 
M: 0.033-0.1(6); S: 2.0-4.0(6) 
Fpre: 0.015-0.5; S: 2.0-5.0(6) 
Fpost: 0.01-0.12; S: 5-20(X10-3) (6) 
ER+ 
CAS:53-16-7 
HMDB:0000145 
CHEBI:17263 
 
List of the steroids discussed in the present review with the major features. Nomenclature of these compounds 
is variable and aliases are given as Supplemental materials.  
 
* CAS: Chemical Abstracts Service, a division of the American Chemical Society (www.cas.org. Accessed on date: 
February 2018); HMDB: Hu an Metabolome Data Base (www.hmdb.ca. Accessed on date: February 2018) [10]; 
CB: Chemical Book (www.chemicalbook.com. Accessed on date: February 2018); ChEBI (www.ebi.ac.uk/chebi. 
Accessed on date: February 2018) [11]; PC: PubChem (www.ncbi.nlm. ih.gov; pubchem.ncbi.nlm.nih.gov. 
Acc ss d on date: February 2018) [9]. 
** M: male subjects; F: female subjects; Fpre: female premenopausal subjects; Fpost: female postmenopausal 
subjects; -S: sulphated compounds. 
*** PR, ER, AR: compound activates he indicated steroid receptor; GABAA allosteric positive (+) or negative (-) 
modulator. ^ This isomer is shown in Figure 2. n.d.: not determined. 
References and sources. (1): 20β-/5β-isomers exist (CB8678436, Chemical Book - www.chemicalbook.com. 
Accessed on date: February 2018); (2): Isomer 5α-pregnan-3β,17α-diol-20-one exists (CB:0291774, Chemical 
Book - www.chemicalbook.com. Accessed on date: February 2018); (3): In general, 5α-reduced and 3α-
hydroxysteroids are positive allosteric modulator of GABAA, whereas 3α- and 3β-sulphated hydroxysteroids and 
5β-reduced steroids are negative allosteric modulator of GABAA. The 3β-hydroxy isomers of THP are inactive [12, 
13]; (4): This compound is GABAA receptor inactive; (5): [14]; (6): [15]; (7): Data extracted from the Human 
Metabolome D ta Base - HMDB (www.hmdb.ca. Accessed on date: February 2018) [10]; (8): This compound is 
strong inhibitor of SRD5As. (9): [16]; (10): [17].
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
1. P 
2. progesterone 
3. 4-pregnene-3,20-dione 
M: 0-0.4 (6) 
Fpre: 0-80(6) 
Fpost: 0-0.4(6)   
PR+ HMDB:01830 
 
1. 17OHP 
2. 17α-hydroxyprogesterone 
3. 17-hydroxypregn-4-en-3,20-dione 
M: 0.61-7.0(6) 
F: 0.21-2.3(6) 
 
PR+ 
 
CAS:68-96-2 
HMDB:0000374 
CHEBI:17252 
PC:6238 
1. 20αDHP 
2. 20α-dihydroprogesterone 
3. 20α-hydroxypreg-4-en-3-one 
PR
EG
N
EN
ES
 
Fpre: 0.8-11.7(6) PR+ 
CAS:145-14-2 
HMDB:0003069 
PC:8956 
1. 17OHP5 
2. 17-hydroxypregnenolone 
3. 5-Pregnen-3β,17α-diol-20-one 
M: 1.0-12 (6)  
F: 0-6.0(6)  
CAS:387-79-1 
HMDB:0000363 
CHEBI:28750 
PC:3032570 
1. P5 
2. pregnenolone 
3. pregn-5-en-3β-ol-20-one 
M: 1-15(6); S: 200-1000(6) 
Fpre: 1.0-15(6); S: 100-1000(6)   
Fpost: 1.0-15(6); S: 10-500(6) 
GABAA- (P5-
S) 
CAS:145-13-1 
HMDB:0000253 
CHEBI:16581 
PC:8955 
1. none 
2. androstanedione 
3. 5α-androstane-3,17-dione 
AN
DR
O
ST
AN
ES
 
M: 0.3(7)  
HMDB:0000899 
CHEBI:22542 
 
1. AN 
2. androsterone 
3. 3α-hydroxy-5α-androstan-17-one 
All: 0.5-0.9(7) 
M: 0.4-4.0(6,10); S: 617-1080(10) 
F: 0.3-0.6(10); S: 359-1070(10) 
AR+ weak 
GABAA+ 
HMDB:0000031 
1. 5βAN 
2. etiocholanolone 
3. 3α-hydroxy-5β-androstan-17-one 
M: 0.09-0.2(10); S: 32-70(10) 
F: 0.1-0.4 (10); S: 34-88(10) 
GABAA+ 
CAS:53-42-9 
HMDB:00490 
CHEBI:28195 
PC:5880 
1. 3αDIOL 
2. androstanediol 
3. 5α-androstane-3α,17β-diol 
M: 0.4-0.5(9,10); S: 35-121(10) 
F: 0.03-0.06 (10); S: 2.4-4.8(10) 
ERβ+ weak 
GABAA+ 
HMDB:0000495 
1. 3βDIOL 
2. 3β-androstanediol 
3. 5α-androstane-3β,17β-diol 
All: 0.15(7) 
M S: 34-103(10) 
F S: 8.7-18(10) 
ERβ+ HMDB:0000493 
1. EPI 
2. epiandrosterone 
3. 3β-hydroxy-17-oxo-5α-androstane 
M: 0.3-0.7(9,10); S: 211-532(10) 
F: 0.3-0.7(10); S: 172-350(10) AR+ 
weak 
CAS:481-29-8 
HMDB:0000365 
CHEBI:541975 
PC:441302 
1. DHT 
2. dihydrotestosterone 
3. 17β-hydroxy-5α-androstan-3-one 
M: 0/85-3.5 (50-100)(6) 
Fpre: 0.08-1.3(6) 
Fpost: 0.03-1.65(6) 
AR+ 
HMDB:0002961 
CHEBI:16330 
PC:10635 
1. EpiT(8) 
2. epitestosterone 
3. 17α-hydroxy-4-androsten-3-one 
AN
DR
O
ST
EN
ES
 
M: 1.3-2.9(7) AR+ weak (9) 
CAS:481-30-1 
HMDB:0000628 
CHEBI:42534  
CB:10204 
1. A5 
2. androstenediol 
3. androst-5-ene-3β,17β-diol 
M: 2.6-3.7(9,10); S: 243-494(10) 
F: 0.8-1.1(10,11); S: 85-302(10) 
AR+ weak 
CAS 521-17-5  
HMDB:0003818 
CHEBI:2710 
PC:10634 
1. 17αA5 
2. 17α-androstenediol 
3. androst-5-ene-3β,17α-diol 
n.d. 
AR+ weak 
GABAA- 
CAS:521-17-5 
HMDB:0003818 
CHEBI:2710 
PC:10634 
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
1. Δ4-A5 
2. 4-androstenediol 
3. androst-4-ene-3β,17β-diol 
n.d.  
CAS:1156-92-9 
HMDB:0005849 
PC:12476620 
1. DHEA 
2. dehydro piandrosterone 
3. (3β)-3-hydroxyandrost-5-en-17-one 
M: 10-25(6); S: 2K-10K(6) 
Fpre: 3.0-30(6); S: 1K-8K(6) 
Fpost: 2.0-20(6); S: 1K-6K(6) 
GABAA- 
(DHEA & 
DHEA-S) 
HMDB:0000077 
1. A4 
2. androstenedione 
3. 4-Andro tene-3,17-dione 
   
   
   
  A
N
DR
O
ST
EN
ES
 
All: 3.1-5.9(7) AR+ 
CAS:63-05-8 
HMDB:0000053 
CHEBI:16422 
1. T 
2. testosterone 
3. 17β-hydroxyandrost-4-ene-3-one 
M: 5-25(6) 
Fpre: 0.2-2.0(6) 
Fpost: 0.2-1.0(6) 
AR+ 
CAS:55-22-0 
HMDB:0000234 
CHEBI:17347 
1. E2 
2. 17β-estradiol 
3. (17β)-estra-1,3,5(10)-triene-3,17-diol 
ES
TR
O
G
EN
S 
M: 0.02-0.04(6)  
Fpre: 0.005-1.0(6) 
Fpost: 0.005-0.08(6) 
ER+ 
CAS:50-28-2 
HMDB:0000151 
CHEBI:16469 
1. E1 
2. estrone 
3. 3-hydroxy-1,3,5(10)-estratrien-17-one 
M: 0.033-0.1(6); S: 2.0-4.0(6) 
Fpre: 0.015-0.5; S: 2.0-5.0(6) 
Fpost: 0.01-0.12; S: 5-20(X10-3) (6) 
ER+ 
CAS:53-16-7 
HMDB:0000145 
CHEBI:17263 
 
List of the steroids discussed in the present review with the major features. Nomenclature of these compounds 
is variable and aliases are given as Supplemental materials.  
 
* CAS: Chemical Abstracts Service, a division of the American Chemical Society (www.cas.org. Accessed on date: 
February 2018); HMDB: Human Metabolome Data Base (www.hmdb.ca. Accessed on date: February 2018) [10]; 
CB: Chemical Book (www.chemicalbook.com. Accessed on date: February 2018); ChEBI (www.ebi.ac.uk/chebi. 
Accessed on date: February 2018) [11]; PC: PubChem (www.ncbi.nlm.nih.gov; pubchem.ncbi.nlm.nih.gov. 
Accessed on date: February 2018) [9]. 
** M: male subjects; F: female subjects; Fpre: female premenopausal subjects; Fpost: female postmenopausal 
subjects; -S: sulphated compounds. 
*** PR, ER, AR: compound activates the indicated steroid receptor; GABAA allosteric positive (+) or negative (-) 
modulator. ^ This isomer is shown in Figure 2. n.d.: not determined. 
References and sources. (1): 20β-/5β-isomers exist (CB8678436, Chemical Book - www.chemicalbook.com. 
Accessed on date: February 2018); (2): Isomer 5α-pregnan-3β,17α-diol-20-one exists (CB:0291774, Chemical 
Book - www.ch mical ook.com. Accessed on date: February 2018); (3): In general, 5α-reduced and 3α-
hydroxysteroids are positive allosteric modulator of GABAA, whereas 3α- and 3β-sulphated hydroxysteroids and 
5β-reduced steroids are negative allosteric modulator of GABAA. The 3β-hydroxy isomers of THP are inactive [12, 
13]; (4): This compound is GABAA receptor inactive; (5): [14]; (6): [15]; (7): Data extracted from the Human 
Metabolo e Data Base - HMDB (www.hmdb.ca. Accessed on date: February 2018) [10]; (8): This compound is 
strong inhibitor of SRD5As. (9): [16]; (10): [17].
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Figure 2. Intracrine networks 
Major intracrine networks metabolising steroids. In this figure, each reaction reports the catalysing enzymes 
whose role in that specific reaction is established based on robust evidences (in vitro, ex vivo, in vivo). Additional 
enzymes whose involvement in the same reactions is less robustly demonstrated or based only on in silico or cell-
free assay are reported in Table II. The role of 17βHSD3 is disregarded in this figure because restricted to tissues 
that are not assessed in the present review (testes, prostate, Table II).  
Colour codes: 
 
 
 
 
 
 
 
 
 
 
OV ovarian specific referring to 3β-HSD2 (see text). 
---- dotted arrows indicate reactions that are not fully demonstrated to occur or for which the responsible enzyme 
is not identified yet. 
 (enzyme name) enzymes indicated by brackets are supposed to catalyse the indicated reaction based on the 
theoretical assumptions, no experimental proof is yet available. 
& these compounds (THP, 3αDHP and allopregnandiol) exist as various hydroxyl α/β isomers (3, 5, 17) with no 
activity, classic action or neuroactivity (see Table II). 
* the role of DHRS11 in steroid metabolism is reported only recently by one publication [44]. 

Ovarian steroidogenesis 
Transformation of cholesterol to 17β-estradiol (E2) involves first the production of 
dehydroepiandrosterone (DHEA) in theca cells through the action of steroidogenic acute 
regulatory protein (StAR) that facilitates the transport of cholesterol into mitochondria, 
followed by CYP11A1 (rate-limiting) and CYP17A1 (Figure 2; the ovarian pathway is indicated 
by the yellow background; reviewed by [19, 53]. CYP11A1 is a type I CYP localised in 
mitochondria that uses nicotine-adenine-dinucleotide-phosphate (NADPH) and ferredoxin 
(Fdx)/ferredoxin reductase (FdR) to cleave the cholesterol side chain and produce 
pregnenolone (P5). Type II CYP17A1, localised in the endoplasmic reticulum (EndRet), has both 
17-hydroxylase and 17,20-lyase activities. It uses NADPH and P450 oxidoreductase (POR) to 
first hydroxylate P5 to 17α-hydroxypregnenolone (17OHP5) (17-hydroxylase action), 
followed by 17,20-lyase action to release DHEA. Gonad specific type 2 3β-hydroxysteroid 
dehydrogenase (3βHSD2) has 3β-dehydrogenase and Δ5 to Δ4 isomerase activities and converts 
DHEA to androstenedione (A4). Next, CYP19A1 catalyses the oxidative demethylation of C19 
androgens to C18 estrogens, with A-ring aromatisation; hence A4 is converted to estrone (E1). 
The final conversion of E1 (with low affinity for the estrogen-receptors -ERs) to E2 (high affinity 
for ERs and high estrogenic potency) is catalysed by 17βHSD1 that reduces 17-keto to 17β-
hydroxyl steroids. In the ovary, the 17-keto group of A4 can be reduced to 17β-hydroxyl by 
AKR1C3/17βHSD5 yielding testosterone (T) that is converted to E2 by CYP19A1. Upon ovulation, 
Yellow Background: Ovarian classic steroidogenesis. 
Red circles: 3β-sulphated hydroxyl groups. 
Orange circles: 3α-sulphated hydroxyl groups. 
 
 
progesterone receptor activation (PRA/B) 
androgen receptor activation (AR) 
estrogen receptor activation (ERα/β) 
GABAA receptor allosteric modulator 
      Biological activity 
   weak            strong 

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
high 3βHSD2 levels in the corpus luteum lead to high progesterone (P) generation from P5. 
 
Intracrine steroidogenesis 
The expression of StAR, CYP11A1 and CYP17A1 is demonstrated in a limited number of 
peripheral tissues (see later and Tables VI-VII). However, pregnenes, pregnanes, androstenes 
and androstanes generated from these initial steps (but also abundantly available as circulating 
precursors) can be further metabolised locally thus generating a plethora of compounds with 
various biological activities (estrogenic, androgenic, progestogenic and neuroactive; Tables I, II 
and Figure 2). The Δ5 to Δ4 isomerisation of androstenes (DHEA, androstenediol -A5- and 
17αA5) and pregnenes (P5, 17OHP5) is catalysed by 3βHSD1, which is the peripheral 
counterpart of ovarian 3βHSD2. Also 3βHSD2, however, whose expression was initially 
considered to be restricted to endocrine tissues, is detected peripherally in recent reports [3, 
54-57]. Due to the high concentration of DHEA (both in blood and tissues), its conversion to A4 
by 3βHSDs is relevant to the formation of downstream androgens and of estrogens. 
Additionally, 3βHSDs convert A5 and the isomer 17αA5 to T and epitestosterone (EpiT). 
Although minor, in the context of women’s health, these pathways are relevant. A5, together 
with 3α and 3βDIOL (generated by AKR1Cs from DHT and AN, see below) activate both ERs and 
have estrogenic action (especially 3βDIOL, a potent ERβ binder). A5 possesses immune 
stimulatory activity whereas its 17α isomer (17αA5) has androgenic, antitumour and 
neuroactivity. Additionally, EpiT is a weak AR binder and a strong endogenous inhibitor of 
SRD5As [58]. The endogenous occurrence of 17αA5 is demonstrated in humans [59] but its 
route of synthesis is unclear [60]. A 17αHSD able to convert A4 to EpiT and DHEA to 17αA5 is 
characterised in mice [61] but no human homologous is described yet. Similarly to the ovaries, 
androgen to estrogen conversion is catalysed by CYP19A1. 
A particularly important reaction is controlled by oxidative and reductive 17βHSDs, which 
interconvert 17-keto and 17β-hydroxysteroids. Since 17β-hydroxysteroids (T and E2) have 
higher affinity for the receptors than the keto-steroids (A4 and E1), this balance determines 
the final androgenic/estrogenic activity. Fourteen 17βHSDs exist, whose specificity is 
determined by tissue distribution, intracellular localisation and biochemistry (Table II; 
reviewed thoroughly in [19, 34, 62-64]. Unpublished data also refer to a 15th 17βHSD (see Table 
II; reported in [65]) with a putative role in androgen metabolism. With the exclusion of 
17βHSD5 (AKR1C3, see below), all other 17βHSDs belong to the short-chain dehydrogenase 
(SRD) family. 
Although all 17βHSDs have been postulated to use steroids as substrates based on cell-free or 
in vitro assays, recent investigations based on substrate specificity [66] and knock-out (KO) 
models (Table IV) better clarified their roles. Type 1 17βHSD is the estrogenic enzyme and 
coverts E1 to E2 both in the ovary and in peripheral tissue. Type 2 17βHSD oxidises 17-hydroxyl 
groups (E2 and T) to the 17-keto forms (E1 and A4), and possesses also a 20α-hydroxyl 
oxidative action, through which this enzyme generates P from 20αDHP. Type 6 17βHSD uses 
5α-reduced androgens and has 17-hydroxyl oxidative activity (converting androsterone -AN- 
50
Chapter 2 

to androstanedione) and 3-hydroxyl oxidative activity (converting 3αDIOL to the most potent 
androgen dihydrotestosterone -DHT). Additional catalytic actions for 17βHSD6 (epimerase or 
17-hydroxydehydrogenase) are demonstrated in vitro (Table II). Type 14 17βHSD is postulated 
to have 17β-hydroxyl oxidative action on various steroids, type 7 is involved in cholesterol 
metabolism as indicated by KO mice (Table IV), whereas there is apparently little/no in vivo 
role of types 8, 9, 10, 11 and 12 17βHSDs on steroid metabolism (Table II and indicated by KO 
mice, Table IV). Recently, a novel SRD, DHRS11, was shown to possess in vitro 17-keto to 17β-
hydroxyl reductive action (able to use E1, Δ5 or Δ4 androstenes, androstanes), plus reductive 
3βHSD activity toward Δ4 pregnenes and other compounds (5β-steroids, bile acids; Table II and 
Figure 2) [44].  
 
Table IV. Mouse models (knockouts - KO or transgenic - TG, i.e., ubiquitous expression of the gene, unless 
specified) for intracrine enzymes 
Gene^ 
Modification  
MGI ID$ Phenotype 
StAR 
Null/KO (1) 
MGI:2388706 
[67][346]  
Endocrine (steroids) & reproductive endocrinology  
- abnormal endocrine organs (adrenal, ovaries, prostate, testis). 
- decreased steroids and increased adrenocorticotropin level. 
- adrenocortical insufficiency. 
- loss of negative feedback regulation at hypothalamic-pituitary levels. 
 
Additional 
Growth retardation neo/post natal lethality (incomplete penetrance). 
Reproductive system: abnormal uterus; incomplete spermatogenesis; abnormal 
genitalia. 
CYP11A1 
Null/KO (2) 
MGI:5464022 
 
 
 
Null/KO (3) 
MGI:2183813 
 
Endocrine (steroids) & reproductive endocrinology 
- abnormal adrenal gland morphology. 
- increased circulating adrenocorticotropin level. 
- lack of steroid production. 
- decreased corticosterone and aldosterone levels. 
 
Additional 
Neonatal lethality (rescued by steroid supplementation); abnormal 
mitochondrion morphology; abnormal lipid level. Reproductive system: 
abnormal genitalia, prostate, testis morphology and spermatogenesis; Nervous 
system: abnormal adrenaline and noradrenaline level; abnormal food intake, 
hypoactivity; postnatal growth retardation.  
CYP17A1 
Null/KO (4) 
MGI:3722780 
 
Null/KO (5) 
MGI:3047328 
 
Null/KO  
MGI:5605834 
Endocrine (steroids) & reproductive endocrinology 
- increased circulating cholesterol level. 
- decreased T level. 
- early reproductive senescence. 
 
Additional 
Homozygous embryonic lethality (Ed7, between implantation and somite 
formation). Reproductive system: abnormal sperm flagellum 
morphology/asthenozoospermia; reduced male fertility. Bone: abnormal bone 
structure, mineral content and density. Metabolism: increased total body fat; 
decreased lean body mass; increased circulating creatinine level; increased 
fasted circulating glucose level. Nervous system: abnormal sexual interaction.  
CYP19A1 
Null/KO (6) 
MGI:2179439 Endocrine (steroids) & reproductive endocrinology 
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Null/KO (7) 
MGI:2154536 
 
 
Null/KO (8) 
MGI:2389548 
 
 
- increased circulating cholesterol, T, DHT, FSH, LH and prolactin. 
- decreased circulating E2 level. 
- abnormal endometrium (thin, decreased uterus weight). 
- abnormal ovary (absence of follicles and corpus luteum, anovulation). 
 
Additional  
Reproductive system: ovary haemorrhage and cysts; increased seminal vesicle 
weight and abnormal seminiferous tubule epithelium and oligozoospermia; 
female infertility and reduced male fertility. Metabolism: increased fat; obesity 
and susceptibility to weight gain. Bone: decreased bone mineral density and 
bone mass; increased bone resorption, osteoclast cell number; abnormal 
compact and trabecular bone morphology. Metabolism: increased circulating 
glucose and triglyceride levels; impaired glucose tolerance; insulin resistance; 
hepatic steatosis; abnormal liver physiology. Nervous system: abnormal short 
term spatial reference memory; abnormal emotion/affect behaviour; abnormal 
barbering behaviour; increased grooming behaviour; abnormal locomotor 
activation, bradykinesia; abnormal mating frequency. 
 
17βHSD1 
Null/KO (9) 
MGI:5576042 & 
3799948 
 
 
Endocrine (steroids) & reproductive endocrinology 
- abnormal corpus luteum morphology and decreased number. 
- increased ovarian E1:E2 and A4:T ratios. 
- increased LH level. 
- reduced P level. 
 
Additional 
Increased circulating alkaline phosphatase level, pigmentation, abnormal retinal 
pigmentation, abnormal lens morphology, abnormal retina morphology, 
abnormal retinal pigmentation. Reproductive system: increased ovary weight; 
reduced female fertility. Metabolism: decreased circulating glucose level. 
Nervous system:  abnormal behaviour, response to light, sleep behaviour, 
decreased exploration in new environment; abnormal motor 
coordination/balance.  
TG (10) 
Reproductive endocrinology 
- female have increased T levels. 
- increased E1E2 conversion. 
- masculinisation in females. 
- develop benign/malignant breast, ovarian and endometrial conditions. 
17βHSD2 
Null/KO (11) 
MGI:3773836 
No clear reproductive endocrinology phenotype  
 
Additional  
Heterozygous mice: growth retardation at birth ant postnatal; premature death; 
renal degeneration. Reproductive system: 70% embryonic lethality (Ed11.5) due 
to placental defects (homozygous); small and abnormal placenta morphology; 
Nervous system: brain phenotype with enlarged ventricles; abnormal cortex 
morphology; impaired balance, coordination, abnormal sleep pattern, 
megacephaly.  
TG (12) 
Reproductive endocrinology  
- low T level. 
 
Additional 
Growth retardation; delayed eye opening; impaired retinoic signalling.  
Reproductive system: disrupted spermatogenesis. Bone: decreased bone 
formation (pre-pubertal age); decreased IGF-I and osteocalcin levels.  
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17βHSD4 Null/KO (13) 
No clear reproductive endocrinology phenotype  
 
Additional 
Neonatal and postnatal lethality; postnatal growth retardation; abnormal 
mitochondrion morphology; abnormal bile salt level; hepatic steatosis. 
Reproductive system: abnormal testis and spermatid morphology; seminiferous 
tubule degeneration; small testis; abnormal gametogenesis; reduced male 
fertility. Nervous system: microgliosis; Purkinje cell degeneration; astrocytosis; 
axon degeneration; abnormal suckling behaviour; increased anxiety-related 
response, tremors, ataxia, impaired coordination, hypoactivity, lethargy; 
abnormal gait. GIT: abnormal intestinal absorption. Metabolism: decreased 
body weight; abnormal lipid homeostasis and decreased fatty acid level.  
17βHSD7 
Null/KO (14) 
MGI:3811923 
 
Null/KO (15) 
MGI:4456868 
[68][347] 
Endocrine (steroids) 
- Cholesterol biosynthesis. 
 
Additional 
Decreased embryo size; embryo lethality due to heart malformations (Ed10.5); 
abnormal blood vessel and capillary morphology. Nervous system: brain 
malformations; forebrain hypoplasia; increased neural tube apoptosis. 
 
 
17βHSD9 
Null/KO (16) 
MGI: 2446073 
 
Null/KO (17) 
MGI:2388375 
 
No clear reproductive endocrinology phenotype  
 
 
Additional 
Visual defects; abnormal eye electrophysiology, delayed dark adaptation. 
17βHSD10 
Null/KO (18) 
No clear reproductive endocrinology phenotype  
 
Additional 
Mitochondria dysfunction; reduced plasma glucose and increase insulin levels. 
Nervous system: neuronal damage.  
TG (brain specific) (19) 
No clear reproductive endocrinology phenotype  
 
Additional 
Nervous system: Protect against ischemia, Parkinson, Alzheimer disease model 
17βHSD11 Null/KO 
(20) 
MGI:5581418 
No clear reproductive endocrinology phenotype  
 
Additional 
Increased total circulating protein level. Nervous system: hyperactivity.  
17βHSD12 Null/KO (21) 
No clear reproductive endocrinology phenotype  
 
Additional 
Embryo lethality Ed 9.5; impaired organogenesis; reduced arachidonic acid 
synthesis. Reproductive system: ovarian dysfunction, fertility problems, smaller 
litters, significantly fewer numbers of ductal branches than wild type female 
mammary glands; ovulation problems. Nervous system: high embryo expression 
in neuronal structures. 
17βHSD13 
Null/KO (22) 
MGI:5007180 No clear phenotype associated. 
17βHSD14 
Null/KO (23) 
MGI:5007181 
No clear reproductive endocrinology phenotype  
 
Additional  
Increased IgG2a level. Reproductive system: oligozoospermia, testis 
degeneration, male infertility. Nervous system: increased response to stress-
induced hyperthermia. 
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17βHSD15 
Null/KO (24) 
MGI:3526658 & 
3586379 
No clear reproductive endocrinology phenotype  
 
Additional 
Abnormal eye electrophysiology, delayed dark adaptation 
AKR1C3/ 
17βHSD5* 
Null/KO (25) 
MGI:3527218 
 
Null/KO (26) 
MGI:3774264 
Reproductive endocrinology  
- long gestation, parturition failure. 
- increased levels of P. 
- prolonged estrous and diestrous. 
 
Additional 
Small litter size, the number of pups, especially live pups, was markedly 
decreased hematopoietic system phenotype. Nervous system: Some behavioural 
phonotype, 
SRD5A1 Null/KO 
(27) 
MGI:1857454 
Reproductive endocrinology 
- parturition defects, rescued by 3α-DIOL supplementation. 
 
Additional 
Decreased litter size; small prostate. 
 
 
SRD5A2 
Null/KO (28) 
MGI:2178039 
Reproductive endocrinology 
- T accumulation in reproductive tissues. 
- impaired androgen-dependent gene expression. 
- parturition defects, rescued by 3α-DIOL supplementation. 
  
Additional 
Decreased litter size; small prostate. 
SRD5A3 Null/KO 
(29) 
MGI:5520177 
Mouse not thoroughly characterized 
 
Embryonic lethality, abnormal heart morphology, abnormal neural tube closure 
SULT1E1 Null/KO 
(30) 
MGI:3529586  
Reproductive endocrinology 
- elevated circulating estrogen levels. 
 
Additional 
Disturbed platelet physiology. Reproductive system: leyding cell hyperplasia and 
abnormal morphology; abnormal testis morphology; abnormal placentation and 
amniotic fluid composition. 
SULT2B1 
Null/KO  
MGI:5432568 
(unpublished) 
Endocrine (steroids)  
disturbed cholesterol metabolism and levels. 
 
^ No report/references was found for 17βHSD3, 17βHSD6, 17βHSD8, 3βHSD1, 3βHSD2, DHRS11, STS, SULT2A1, 
SULT1A1. 
* The human AKR1C3/17βHSD5 KO refers to mice with disrupted AKR1C18, however, functional conservation 
between the four human AKR1Cs and the eight mouse AKR1Cs in unclear [69]. 
$Reference ID refers to the Mouse Genome Informatics (MGI; www.informatics.jax.org. Accessed on date: 
February 2018) [70]. 
References. (1): [67]; (2): [71]; (3): [72]; (4): [73]; (5): [74]; (6): [75]; (7): [76]; (8): [77]; (9): [78]; (10):  
[79, 80]; (11): [81]; (12): [82]; (13): [83]; (14): [84]; (15): [68]; (16): [85]; (17): [86, 87]; (18): [88, 89]; (19): [88, 
89]; (20): [90]; (21): [91, 92]; (22): [93]; (23): [93]; (24): [94]; (25): [95]; (26): [96]; (27): [97]; (28): [98]; (29): [90]; 
(30): [99, 100]. 
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Androgens and progestogens can be further metabolised by aldo-ketoreductases (AKRs) and 
5α-reductases (SRD5As; Figure 2). Cytoplasmic AKRs (AKR1C1, 1C2, 1C3/17βHSD5 and 1C4) 
have broad substrate specificity with non-stereo-selective 3α/3βHSD, 17- and 20-ketosteroid 
reductase activities (Table II; [26, 27]). Together with the fact that they have wide tissue 
distribution (only AKR1C4 is restricted), AKR1Cs contribute to make intracrine networks flexible 
and intricate [45, 101]. 
SRD5As convert 3-keto Δ4 androstene and pregnene to 5α-reduced steroids (androstanes and 
pregnanes), hence they are important in progestogen, androgen (DHT production) and 
neurosteroid metabolism [102]. SRD5A1 and 3 are widely expressed, in contrast to SRD5A2. 
Human 5β-reductase activity, catalysed by AKR1D1, is restricted to the liver, where 5β-steroids 
are directed to clearance/catabolism. However, some 5β-compounds are neuroactive and 
recent studies indicate the presence of AKR1D1 in placenta and myometrium [28], 5β-steroids 
will not be further considered. 
The sulphatase pathway is finally responsible for the balance between sulpho-conjugated and 
free steroids. Sulpho-conjugated steroids (-S) possess higher water solubility, increased 
stability and longer half-life than unconjugated compounds (e.g. 10-12 hours versus 20-30 
minutes for estrogens), and although they cannot bind steroid-receptors, they serve as a 
reservoir for the formation of biologically active steroids [103]. Sulphotransferases (SULTs) are 
phase-I detoxifying enzymes that use bis-phospho-nucleotide 3′-phospho-adenosine-5′-
phosphate- (PAP)-sulphate as donor to conjugate 3β-hydroxyl steroids (e.g. estrogens, DHEA, 
P5, cholesterol; red circles in Figure 2) with a sulphate group [6, 52]. Distinct SULTs have 
different specificities towards substrates, with SULT1E1 being the major estrogen sulphating 
enzyme (with little contribution of SULT1A1), and SULT2A1 being specific for DHEA (but also 
for P5, 17OHP5 and A5) (Table II). Steroid sulphatase (STS) is a membrane-bound microsomal 
enzyme that catalyses the hydrolysis of sulphate ester bonds from sulphated-steroids 
(cholesterol-S, P5-S, 17OHP5-S, DHEA-S, E1-S) [6, 15], thus releasing unconjugated compounds.  
Although sulphated-3α-hydroxysteroids are not thoroughly studied, they are detected in 
biospecimens (AN-S, 3αDIOL-S; Table I and orange circles in Figure 2). They are most likely 
produced by SULT2A1 (active on 3α-hydroxy bile acids) [6, 52] but no 3α-stereo specific 
sulphatase is known to date. Some intracellular sulphated-steroids are converted to other 
compounds without prior desulphation [104].  
 
In conclusions, intracrinology presents redundant and complex pathways, which generate 
compounds with various activities. Genetic variants in intracrine genes are associated with 
various diseases (classically endocrine and not; Table V). Even in the absence of the enzymatic 
machinery to metabolise cholesterol (StAR, steroidogenic factor, CYP17A1 and CYP11A1), 
DHEA, P5 and especially their sulphated-conjugates have high blood concentrations (Table I), 
and are used to generate all other steroids in peripheral tissues.   
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Table V. Diseases associated with gene variants in intracrine enzymes 
Name Affected system or 
tissue (Disease)  
Phenotype OMIM ID
# 
(Reference) 
StAR Endocrine system 
Lipoid adrenal 
hyperplasia 
Deficiency of adrenal or gonadal steroids 
All individuals are phenotypic females 
Infant mortality (mineral- & glucocorticoid deficiency 
OMIM: 
201710 (1) 
CYP11A1 Endocrine system 
Congenital adrenal 
insufficiency, with 
46XY sex reversal 
Acute adrenal insufficiency in infancy or childhood 
Abnormality of cholesterol metabolism 
Absence of secondary sex characteristics 
OMIM: 
613743 (1) 
Reproductive (ass^) SNPs^^ associated with endometrial cancer (2) 
Bone (ass^) SNPs associated with skeletal adverse events to AI (3) 
CNV (ass^) SNPs associated with neurological disturbances  (4) 
CYP17A1 Endocrine system 
Congenital adrenal 
insufficiency (17α-
hydroxyl. deficiency) 
Excessive corticosteroids leading to hypertension  
Low aldosterone synthesis 
Abnormal sex determination and secondary sex 
characteristics, amenorrhea 
OMIM: 
202110 (1) 
GIT (ass^) SNPs associated with risk of cancer in the CRC## (5) 
Reproductive (ass^) SNPs associated with endometrial cancer (6) 
CYP19A1 Reprod Endocrin** 
Aromatase deficiency 
Pseudo hermaphroditism in female 
Cystic ovaries, delayed bone maturation, adiposity 
OMIM: 
613546 
Aromatase excess 
syndrome 
Heterosexual precocity and gynecomastia in males  
Isosexual precocity in females  
OMIM: 
139300 
Reproductive (ass^) SNPs associated with endometrial cancer and ovarian 
cancer risks, endometriosis risk and risk to develop 
preeclampsia 
(6-14) 
Bone (ass^) SNPs associated with osteoporosis and fracture risk  (15,16) 
Lung (ass^) SNPs associated with lung cancer  (17) 
GIT (ass^) SNPs associated with gastric cancer  (18) 
3βHSD1 Endocr syst* (ass^) SNPs associated with hypertension  (19) 
Skin (ass^) SNPs associated with acne susceptibility (20) 
3βHSD2 Endocrine system & 
Reprod Endocrin 
Congenital adrenal 
insufficiency (3β-HSD2 
deficiency) 
Impaired steroid biosynthesis 
Low cortisol, aldosterone, P androgens, estrogens. 
Male new-borns exhibit pseudo hermaphroditism 
Incomplete masculinization of the external genitalia 
Affected females can have partial virilisation 
OMIM: 
201810 (1) 
Urogenital (ass^) SNPs associated with bladder cancer  (21) 
17βHSD1  Reproductive (ass^) SNPs associated with E2 levels and with endometriosis, 
cancer risk, abortion 
(22-25) 
17βHSD3 Reprod Endocrin 
ketosteroidreductase 
deficiency of testis  
Males: pseudo hermaphroditism, gynecomastia 
Infertility 
OMIM: 
264300 (1) 
17βHSD4 CNS &  
Reprod Endocrin 
Perrault syndrome 1 
Ovarian dysgenesis, amenorrhea, low estrogens  
Sensorineural deafness, 
Neurologic manifestations (mild mental retardation) 
OMIM: 
233400 
 
CNS 
D-bifunctional protein 
deficiency 
Abnormal peroxisomal fatty acid beta-oxidation 
Deterioration of nervous system functions  
Infantile-onset of hypotonia, seizures, and abnormal facial 
features, death before the age of 2 years  
OMIM: 
261515 
17βHSD6 Reproductive (ass^) SNPs associated with PCOS*** (26) 
17βHSD9 Eye 
Fundus albipunctatus 
Fleck retina disease, night blindness, delayed cone and rod 
photopigment regeneration. 
OMIM: 
136880 
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17βHSD10 CNS 
HSD10 mitochondrial 
disease 
X-linked neurodegenerative disorder 
Multisystemic features, mitochondrial dysfunction 
OMIM: 
300438 
 Turner type X-linked 
mental retardation 
Moderate to profound mental retardation Macrocephaly 
and variable skeletal features 
OMIM: 
300706 
17βHSD12 Reproductive (ass^) (Male) SNPs associated with prostate cancer (27)  
Lung (ass^) SNPs associated with pulmonary function  (28) 
17βHSD15 Eye & CNS 
Retinal dystrophy, 
juvenile cataracts, 
short stature 
Decreased visual acuity, retinitis pigmentosa 
Psychomotor delays from early childhood, lack of fine 
motor skills and coordination, learning difficulties, facial 
dysmorphism 
OMIM: 
616108 
AKR1C1  Lymphocytes (ass^) SNPs associated with non-Hodgkin lymphoma (29) 
  Lung (ass^) SNPs associated with lung cancer  (29) 
CNS (ass^) SNPs associated with panic disorders (29) 
AKR1C2  Reprod Endocrin 46XY 
sex reversal 8 
Males: ambiguous external genitalia, cryptorchidism  
Disturbed endocrine features 
OMIM 
614279 
Endocr. syst. (ass^) SNPs associated with weight-gain predisposition  (29) 
Lung (ass^) SNPs associated with lung cancer  (29) 
AKR1C3 
  
Reproductive (ass^) SNPs associated with T levels and PCOS (29,30) 
Lymphocytes (ass^) SNPs associated with large B cell lymphoma (29) 
Lung (ass^) SNPs associated with lung cancer  (29) 
Leukocytes (ass^) SNPs associated with lung childhood leukaemia (29) 
Urogenital (ass^) SNPs associated with bladder cancer  (29) 
CNS (ass^) SNPs associated with amyotrophic lateral sclerosis (29) 
AKR1C4 Reprod Endocrin 46XY 
sex reversal 8 
Males: ambiguous external genitalia, cryptorchidism  
Disturbed endocrine features 
OMIM 
614279 
-- (ass^) SNPs associated with responses to anthracycline (29) 
CNS (ass^) SNPs associated with paranoia risk  (29) 
SRD5A1 Reproductive (ass^) Haplotypes associated with PCOS and hirsutum (31) 
SRD5A2 Reprod Endocrin 
Pseudovaginal 
perineoscrotal 
hypospadias 
Males: pseudo hermaphroditism, ambiguous genitalia, 
cryptorchidism, small prostate 
No Mullerian structures, masculinization at puberty  
No breast development or menstruation at puberty  
Abnormal plasma DHT (and T) level 
OMIM: 
264600 
Reproductive (ass^) Haplotypes associated with PCOS  (31) 
Bone (ass^) SNPs associated with low bone mineral density  (32) 
SRD5A3 CNS 
Type Iq congenital 
glycosylation disorder  
Developmental delay, midline brain malformations 
Variable extents of visual loss  
OMIM: 
612379 
CNS 
Kahrizi syndrome 
Mental retardation, delayed motor development, speech 
impairment, coarse facial features 
OMIM: 
612713 
STS Skin 
X-linked ichthyosis 
Cutaneous manifestations: dark brown, polygonal scales 
and generalized dryness 
OMIM: 
308100 (40) 
Bone 
bone dysplasia  Chondrodysplasia punctata and bone dysplasia 
(33) 
SULT1E1 Reproductive (ass^) SNP associated with estrogen dependent diseases (34) 
SULT2A1 Reproductive (ass^) SNP associated with DHEA-S, androgens and PCOS (40,35) 
SULT2B1 Skin 
congenital autosomal 
recessive ichthyosis  
Generalized desquamation, dry scaly skin, hyperkeratosis, 
erythema 
OMIM: 
604125 
SULT1A1 Reproductive (ass^) SNPs associated with endometrial cancer (11,36) 
Bone (ass^) SNPs associated with low bone mineral density  (32) 
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GIT (ass^) SNPs associated with risk of cancer in the GIT (37-38) 
-- (ass^) SNPs associated with activity and termostability (37,39) 
 
Selected papers reporting association between SNPs and diseases are reported. Association studies with 
enzymes involved in steroid signalling but not discusses in the present review exist (for some references, see: 
[15, 19, 105, 106]. 
* Endocr syst: Endocrine system. 
** Reprod Endocrin: Reproductive endocrinology. 
*** PCOS: polycystic ovarian syndrome. 
^ ass: association studies, case controls. 
^^SNP: single nucleotide polymorphism. 
# OMIM: Online Mendelian Inheritance in Man. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins 
University (Baltimore, MD). (https://omim.org/. Accessed on date: February 2018). 
## CRC: colorectal cancer. 
References. (1): [19]; (2): [107]; (3): [108]; (4): [109]; (5): [110]; (6): [111]; (7): [112]; (8): [113]; (9): [114]; (10): 
[115]; (11): [116]; (12): [117]; (13): [118]; (14): [119]; (15): [120]; (16): [121]; (17): [122]; (18): [123]; (19): [124]; 
(20): [125]; (21): [126]; (22): [127]; (23): [128]; (24): [129]; (25): [130]; (26): [131]; (27): [132]; (28): [133]; (29): 
[134]; (30): [135]; (31): [136]; (32): [137]; (33): [138]; (34): [139]; (35): [140]; (36): [141]; (37): [142]; (38): [143]; 
(39): [144]; (40): [15]. 
 
Drug development 
Natural hormones have been historically used as drugs, and depending on definitions, 
approximately 90-marketed drugs share a steroidal core (see https://www.drugbank.ca). 
Steroids (T, E2, cortisol, DHEA), simple derivatives (ethinylestrogen, prednisolon) or more 
complex analogues (abiraterone, fulvestrant) are used in various conditions. This old-and-
proven steroidal chemistry based approach is used even in modern era.  
By targeting steroid intracrine metabolism, the effects of steroids can be modulated locally. 
Table III overviews the available drugs targeting intracrine enzymes and their developmental 
status. CYP19A1 (aromatase) inhibitors, currently at their third generation, started to be used 
for breast cancer during the 80‘s of last century [145], and was followed by drugs able to target 
other enzymes (CYP11A1, CYP17A1, SRD5As; Table III).  
 
Table III. Drugs targeting intracrine enzymes  
  Inhibitor name (if known); (Drug Bank ID#) 
 Developmental phase & Approved drugs 
NName Discovery Preclinical 
Indication 
Clinical 
Indication 
Inhibitor name  Indication 
CYP11A1 ✓ ✓ ✓ 
Aminoglutethimide 
(DB00357##) 
Cushing's syndrome 
Breast cancer 
CYP17A1 ✓ ✓ ✓ 
Abiraterone 
(DB05812) 
Prostate cancer, metastatic, 
castration-resistant  
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CYP19A1 
 ✓ ✓ 
Letrozole 
(DB01006)(19, 22, 24) 
Anastrozole  
(DB01217) (20, 23) 
Exemestane 
(DB00990) (21) 
Advanced stage 
endometrial cancer, 
NSCLC^, LAM^^ 
Anastrozole  
(DB01217)  
Letrozole  
(DB01006) 
Exemestane  
(DB00990) 
Formestane(1) 
Testolactone* 
(DB00894) 
 
 
Breast cancer: adjuvant 
treatment, metastatic  
 
 
 
Breast cancer, palliative 
3βHSD1 ✓ ✓ ✓ 
Trilostane* 
(DB01108) 
Cushing's syndrome 
(veterinary use) 
3βHSD2 ✓ ✓ ✓ 
Trilostane* 
(DB01108) 
Cushing's syndrome 
(veterinary use) 
17βHSD1 
 ✓ 
Endometriosis(2,3) 
Endometrial cancer(4) 
Breast cancer(5-6) 
Endometrial 
hyperplasia(7) 
   
17βHSD2 (8,9)     
17βHSD3& 
&& ✓ 
Prostate cancer(10)    
17βHSD7 (11)     
AKR1C1 (12)     
AKR1C2  (12)     
AKR1C3 
 ✓ ✓ 
ASP-9521 (13)  
Prostate cancer** 
BAY 1128688 
Endometriosis*** 
  
AKR1C4 (12)      
SRD5A1 ✓ ✓ ✓ 
Dutasteride 
(DB01126) Prostatic hyperplasia (benign) 
SRD5A2 ✓ ✓ ✓ 
Finasteride 
(DB01216) 
Dutasteride 
(DB01126) 
Prostatic hyperplasia (benign) 
SRD5A3 ✓ ✓ ✓ 
Dutasteride 
(DB01216) Prostatic hyperplasia (benign) 
STS 
 ✓ ✓ 
Irosustat (DB02292)  
Endometrial cancer 
(14, 15) 
Breast cancer(14, 16, 17) 
 
E2MATE/PLG2001 
Endometriosis(18) 
  
SULT1E1 
 ✓ ✓ ✓ 
Cyclizine (DB01176) antistaminic for 
nausea/vomiting 
 
  
& ‘Clinical phase’, i.e., in phase I, II or III trial; ‘Preclinical phase’ refers to in vivo testing; ‘Discovery phase’ any 
previous phase with some candidate compound. 
# Drug Bank ID if the compound is deposited in Drug Bank database (www.drugbank.ca/drugs. Accessed on date: 
February 2018) [146]. 
## Aminoglutethimide (ID: DB00357) is an important inhibitor of CYP11A1 with inhibitory activity on CYP19A1 as 
well. 
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* No longer on the market. 
&& 17βHSD3 is testis specific and the reactions catalysed by this enzyme are not reported in Figure 2. 
** This trial for prostate cancer was prematurely terminated (www.clinicaltrials.gov, NCT01352208). 
*** Phase I trial is concluded (www.clinicaltrials.gov, NCT02434640. Accessed on date: February 2018) and a 
phase II trial started 2016 (http://adisinsight.springer.com/drugs/800041929). 
^ NSCLC: non-small cell lung cancer 
^^ LAM: lymphangioleiomyomatosis 
References. (1): [33];  (2): [147]; (3): [148]; (4): [149]; (5): [80]; (6): [150]; (7): [79]; (8): [151]; (9): [152]; (10): 
[153]; (11): [154]; (12): [155]; (13): [156]; (14): [49]; (15): [157]; (16): [158]; (17): [159]; (18): [160]; (19): [161]; 
(20): [162]; (21): [163]; (22): [164]; (23): NCT00932152; (25): [165].  
 
More recently, there is a re-emerging interest in developing novel intracrine drugs. A number 
of compounds are in their clinical phases, like STS inhibitors [49, 157, 160, 166, 167] or 
inhibitors of AKR1C3/17βHSD5, which are of particular interest because this enzyme has crucial 
role in androgen/estrogen and prostaglandin biosynthesis [168]. Bayer’s AKR1C3/17βHSD5 
inhibitor BAY 1128688 has a modified estrogen core, it interferes with both pathways, and is 
in phase II clinical trial for endometriosis [169]. Astellas Pharma potent and selective 
AKR1C3/17βHSD5 inhibitor ASP-9521 had only modest effect in a phase II study on prostate 
cancer as single drug, but combination therapy approaches remain to be studied [156, 170]. 
HSD inhibitors are being studied in the area of hormone-dependent diseases, with 11β-HSD 
inhibitors being in clinical trials for metabolic disorders [171] and 17β-HSD inhibitors 
approaching the clinical phase for a number of gynaecological indications (Table III; [172]).  
 
Intracrinology in peripheral tissues 
In this paragraph, intracrinology of endometrium and lungs is reviewed. To comprehensively 
understand the ability of these tissues and systems to generate estrogens and other steroids, 
we have performed a systematic search of all original papers published in English until June 
2018 that described the levels of intracrine enzymes (those indicated in Table II - mRNA, 
protein or activity) in healthy tissues. The results of this systematic review are summarised in 
Tables VI and VII and are briefly overviewed in each section dedicated to the distinct tissues or 
systems. Reports describing the enzymes in cultured cells or cell lines were excluded (may have 
been discussed elsewhere, though). Each section follows then with a non-systematic overview 
of the role of intracrinology in pathophysiology. In total 173 papers were reviewed on the lower 
female genital tract and extra gynaecological tissues such as the lungs, gastrointestinal tract, 
brain, colon and bone. For details of this search, see our review Konings et al. 2018 in Frontiers 
in Pharmacology. Also, a brief non-systematic description of the intracrinology of the skin, 
immune system and adipose tissue is also given. In this current chapter only the endometrium 
and lungs are discussed. 
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Table VI. Expression of intracrine enzymes in endometrium – results of the systematic search 
 
   Menopausal 
status 
 
Name  Technique# Pre  Post References 
StAR mRNA  RT-PCR yes yes [37, 54, 173] 
CYP11A1 mRNA  RT-PCR yes n.d. [54-56, 174, 175] 
  RT-PCR no n.d. [174] 
CYP17A1 mRNA  RT-PCR yes n.d. [54-56]  
  RT-PCR no n.d. [174] 
  IHC no no [176] 
CYP19A1 mRNA  RT-PCR yes yes [23, 54, 148, 177-188] 
  RT-PCR no no [176, 189-195] 
  ISH no n.d. [176] 
 Protein  IHC yes yes [196-201] 
  IHC no no [176, 177, 189, 193, 202-204] 
  WB n.d. yes [205] 
  activity no no [176, 191, 192]  
  activity yes yes [206-211] 
3βHSD1 mRNA  RT-PCR yes yes [54, 174, 175, 178, 212, 213] 
 Protein*  IHC yes n.d. [174, 213]  
  IHC no no [176] 
3βHSD2 mRNA  RT-PCR yes yes [54-57]  
17βHSDs      
oxidative 
activity  
 yes yes [182, 214-224] 
reductive 
activity 
  yes yes [148, 194, 215, 216] 
   no no [214] 
17βHSD1 mRNA  RT-PCR yes yes [57, 148, 178, 179, 181, 184, 194, 225-227] 
  NB yes n.d. [225] 
  RT-PCR no no [38, 214] 
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 Protein  IHC yes yes [179, 184, 226, 228-231] 
  IHC no no [214] 
17βHSD2 mRNA  RT-PCR yes yes 
[57, 113, 148, 178-181, 184, 185, 194, 213, 214, 217, 
225-227, 231-233] 
  NB yes n.d. [225] 
 Protein  IHC yes yes [36, 179, 184, 214, 226, 234, 235] 
17βHSD4 mRNA  RT-PCR yes yes [148, 178, 179, 181] 
  NB yes n.d. [35] 
17βHSD6 mRNA  RT-PCR yes n.d. [181, 236] 
17βHSD7 mRNA  RT-PCR yes yes [23, 148, 178, 181-183, 227] 
17βHSD8 mRNA  RT-PCR yes yes [23, 178] 
17βHSD10 mRNA  RT-PCR yes n.d. [181] 
17βHSD12 mRNA  RT-PCR yes yes [23, 148, 178, 181-183] 
17βHSD14 mRNA  RT-PCR yes n.d. [181, 184] 
AKR1Cs      
AKR1C1 mRNA  RT-PCR yes yes [23, 175, 178, 233, 237] 
AKR1C2 mRNA  RT-PCR yes yes [175, 233] 
AKR1C3/ 
17βHSD5 
mRNA  RT-PCR yes yes [23, 148, 175, 178, 181, 182, 213, 233, 237, 238] 
 Protein  IHC yes yes [23, 213, 239-241] 
SRD5As      
SRD5A1 mRNA  RT-PCR yes yes [56, 175, 233, 242]  
 Protein  IHC yes yes [242-244] 
SRD5A2 mRNA  RT-PCR yes yes [56, 175, 233, 242]  
 Protein  IHC yes yes [242-244] 
SRD5A3  RT-PCR yes n.d. [56]  
Sulphatase pathway    
STS mRNA  RT-PCR yes yes [23, 56, 178, 179, 183-185, 194, 226, 227, 245-248] 
  RT-PCR no no [47] 
  Comp-RT yes n.d. [249] 
 Protein  IHC yes yes [36, 179, 184, 246, 249] 
  IHC no no [47] 
  activity yes yes [194, 207, 211, 215, 245, 250-253] 
  IHC no no [246] 
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SULT1E1 mRNA  RT-PCR yes yes 
[23, 47, 179, 183-185, 194, 211, 226, 227, 245, 246, 
248, 254, 255] 
   NB yes n.d. [256] 
 Protein  IHC yes yes [36, 47, 184, 199, 246] 
  activity yes yes [194, 207, 245, 246] 
SULT1A1 mRNA  RT-PCR yes yes [254, 255] 
SULT1A1   NB yes n.d. [256]*** 
SULT2A1   NB no n.d. [256] 
SULT2B1 mRNA  RT-PCR yes yes [254, 255] 
 
Primary/original references were analysed and reviews were excluded (and are cited ad hoc in the text). The 
table report only the enzymes whose expression was assessed in reviewed studies**. 
 
# Technique abbreviations. For mRNA detection, NB: northern blot; ISH: in situ hybridisation; RT-PCR: reverse 
transcription semi or quantitative PCR; Comp-RT: competitive RT-PCR. For protein detection: IHC: 
immunohistochemistry; WB: western blotting. For enzyme activity measurement: activity. 
* Most commercially available antibodies do not distinguish between 3βHSD1 and 3βHSD1. 
** No publication was found describing the expression of 17βHSD9, 11, 13, 15, DHRS11 and AKR1C4. 
*** The same study also detected expression of SULT1A3 [256]. 
n.d.: not determined. 
 
Endometrium 
The actions of steroid hormones in the endometrium are mediated by hormone-receptors via 
the classical mechanisms, although non-genomic and rapid signallings are also present [257-
260]. Estrogens and P control the menstrual cycle [53, 257] and the endometrium during the 
window of implantation (WOI), occurring in the mid-luteal phase [261]. 
In rats, the WOI is characterised by high E2 plasma levels, and endometrial ERα and PR 
expression shows specific and varying cytosolic/nuclear patterns [262]. ERα and PR expression 
decreases after ovulation and in preimplantation stages in both mice [263] and primates 
(Macaca mulatta) [264].  
Rodent genetic models unravelled some molecular mechanisms underlying the estrogen-
dependency of these processes. ERα-KO mice are infertile, no implantation occurs, 
endometrium is hypoplastic and estrogen response is absent [265, 266]. Not only its absence, 
but also sustained estrogen signalling has deleterious effects on endometrial receptivity, as 
recapitulated by mice with uterine COUP-TFII ablation. These mice exhibit increased estrogen 
signalling and asynchrony between embryo competency and uterine receptivity with 
consequent implantation defects. This effect is rescued by treatment with the antiestrogen ICI-
182780 [267]. Additionally, the duration of E2 exposure and its dosage affect endometrial 
receptivity and WOI length in mice [268]. 
Available human data, mostly obtained in the context of assisted reproduction technologies 
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(ART), also indicate that steroid stimulation retards or shortens the luteal phase, the WOI, 
causes shifts in the appearance of pinopodes (a classical WOI marker) and causes asynchrony 
between ovarian and menstrual cycles [269]. 
Intracrinology in healthy endometrium – systematic search 
Initial studies on steroid hormone metabolism in the endometrium date back to 1965 with first 
demonstration of the STS activity, followed by investigation on the oxidative and reductive 
17βHSD activities (Table VI).  
Both pre and postmenopausal tissues possess oxidative and reductive 17βHSD activities and 
the expression of 17βHSD1, 2, 4, 6, 7, 8, 10, 12, 14 and AKR1C3/17βHSD5 was detected at the 
mRNA or protein levels. Sulphatase pathway (STS and SULT1E1; recently reviewed [6]), 
CYP19A1, 3βHSDs, SRD5As and AKR1Cs are also present, indicating that human endometrium 
can metabolise sulphated-compounds and DHEA to form androgens and estrogens. 
Few 17βHSDs have been characterised by IHC. The low expression of 17βHSD1 poses sensitivity 
problems using standard detection methods [36], and few authors reporting endometrial 
absence of 17βHSD1 (Table VI). Type 1 17βHSD localises in the cytoplasm of epithelial cells 
[179, 184, 226, 228] and it is also detected in primary stroma cells cultured in vitro [228, 270]. 
Type 2 17βHSD, AKR1C3/17βHSD5 and 3βHSD1 give strong reactivity in the glandular 
epithelium [23, 174, 179, 184, 213, 226, 228, 239, 240].  
Also CYP19A1 has low expression and some authors detected this enzyme only in association 
with diseases (see below and recently reviewed [5]). Although CYP19A1 immunoreactivity was 
initially associated with stroma cells [176], subsequent investigations showed also glandular 
expression [189, 199] and laser-capture-microdissected stroma/epithelial components 
detected CYP19A1 mRNA in both cell types [180]. 
The mRNA of those enzymes converting cholesterol to DHEA (CYP11A1, CYP17A1, StAR) and 
(ovarian) 3βHSD2 was reported in recent studies, suggesting that the endometrium can 
produce steroids from cholesterol (Table VI).  
 
Intratissue steroid levels 
Endometrial steroid levels were recently profiled by LC-MS. E2 levels differ between tissue and 
serum during the menstrual cycle, being up to five-times higher in tissue than in serum during 
the proliferative phase and 1.5-fold higher in the luteal period [56, 181]. T levels were lower in 
tissue than in serum with no cyclic changes. The levels P and P5 (and their 17-hydroxy 
derivatives) did not vary between serum and tissue, indicating that, contrarily to estrogens, 
progestogen intra-tissue levels are determined by passive diffusion from the blood [56].  
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Intracrinology and reproduction 
Animal models show not only that intracrine enzymes are expressed in the endometrium, but 
also they vary the expression levels during the endometrial phases and during implantation, as 
shown already during the 80’s in rhesus monkeys for the oxidising 17βHSD activity [271]. 
In rodents, STS activity measured with [3H]E1-S in 6-days pregnant rats was lower around the 
implantation site compared with non-implantation sites [272]. In situ hybridisation signal of 
17βHSD7 mRNA varied spatio-temporally throughout implantation and early gestation, being 
initially detected on luminal epithelium around the implantation site and absent in decidua 
(embryonic day, Ed5.5). At Ed8 and Ed9.5, 17βHSD7 expression increased in the decidua 
capsularis (the part that interacts with the trophoblast) and later (after E9) in the junctional 
zone of the developing placenta and in the spongiotrophoblasts [273]. 
A brilliant study in mice showed that decidualisation is dependent on local E2 produced 
through CYP19A1. CYP19A1 expression increased during pregnancy and decidualisation was 
unaffected by ovariectomy. In contrast, treatment with the aromatase inhibitor (AI) letrozole 
impaired decidualisation and decreased decidual marker expression (e.g. PRP, BMP2 and CX43) 
[274].  
 
In human endometrium, 17βHSD2 and SULT1E1 are induced by P as their expression peaks in 
the luteal phase [179, 181, 226, 246, 248, 256, 275]. Since both enzymes decrease intra-tissue 
estrogen levels, their up-regulation is one of the mechanisms of the uterine antiestrogenic 
effects of P. The P-dependency of 17βHSD2 and SULT1E1 was recapitulated in vitro using 
explant cultures and primary cells [179, 248, 275]. Luteal peak expression of other SULTs (1A1 
and 2B1) was also reported [256, 276]. Some reports also suggested that STS expression 
increased in the luteal phase [245, 248] with a potential role during decidualisation [275]. Mid-
luteal phase endometrium shows also peaking expression of 3βHSD1 (mRNA and protein) [174, 
213].  
 
Two studies on human ectopic pregnancies explored the endometrium around the implanted 
blastocyst. Expression of 3βHSD1 (mRNA and protein) was highest in decidua obtained from 
ectopic pregnancies [174] and in a study on 23 tubal pregnancies, 17βHSD1 showed highest 
immunoreactivity at the foetal-maternal interface [230], suggestive for a role of these enzyme 
in the nidation site.  
 
Endometriosis 
Endometriosis, an estrogen-dependent benign disorder affecting up to 10% of reproductive-
aged women, is associated with pelvic pain, infertility, decreased life-quality and important 
health care/social costs [277-282]. Endometriosis is characterised by the growth of 
endometrium-like tissue outside the uterus (ectopic locations), beside the ovaries 
(endometrioma), as peritoneal implants, or as deep-lesions infiltrating peritoneal organs (deep 
endometriosis). 
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The expression of intracrine enzymes in endometriosis was reviewed in 2012, [283] and among 
other studies, 20 papers published between 1996 and 2009 specifically described the levels of 
intracrine enzymes in eutopic and ectopic endometrium from patients and control women. 
With the exclusion of one study that included over 100 patients [193], the rest included small 
study populations, and in most cases, the various endometriosis types (ovarian, peritoneal and 
deep infiltrating) were pooled together. Various techniques were used (RT-qPCR, 
immunohistochemistry, enzyme activity assay). Overall, no clear conclusion could be drawn for 
these studies. Comparing endometriosis with controls, CYP19A1 was up-regulated (six studies), 
unchanged (three studies) and one study found no expression of this gene. With respect to 
oxidative and reductive 17βHSDs, 17βHSD1 was reported up-regulated (three studies), 
17βHSD2 was reported down-regulated or unchanged and two studies reported an up-
regulation of 17βHSD7 and 12 in endometriosis versus controls [283]. 
Subsequent investigations also continued to report inconsistent results. No change in mRNA 
[148] or increased expression of CYP19A1 in ovarian endometriosis versus controls [181] were 
reported. An increased expression of CYP19A1 was also described using in vitro spheroids 
derived from endometrial stroma cells from patients compared with controls [228]. 
The mRNA expression of 17βHSD1 was higher in endometriosis compared with normal tissue 
using patient biopsies as well as spheroid cultures derived from endometrial stroma cells of 
patients and controls [148, 228]. One study assessing the three endometriosis types separately 
(60 patients in total) described that the increased 17βHSD1 level was restricted to 
endometrioma during the secretory phase of the menstrual cycle [181], whereas a second 
study on 79 patients and 41 controls, found no change in 17βHSD1 level, but described an 
increased 17βHSD1/2 ratio [226]. 
Regarding 17βHSD2, recent investigations reported both unchanged [148] and down-
regulated mRNA in patient biopsies compared with controls [181, 226]. No variations were 
found in 17βHSD4, 5, 7 and 12 [148, 178] but an increased level of 17βHSD6 mRNA was 
detected in endometriosis compared with controls [181]. 
A few studies reported detectable levels of the enzymes involved in the generation of DHEA 
from cholesterol (StAR, CYP11A1 and CYP17A1) in endometriosis [37, 54-56, 173-175], 
suggesting that, in contrast to eutopic endometrium, endometriosis is able to produce steroids 
from cholesterol. However, it has also been argued that the presence of paracrine confounders 
of ovarian origin in studies using endometriomas could bias the results [284].  
The contribution of STS, SULT1E1 and other SULTs was investigated by numerous studies and 
also in this case, conclusions are unclear (recently reviewed, [6]. A recent investigation 
enrolling 78 specimens, described increased STS levels in endometriosis versus control samples 
and found that the overall balance between STS and SULT1E1 differed between eutopic and 
ectopic tissue, implying an unbalanced flux of sulpho-conjugated estrogens in this disease 
[248]. The same research group also described an aberrant regulation of the enzymes involved 
in the estrogen oxidative metabolism in endometriosis [285]. 
Although the level of the single enzymes in the intracrine machinery varies with apparently no 
clear association with the disease condition, the intracrinological nature of endometriosis was 
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recently proven by comparison between serum and tissue levels of steroids in 60 patients 
(eutopic and ectopic endometrium) and 16 controls. Although E2 changed cyclically in eutopic 
tissue, E2 levels remained constant in the lesions and inversely correlated with the mRNA level 
of 17βHSD2 and 17βHSD6 suggesting an impairment in E2 deactivation to E1. P levels were 
equal in serum and control tissues, but resulted higher in patients and correlated with high 
3βHSD2 mRNA. T, low in the tissue of controls, was over 13-times more concentrated at 
ectopic locations and correlated with low expression of SRD5A3 [56, 181].  
 
Endometrial cancer (EC) 
EC is the most common gynaecological malignancy in western society and 80% of all cases are 
estrogen-driven [286, 287]. Major serum steroids are increased in patients with EC, including 
several substrates for intracrine E2 synthesis [183, 288]. In addition, tissue-steroid levels differ 
between cancer, normal tissue and serum and correlate with the levels of specific intracrine 
enzymes (see below) [243]. 
A systematic review recently explored all studies published between 1990 and 2017 assessing 
the expression of 17βHSD1, 2, STS, SULT1E1 and CYP19A1, with results that describe 
unbalanced intracrine regulation and important inter-patient variability [289]. Most studies 
compared cases with controls or tumour tissue with adjacent normal endometrium. Compared 
with normal tissue (from controls or adjacent to tumour), 17βHSD1 was found increased in EC 
[182], decreased [23, 183] and undetected [214, 290]; 17βHSD2 was found decreased [246, 
290] or increased [175, 182, 183]; AKR1C3/17βHSD5 was found unchanged [175, 182], 
increased [291] and decreased [239]; 17βHSD7 both decreased [23] and unchanged [182, 183] 
and 17βHSD12 was unchanged [23, 182] or increased in tumours versus controls [183]. One 
recent report described decreased 17βHSD14 levels in tumour compared with adjacent tissue 
[184]. Controversial results apply to CYP19A1, described as increased [23, 176, 214, 246] and 
unchanged [182, 186, 206]. STS/SULT1E1 expression is also inconsistent in different studies 
(recently reviewed in [6, 15]. 
Recent studies exploring the association between enzyme levels and tumour characteristics 
found a correlation between STS with tumour grade and lymphovascular invasion [184] and 
described an association between high CYP19A1 or 17βHSD1 and poor patient prognosis [36, 
292].  
Other investigations emphasised the potential antiestrogenic and protective roles of 
androgens and P. Formation of DHT (via conversion of A4 to T by AKR1C3/17βHSD5 and of T 
to DHT by SRD5As) has potential antiestrogenic action because it devoids tissue from T 
(substrate of CYP19A1 yielding E2) and because it has direct endometrial antiproliferative 
effects via AR [291]. Similar to the AKR1C3/17βHSD5 data reported earlier, results on SDR5A 
expression are inconclusive as SRD5A2 was down-regulated in a study on 47 tumour specimens 
compared with adjacent normal tissue [175], but both SRD5A1 and SRD5A2 resulted 
unchanged in another study on 122 tumours (although only five controls were studied) [243]. 
This last study found however increased androgen levels (T and DHT) in tissue versus blood. 
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High DHT levels were restricted to samples with high SRD5A1 immunohistochemical staining. 
In addition, AR and SRD5A1 positivity was associated with good patient prognosis [243]. The 
prognostic value of AR is confirmed by independent investigations [293]. 
P is well-known for its antiestrogenic action, PR positivity is a good prognostic marker [294] 
and P synthesis and metabolism are disturbed in EC [175]. Interestingly, in a study on 47 
tumours and adjacent normal tissues, EC had decreased StAR and CYP11A1 mRNA levels, 
indicative of diminished de novo steroid synthesis [37, 175]. At the same time, EC showed 
decreased SRD5A2 and increased 17βHSD2 indicative of a diminished rate of conversion of P 
to 5αDHP and of 20αDHP to 5α-pregnan-20-ol-3-one, but increased conversion of 20αDHP to 
P (see Figure 2). 
 
Other endometrial/gynaecological disorders 
Although literature is scarce, a potential role of intracrinology is postulated for ovarian cancer 
[291], for adenomyosis and fibroids [6], for sarcoma, where CYP19A1 expression may have 
prognostic significance [197] and among infertile women [187].  
 
Intracrine drug targets 
Endometriosis: blocking the systemic estrogen signalling via P, or GnRH agonist is standard care 
[277]. Blocking the intracrine E2 generation is the future approach with on-going 
preclinical/clinical research. 
STS inhibition showed promising results. Irosustat (Table III) inhibited up to 100% the formation 
of free steroids using ex-vivo material from 27 patients [207] and STS inhibition showed good 
results in a mouse model of endometriosis, where decreased size and weight of the lesions 
was observed [295]. A phase-I clinical trial on 24 volunteers proved the safety of the STS 
inhibitor E2MATE (PLG2001), which reduced STS activity by over 90% and induced changes in 
endometrial markers (both alone or co-administered with norethindrone acetate) [160]. 
Inhibitors of 17βHSD1 are in preclinical phase, and promising results are described using a 
primate model of endometriosis, where decreased behaviour/pain symptoms were reported 
[147] and using ex-vivo material from endometriosis patient (over 70% of the patients showed 
over 80% of enzyme inhibition) [148].  
AKR1C3/17βHSD5 inhibition can interfere with E2, androgen synthesis, and reduce 
prostaglandin-associated inflammation/proliferation and an inhibitor has recently entered a 
phase II trial for endometriosis (Table III). Overall, AIs have limited efficacy for endometriosis 
[296, 297], 
 
EC: only in case of advanced stage/metastatic disease hormonal care is given (progestogen, 
tamoxifen or AIs). AIs alone have limited efficacy with low response rates [161-163]. Promising 
data were obtained using dual regimen (AI and mTOR inhibitor [164]) and additional trials on 
combinatory regimen are on-going. STS inhibitors showed promising results in a mouse 
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subcutaneous model of EC, with decreased tumour growth by 48-67% [298]. However, a phase 
II trial on advanced stage EC was stopped because of the absence of added benefit compared 
with progestogen treatment [49, 157].  
Preclinical studies on 17βHSD1 inhibitors showed promising results in a mouse model of 
endometrial hyperplasia [79, 299] and in various models of EC [300].  
 
Endometrium: conclusions 
The ability to synthesise DHEA from cholesterol (reported by few studies) needs confirmation. 
However, the endometrium possesses the enzymatic machinery to metabolise sulphated-
compounds and DHEA and form androgens and estrogens, (although this contention is 
wrangled by other authors [21, 22]. Further, the endometrium can metabolise androgens and 
progestogens via AKR1Cs and SRD5As to produce a wide range of compounds, including 
estrogens (Table VI and Figure 3). The morphological changes during the menstrual cycle are 
accompanied by cyclic changes in intracrine steroid and enzyme levels, indicating that steroid 
exposure needs to be cyclically regulated to support endometrial physiology.  
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Figure 3. Effect of steroids (mainly estrogens) and intracrine networks in central nervous system, lungs, digestive 
system, uterus and bone  
Italics and by brackets are those metabolism/reactions that need conformation by independent authors (because 
validated at the mRNA level only or in few studies).  
* EC: epithelial cells. 
** SMC: smooth muscle cells. 
# Chol: cholesterol  
The drawing was kindly generated by Margaretha A. Skowron (Department of Urology, University Düsseldorf, 
Germany) for this review. 
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Lungs 
Sex steroids play an important role in lung development and homeostasis. Androgens, 
progestogens and estrogens are present and exert genomic and non-genomic actions via their 
hormone-receptors. Classical ERs (with ER as predominant form) and membrane GPER are 
expressed [149, 301, 302]. Sex steroids remain active in the lung throughout lifetime and 
modulate lung function in both a beneficial or detrimental way, extensively reviewed [303-
305].  
E2 and P regulate epithelial sodium channel expression in alveolar epithelial cells [306]. In 
alveolar smooth muscle cells, E2 induces bronchodilation via the reduction of intracellular Ca2+ 
[307]. 
Both human and animal studies support a promoting role for estrogens and inhibitory role for 
androgens in lung development and maturation. During gestation and neonatal period AR is 
expressed in mesenchymal and epithelial cells. Androgens inhibit the production of surfactants, 
which starts later in male than in female neonatal lungs [308], but also support the developing 
lung during branching morphogenesis [309]. 
 
Lung intracrinology in lungs – systematic search 
Adult human lungs express CYP19A1 and most 17βHSDs (1, 2, 4, 7, 8, 11, 12, 17βHSD5/AKR1C3; 
Table VII). STS, SULT and 17βHSD1, 12 and 17βHSD5/AKR1C3 immunoreactivity localises in the 
bronchial epithelium (weak for types 1 and 12, strong for type 5) and alveolar macrophages 
[24, 43, 149, 310].  
Intracrinology controls lung development and maturation as shown in various animal models 
[311] and intracrine enzymes are expressed already during foetal stages. Human foetal lungs 
possess StAR, CYP11A1, 3βHSD1 mRNA [312], SULT1E1 activity [313] and show 17βHSD1 and 
2 mRNAs expression at 13 and 20 weeks of gestational age [314]. High mRNA levels of AR, 
17βHSD2 and 17βHSD5/AKR1C3 in mid-late gestation period and adult lungs indicate the 
present of androgen metabolism [315]. Immunoreactivity for 17βHSD11 is detected in 
bronchioles of 14 and 31 weeks old foetuses, whereas other structures are negative (e.g. 
alveoli, ciliated epithelium, acini of the trachea). The expression of 17βHSD11 increases during 
the second half of pregnancy and maintains similar patterns in neonatal (14 days) and adult 
lugs [316]. 
 
Table VII. Expression of intracrine enzymes the lungs – results of the systematic search 
Gene 
Detection 
Lung Reference 
molecule technique# 
StAR mRNA  RT-PCR yes^ [312] 
CYP11A1 mRNA  RT-PCR yes^ [312] 
  Comp-RT n.d.  
 Protein  WB   
CYP17A1 mRNA  RT-PCR no^ [312] 
  RT-PCR --  
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 Protein  WB n.d.  
  IHC n.d.  
  Activity n.d.  
CYP19A1 mRNA  RT-PCR yes [149, 312, 317, 318] 
  Comp-RT n.d.  
  ISH n.d.  
 Protein  IHC yes [149, 319-321] 
  ELISA yes [317, 322, 323] 
  Activity yes [321] 
3βHSD1 mRNA  RT-PCR yes^ [312] 
3βHSD2 mRNA  RT-PCR no^ [312] 
17βHSDs   
HSD17B oxidative activity n.d.  
HSD17B reductive activity n.d. [54-56] 
17βHSD1 mRNA  RT-PCR yes [149, 314, 324] 
  Comp-RT n.d.  
 mRNA  ISH n.d.  
17βHSD1 Protein  Comp-RT n.d.  
  IHC yes [149, 320, 324] 
  WB yes [324] 
17βHSD2 mRNA  RT-PCR yes [149, 314, 315] 
  Comp-RT n.d.  
  NB n.d.  
 Protein  IHC yes [320] 
  WB n.d.  
17βHSD3 mRNA  RT-PCR n.d.  
  Comp-RT n.d.  
17βHSD4 mRNA  RT-PCR yes [149] 
  Comp-RT n.d.  
  NB yes [35] 
17βHSD6 mRNA  RT-PCR   
17βHSD7 mRNA  RT-PCR yes [39, 149] 
17βHSD8 mRNA  RT-PCR yes [40] 
17βHSD9 mRNA  RT-PCR n.d.  
17βHSD10 mRNA  RT-PCR n.d.  
 Protein  IHC n.d.  
  C-ELISA n.d.  
17βHSD11 mRNA  RT-PCR yes [42] 
 mRNA  NB yes [42] 
 Protein  IHC yes [316] 
17βHSD12 mRNA  RT-PCR yes [43, 149] 
 mRNA  NB yes [43] 
 mRNA  NB n.d.  
 Protein  IHC Yes$ [43] 
AKR1Cs     
AKR1C activity   n.d.  
AKR1C1 mRNA  RT-PCR n.d. 
 
AKR1C2 mRNA  RT PCR n.d.  
  Comp-RT n.d.  
AKR1C3 mRNA  RT PCR yes [149, 315] 
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  Comp-RT n.d.  
  NB n.d. [46] 
 Protein  IHC yes [24, 310] 
AKR1C4 mRNA  RT-PCR n.d.  
  Comp-RT n.d.  
SRD5As     
SRD5A1 mRNA  Comp-RT n.d.  
 Protein IHC yes [325] 
  activity n.d.  
SRD5A2 mRNA  Comp-RT n.d.  
 Protein IHC yes [325] 
Sulphatase pathway   
STS mRNA  RT-PCR yes [149] 
  RT-PCR no [47] 
 Protein  IHC yes [326] 
  IHC no [47] 
  Activity yes [327, 328] 
SULT1E1 mRNA  RT-PCR yes [47, 149] 
  RT-PCR n.d.  
  NB n.d.  
 Protein  IHC yes [47, 326] 
  IHC --  
  WB yes [329] 
  Activity yes [313]  
SULT2A1 mRNA  RT-PCR n.d.  
 Protein  IHC yes [329] 
  Activity n.d.  
SULT1A1 mRNA  RT-PCR n.d.  
 Protein  IHC n.d.  
  WB yes [329] 
SULT2B1 mRNA  RT-PCR yes [330, 331] 
  NB yes [330, 331] 
  NB no [332] 
 Protein  IHC yes [330, 331] 
Primary/original references were analysed and reviews were excluded (and are cited ad hoc in the text). The 
table report only the enzymes whose expression was assessed in reviewed studies**. 
 
# Technique abbreviations. For mRNA detection, NB: northern blot; ISH: in situ hybridisation; RT-PCR: reverse 
transcription quantitative (or semi-quantitative) PCR; Comp-RT: competitive RT-PCR assay; NB: northern 
blotting. For protein detection: IHC: immunohistochemistry; C-ELISA: competitive ELISA assay; WB: western 
blotting; activity: enzyme activity measurement. 
* CYP11A1 and CYP17A1 activities were detected in primary cells of bone. 
** No publication was found describing the expression of 17βHSD13, 14, 15 and DHRS11. 
^ Detected in foetal lung tissue. 
$ IHC signal in bronchial epithelium. 
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Intracrinology and lung diseases  
Altered intracrinology is involved in lung disorders already from neonatal stages towards 
adulthood, and SNPs in intracrine genes are associated with the onset of disease [122]. Higher 
concentration of estrogens were measured by LC-MS in women with multiple-synchronous-
lung adenocarcinoma compared with single adenocarcinoma [333] and in neoplastic tissue 
compared with adjacent normal lungs [320, 334]. Type 1 17βHSD mRNA, protein and activity 
are present in various non-small-cell-lung-cancer (NSCLC) cell lines where the mitogenic effect 
of E1 is abrogated by 17βHSD1 knockdown [320, 335]. In specimens from 48 NSCLC patients, 
17βHSD1 expression was associated with squamous cell carcinoma and stage 3A disease [324]. 
In another study on 103 NSCLC specimens, high 17βHSD1 immunoreactivity was associated 
with low intratumoural E1 and high E2:E1 ratio, whereas higher 17βHSD2 immunoreactivity 
was associated with high intratumoural E1. Multivariate regression analysis also demonstrated 
that increased 17βHSD1 immunoreactivity in tumours was an independent negative prognostic 
factor [320].  
CYP19A1 is expressed in lung cancer and has potential therapeutic value [319, 334, 336]. A 
recent IHC study on 335 NSCLC specimens found an inverse association between CYP19A1 
expression with disease specific survival [322]. Similar data, although restricted to women only, 
were confirmed in an independent study on 150 primary lung adenocarcinoma specimens, 
where CYP19A1 was found as the main driver of local estrogen supply [323]. Another study on 
110 lung adenocarcinoma specimens found an association between CYP19A1 mRNA (RT-qPCR) 
and poor prognosis in females, never-smokers and harbouring EGFR mutations [318]. However, 
a recent mRNA study on 96 NSCLC patients showed that CYP19A1 in combination with ER is a 
good prognostic marker [317]. 
STS and SULT1E1 immunoreactivity is detected in the majority of NSCLC cases, and STS is a 
good prognostic marker [326]. 
Lymphangioleiomyomatosis (LAM) is a rare, potentially fatal disease affecting predominantly 
young women. It is strongly hormone sensitive and it is hypothesised to originate from the 
uterus as lung metastasis [337]. The levels of ERs, PR, AR, CYP19A1, STS, 17βHSD1 and SRD5A2 
were recently assessed among 30 LAM biopsies. CYP19A1 expression resulted a useful 
classification marker with implication for potential therapy [338]. A recent study on specimens 
from 73 patients with chronic obstructive pulmonary disease (COPD) and 48 controls described 
an association between both CYP19A1 and 17βHSD1 with COPD [149]. CYP19A1 is also 
implicated in interstitial pneumonia interstitial pneumonia, where local E2 concentration and 
CYP19A1 activity and immunoreactivity were elevated in diseased compared with normal 
tissue [321].  
 
Potential novel treatments 
Blocking the estrogen signalling showed promising preclinical results in animal models of lung 
cancer [336]. In humans, antiestrogen treatments (ER antagonists, GnRH, oophorectomy, P) 
have been used in LAM [339] and lung cancer patients  [318, 336]. A phase II study on advanced 
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NSCLC patients non-responsive to platinum-based drugs tested the dual-regimen 
mTOR/CYP19A1 inhibitors. Unfortunately, this study was prematurely terminated due to high 
toxicity [340] and one additional trial using ER antagonist plus AI (fulvestrant and anastrozole) 
as consolidation therapy in postmenopausal women with advanced NSCLC (NCT00932152) was 
terminated due to poor recruitment. 
Better results were obtained using the AI letrozole as single agent or in combination with 
rapamycin in a phase II trial on 17 postmenopausal women with LAM (NCT01353209). AI 
treatment was safe and well tolerated also in the dual drug regimen [165].  
 
Lungs: conclusions 
Steroids are involved in lung maturation, development and in susceptibility to diseases. Most 
17βHSDs, STS/SULT1E1, CYP19A1 are expressed indicating the lung’s ability to metabolise 
androgens, estrogens and progestogens. Evidence of 3βHSDs is limited to foetal tissues (Table 
VII and Figure 3). Approaches aimed at decreasing local estrogens may offer future novel 
treatments for various lung diseases. 
 
Conclusions & recommendations 
Intracrinology consists of a complex and intricate network of alternative and redundant 
pathways that generate, deactivate steroids in peripheral tissues and ultimately control steroid 
exposure in a tissue specific manner. A number of compunds have that ability to bind and 
activate more than one nuclear receptor thus exerting multiple biological actions. Blood 
steroids represent a reservoir of substrates that support these intracrine networks. Studies 
retrieved by the systematic search demonstrated that most investigations rely on RT-PCR or 
IHC to detect enzyme and protein, and frequently without multiple-techique confirmation of 
the data. Since both techniques present limitations, and antibodies for IHC often perform sub-
optimally (detection limit is not sufficient to detect some intracrine enzymes, crossreacivity 
between isofomrs) these techniques are not always suitable to infer the real biological role of 
a reaction/enzyme. 
However, the recent technological advances in steroid profiling together with an improved 
knowledge of intracrine enzymes and to possibility to validate data using multiple approaches 
(RNA, protein, activity, steroid profiling) create today unprecedented opportunities to expand 
our understanding of intracrinology, its relation with endocrinology and to exploit this 
knowledge in patient care. Improved multiplex platforms allowing to profile in peripheral 
tissues all steroids depicted in Figure 2 are awaited and will elucidate the relevant tissue-
specific networks. It is envisaged that novel prognostic markers and drug targets will become 
of clinical relevance soon. 
We should however be aware that the redundant actions of intracrine enzymes, their substrate 
promiscuity, the existence of alternative pathways and the patient-to-patient variability might 
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result in drug insensitivity. Dual/triple inhibitors will help solving this problem. In addition, in 
order to optimise research on novel drugs, the classical preclinical drug discovery pipelines 
(safety, pharmacokinetics and dynamics), should encompass parallel research lines to learn 
how to pre-select potentially responsive patients.  
Finally, since we know that steroidal and intracrine drugs have a profound effects on the CNS, 
in order to avoid halting drug development during the clinical phases because of the 
occurrence of unwanted (and unpredicted) side effects (causing large loss of resources), it is 
desirable that the preclinical phases will be accompanied by in depth research on the 
neurological effects of potential novel drugs. 
 
  
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Nomenclature of compounds and enzymes can be variable between different sources, and such 
abundance of synonymous terms can be sometimes misleading. Two panels presented as 
supplemental materials report the most commonly used synonyms for compounds and for enzymes: 
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Abstract 
The enzyme type 1 17β-hydroxysteroid dehydrogenase (17β-HSD 1), responsible for 
generating active 17β-estradiol (E2) from low-active estrone (E1), is over-expressed in 
endometrial cancer (EC) thus implicating an increased intra-tissue generation of E2 in this 
estrogen-dependent condition.  
In this study we explored the possibility of inhibiting 17β-HSD 1 and impairing the generation 
of E2 from E1 in EC using in vitro, in vivo and ex vivo models.  
We generated EC cell lines derived from the well-differentiated endometrial adenocarcinoma 
Ishikawa cell line and expressing levels of 17β-HSD 1 similar to human tissues. In these cells, 
HPLC analysis showed that 17β-HSD 1 activity could be blocked by a specific 17β-HSD 1 
inhibitor. In vitro, E1 administration elicited colony formation similar to E2, and this was 
impaired by 17β-HSD 1 inhibition. In vivo, tumors grafted on the chicken chorioallantoic 
membrane (CAM) demonstrated that E1 upregulated the expression of the estrogen 
responsive cyclin A similar to E2, which was impaired by 17β-HSD 1 inhibition. Neither in vitro 
nor in vivo effects of E1 were observed using 17β-HSD 1 negative cells (negative control). 
Using a patient cohort of 52 primary ECs, we demonstrated the presence of 17β-HSD 1 enzyme 
activity (ex vivo in tumor tissues, as measured by HPLC), which was inhibited by over 90% in 
more than 45% of ECs using the 17β-HSD 1 inhibitor. Since drug treatment is generally 
indicated for metastatic/recurrent and not primary tumor, we next demonstrated the mRNA 
expression of the potential drug target, 17β-HSD 1, in  metastatic lesions using a second cohort 
of 37 EC patients. 
In conclusion, 17β-HSD 1 inhibition efficiently blocks the generation of E2 from E1 using various 
EC models. Further preclinical investigations and 17β-HSD 1 inhibitor development to make 
candidate compounds suitable for the first human studies are awaited. 
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Introduction 
Endometrial cancer (EC) is the most frequent gynecological malignancy in the Western world 
[1]. About 80% of all cases are estrogen-dependent type-1 endometrioid endometrial 
carcinoma, characterized by low-grade histology and hormone receptor expression. Most of 
these patients present with complaints of abnormal uterine bleeding, are diagnosed at early 
stage and have a favorable outcome after surgery (hysterectomy with bilateral salpingo-
oophoretomy). Yet, advanced stage or recurrent EC patients have limited treatment options. 
Obesity, early menarche, nulliparity, late menopause and use of tamoxifen are associated with 
estrogen exposure (systemic) and are risk factors for EC, especially type 1 [1, 2]. In addition, 
local estrogen synthesis through 17β-hydroxysteroid dehydrogenases (17β-HSDs) also 
contributes significantly to estrogen exposure in endometrial cells [3, 4]. Reductive 17β-HSDs 
catalyze the conversion of the low-active estrone (E1) to active 17β-estradiol (E2), whereas 
oxidizing 17β-HSDs catalyze the oxidation of E2 to E1 [3, 5].  
In a previous study, we showed that 17β-HSD reductive activity was increased in EC versus 
both normal tissue adjacent to the tumor and healthy postmenopausal endometrium. This was 
mainly due to the reductive 17β-HSD type 1, whose mRNA was up-regulated in EC versus 
controls [3].  
Based on these results we hypothesized that 17β-HSD type 1 could be of therapeutic value in 
EC. In the present study, a well characterized 17β-HSD type 1 inhibitor (FP4643) was tested 
using in vitro and in vivo models based on the Ishikawa endometrial cancer cell line (modified 
to express 17β-HSD 1) and ex vivo on patient specimens. 
 
Materials and Methods  
Ethical Statement 
Procedures were conducted in accordance with ethical standards, national guidelines, and 
international guidelines according to the Declaration of Helsinki and were approved by the 
local ethics authority (METC 14-4-003). 
 
Ishikawa cell line, plasmids, stable transfection 
The estrogen receptor (ERα) and progesterone receptor (PR) positive and estrogen-dependent 
human endometrial adenocarcinoma cell line Ishikawa (ECACC, Sigma-Aldrich, Zwijndrecht, 
The Netherlands) was routinely cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) 
supplemented with sodium-pyruvate, L-glutamine, penicillin-streptomycin and 10% fetal 
bovine serum at 37 °C with 5% CO2 in humidified air. Ishikawa cells do not express 17β-HSD 
types 1 or 2 and are devoid of 17β-HSD reductive and oxidative activity (results not shown). 
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To generate Ishikawa clones expressing 17β-HSD type 1, cells were subjected to two rounds of 
genetic modification. In the first round, the reporter gene luciferase was introduced. Lentiviral 
particles were produced as described previously [6]. Ishikawa cells were transduced with a 
construct harboring a CMV-driven firefly luciferase cDNA (Photinus pyralis) and fused by 2TA 
peptide to a green fluorescent protein (GFP from Pontellina plumata). Clones from single cells 
were retrieved using cloning cylinders and expanded. To avoid clone specific effects, a number 
of lines originated from single clones were characterized for the expression of luciferase, GFP, 
ERα and for estrogen responsiveness (not shown). Two clones were selected for the second 
round of genetic modification (Ishi-M1 and Ishi-M3), and were stably transfected with the 
plasmid pCEP4 containing the 17β-HSD type 1 cDNA [7] or with the empty vector. Transfection 
was performed as described [3] using the jetPEI reagent (Q-Biogene, Heidelberg, Germany) 
and hygromycin-B (Invitrogen, Carlsbad, CA, USA) for selection. Clones originating from single 
cells were isolated by serial dilutions in 96-well plates and microscopic examination. This 
procedure was repeated twice. 
A number of clones was further thoroughly characterized by reporter gene assay, RT-qPCR, 
western blot, enzyme activity and growth rate analyses to confirm they maintained reporter 
gene expression, cytological and molecular characteristics of the parental Ishikawa cell line. 
Clones Ishi-M1-HSD-B, Ishi-M3-HSD-A (17β-HSD type 1) and clone Ishi-M3-EV-C (empty vector 
control) were used for further experiments. A full description and characterization of these 
lines is given in Supplementary materials and methods and Supplementary Figures S1 and S2. 
The authenticity of clones Ishi-M1-HSD-B and Ishi-M3-HSD-A was confirmed by short tandem 
repeat analysis (STR).  
 
Cell treatment in vitro with estrogens and inhibitor 
Three days before and during experiments with steroid stimulations, cells were cultured in 
RPMI 1640 (without phenol-red) containing sodium-pyruvate and L-glutamine, and 
supplemented with 5% hormone-stripped serum (c.c.pro GmbH, Neustadt, Germany). Cells 
were treated with either 0.1 nM E1 (Sigma Aldrich, Zwijndrecht, The Netherlands) or with 
combination of 0.1 nM E1 with 500 nM 17β-HSD type 1 inhibitor FP4643 (Forendo Pharma Ltd. 
Turku, Finland). This inhibitor has been previously thoroughly described and characterized [8-
11]. As a positive control, 0.1 nM E2 (Sigma Aldrich, Zwijndrecht, The Netherlands) was used. 
Vehicle or compound FP4643 alone were considered negative controls. 
 
17β-HSD type 1 inhibitor - FP4643 
Compound FP4643 is an estrone-substitute at the 15th carbon position (3-hydroxy-15-(4-
morpholin-4-yl-4-oxo-butyl)-estra-1,3,5(10)-trien-17-one) described by Messinger and 
coworkers as compound 21 [11]. This compound is thoroughly characterized by the 
manufacturer (Forendo Pharma Ltd. Turku, Finland) and subsequent studies (compound 3 in 
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reference [10]) for being potent and specific inhibitor of the 17β-HSD type 1, with little affinity 
toward the other 17β-HSDs and toward ERα. This inhibitor has been previously thoroughly 
described and characterized using in vivo models [8, 9]. 
 
Colony formation assay 
Ishi-M1-HSD-B, M3-HSD-A and M3-EV-C clones were seeded into 6-well plates at a density of 
3,000 cells/well. Treatments were performed in triplicate in each experiment. After incubation 
for 10-14 days, cells were washed with 100 mM phosphate buffer saline (PBS) pH 7, fixed with 
3.7% paraformaldehyde for 10 minutes and stained with 1% crystal violet (Millipore B.V., 
Amsterdam, The Netherlands) for 30 min. Pictures were taken and the total colony area was 
determined using ImageJ software (National Institutes of Health, Bethesda, MD, USA).  
 
Chicken chorioallantoic membrane (CAM) assay  
The CAM assay, initially used in angiogenesis research, is becoming increasingly more popular 
in other research areas. CAM contains extracellular matrix (ECM) proteins, and mimics the 
physiological cancer cell (micro)environment [12], and is a suitable and versatile model in 
cancer biology and pharmacological research [13]. 
The CAM protocol was described earlier [13, 14]. In brief, fertilized white leghorn chicken eggs 
were incubated at 37 °C with 45% humidity for three days and tilted every 30 min. To expose 
the chorioallantoic membrane (CAM), a 1.5 cm2 hatch was made in the eggshell on embryonic 
day four (E4). On E7, the CAM was irritated with lens paper and 0.5 cm (diameter) sterile 
silicone rings were placed directly onto the CAM. Next, tumor grafts were seeded by 
suspending two million cells (Ishi-M1-HSD-B, M3-HSD-A or M3-EV-C) in 25 µl matrigel (Corning, 
New York, USA). Two grafts were made per egg. From E8 till E13 the CAMs were treated 
topically daily (by dropping the treatment on the top of the CAM) with no stimulation (vehicle 
alone), 1.0 nM E2, 0.1 nM E1, E1 (0.1 nM) plus FP4643 (2500 nM or as indicated) or FP4643 
alone. The vehicle consisted of 0.9% NaCl, 25% ethanol and 1% DMSO. Treatments were 
applied on the CAM as 40 μl solutions (containing 500X concentrated stimuli) and final 
concentrations were calculated based on the total volume of the egg (e.g. approximately 18-
20 ml per egg). On E14, the tumor grafts with adjacent CAM were harvested, fixed with 
formalin for 30 min and embedded in paraffin for immunohistochemical analyses. 
 
Histology, cytology and immunohistochemical analyses 
Four m-thick sections of formalin-fixed paraffin-embedded (FFPE) CAM tissue were cut and 
then stained using hematoxylin & eosin (Sigma-Aldrich, Zwijndrecht, The Netherlands) for 
evaluation of the histology. For immunohistochemical analyses, slides were baked for 20 min 
at 80 ˚C on a heat plate and deparaffinized then by rehydration. Next, the endogenous 
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peroxidase activity was quenched with H2O2 (3% in methanol) and heat-induced antigen 
retrieval was performed in Tris-EDTA buffer pH 9. Non-specific antibody binding was blocked 
using 5% goat serum for Cyclin A, 17β-HSD 1 and PR detection, followed by overnight 
incubation at 4 ˚C with the following antibodies: sc-23900 for Ki-67 (1:50), sc-751 for Cyclin A 
(1:500), B-30 for PR (1:50; all from Santa Cruz Biotechnologies, Heidelberg, Germany), EP1682-
Y for 17β-HSD 1 (1:100; Epitomics, California) and D5 for ER-α (1:100; Dako, Glostrup, 
Denmark). To visualize antibody binding, avidin/biotin-based peroxidase system (Vectastain 
ABC-kit, Vector laboratories, Peterborough, UK) and diaminobenzidine (DAB; Dako, Glostrup, 
Denmark) were used according to manufacturer’s recommendations. Sections were 
counterstained with hematoxylin (Merck, Darmstadt, Germany). The Allred method with slight 
modifications [3] was used to quantify the immunoreactivity by three independent observers 
(KvK, GFJK and AR) who were blind to each other’s results: staining intensity (I) was graded 
from 0 to 3, percentage of positive cells (P) from 0 to 5. Final score was computed by 
multiplying I X P. 
 
Patient specimens 
Cohort one: tumor biopsies were obtained from 52 women undergoing hysterectomy for 
uterine cancer (47) or endometrial hyperplasia (5) and hospitalized at Maastricht University 
Medical Centre between 2008 and 2015. Clinical characteristics, surgical and follow-up care 
are described in supplementary material, Table S1. Biopsies were immediately frozen in liquid 
nitrogen and kept at -80 ˚C for further processing. None of the patients had used hormonal 
medication within the last six months prior to surgery. The study protocol was approved by the 
Local Ethical Committee (protocol no. METC 14-4-003) and the harvesting of pathology 
material was approved by the Maastricht Pathology Tissue Collection committee (protocol no. 
MPTC 2012-03). 
Cohort two: a second patient cohort consisting of a subpopulation of 37 patients with 
metastatic uterine cancer from a population-based series prospectively collected in Hordaland 
county in Norway from 2001 to 2014 was used for mRNA analyses of 17β-HSD 1. The patient 
cohort and gene expression analyses has been previously described [15]. 
 
Frozen tissue processing 
Frozen biopsies were processed for further analyses (RNA isolation and ex vivo 17β-HSD 1 
activity measurement and inhibition) as described previously [3, 8]. In brief, 10 m-thick cryo-
sections were cut, and 10 sections were used for RNA isolation by immediate homogenization 
in TRIzol reagent (Invitrogen, Carlsbad, CA, USA); 10 sections were used for enzyme activity by 
homogenization in MPER buffer (Promega, Mannheim, Germany) just prior to use. The 
presence of endometrial cancer in the biopsies was confirmed by histology that was performed 
at the start, the end and approximately at every 100 m thickness of the material cut for lysate 
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preparation. The histology and tumor grading was determined by an expert 
gynaecopathologist (LK). 
 
17β-HSD enzyme activity and inhibition ex vivo (cell-free assays) 
Methods were as described previously [3, 8, 16]. In brief, fresh homogenates prepared in MPER 
buffer (see frozen tissue processing) were cleared from debris (centrifugation) and protein 
concentration was determined (BC Assay Protein Quantitation Kit, Uptima-Interchim, 
Montlucon, France). Reactions (0.5 ml final volume in 50 mM KH2PO4, pH 7.4 and 
supplemented with 3.3 mM magnesium chloride) were carried out at 37 °C for 24 h using 10–
20 μg of protein lysates, 10 nMol E1 (in the presence or absence of 0.5 μM FP4643), 2.0 mM 
NADP+ and the NADPH-regeneration system based on glucose-6-phosphate (3.3 mM) plus 
glucose-6-phosphate dehydrogenase (2.5 U/ml). Steroids were derivatized with a fluorescent 
moiety, measured by HPLC (LC-10AD), and analyzed using Labsolutions software (Shimadzu, 
Kyoto, Japan). 
 
mRNA expression levels  
Patient cohort one: mRNA levels for ERα (ESR1) and 17β-HSD 1 (HSD17B1) were measured by 
RT-qPCR, normalized to three reference genes and expressed as relative values 
(supplementary materials, Materials and Methods). For ESR1, a threshold for positivity in each 
biopsy was determined based on the detection of ERα by immunohistochemistry/fluorescence 
in the same sample, which was performed on 12 biopsies analyzed in a previous study [3] and 
common to the present  investigation. Type 1 17β-HSD (HSD17B1) mRNA levels were clustered 
in two quantiles, one with low expression (n=17) and one with high expression (n=16; RNA was 
not available for 19 samples). 
Type 1 17β-HSD enzyme activity is expressed as nMol E2/mg protein and showed good 
correlation (r2=0.8) with the enzyme activities measured in a previous study [3] using biopsies 
from 13 patients common to the present investigation (data not shown). Enzyme activity levels 
were analyzed both as continuous variables as well as tertiles consisting equal number of 
samples.  
Patient cohort two: the mRNA level for 17β-HSD 1 was derived from microarray analyses 
performed previously [17-19]. In brief, RNA was extracted from fresh frozen tumor tissue, 
hybridized to the cDNA array (Agilent Whole Human Genome Microarray Kit, 44K) according 
to the manufacturer instructions (www.agilent.com). Arrays were scanned using the Agilent 
Microarray Scanner Bundle. Median spot intensity was used to define the intensity signal and 
expression data were quantile-normalized and log2-transformed. Expression data for 17β-HSD 
1 was extracted using max probe (Probe name A_24_P56833). 
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Statistics 
SPSS (version 23, IBM Chicago, IL, USA) was used for data analysis. Comparison of 
characteristics and study variables between groups was performed by ANOVA and Bonferroni 
or Chi-square tests, for continuous or categorical data respectively (as indicated in figure 
legends). Replicates (three) of the in vitro experiments were analyzed using GraphPad Prism 
and the Student’s t-test. P<0.05 was considered significant. 
 
Results  
Inhibition of 17β-HSD type 1 impairs E2 synthesis from E1 
Human endometrial adenocarcinoma Ishikawa cells, well-differentiated and estrogen-
dependent but devoid of any 17β-HSD reductive or oxidative activity, were genetically 
modified to express 17β-HSD 1. Two 17β-HSD 1 positive clones (Ishi-M1-HSD-B and Ishi-M3-
HSD-A) and one empty vector clone (Ishi-M3-EV-C, negative control) were selected for our 
studies. Selected clones maintained all major features of the parental Ishikawa cells (a full 
description of their generation and characterization is given in supplemental materials, 
materials and methods, Figure S1 and S2). The estrogen sensitivity of these cells was also 
confirmed in nude-mice xenografts (results not shown).  
Using a cell-free assay, an in tube reaction using cell lysates, both 17β-HSD 1 positive clones 
displayed linearity between reductive activities and cell/protein input (Figure 1A). Ishi-M1-
HSD-B had lower 17β-HSD 1 activity than Ishi-M3-HSD-A, which corresponded to analogue 
protein levels measured by fluorescence-activated cell sorting (FACS; not shown) and western 
blot (supplementary material, Figure S2B). Overall, enzyme activities were within the range 
measured in human tissue (highest and lowest quartiles for Ishi-M3-HSD-A and Ishi-M1-HSD-
B, respectively; supplementary material, Figure S2C). The specific 17β-HSD 1 inhibitor FP4643 
was used to determine whether the formation of E2 could be impaired. Both Ishi-M3-HSD-A 
and Ishi-M1-HSD-B clones showed a dose-dependent inhibition of E2 formation by FP4643 
(cell-free assay; Figure 1B). An inhibition of 80% was reached at a concentration of 100–200 
nM, over 90% with a concentration of 500 nM and the IC50 for FP4643 was estimated to be 50 
nM.  
To evaluate the possibility of inhibiting 17β-HSD 1 and blocking the reduction of E1 to E2 in 
whole cells, i.e. in the presence of membrane systems and cellular pathways and not in cell-
free assays, in vitro colony formation assay (CFA) was performed (Figures 1C and D). E2 
significantly increased the formation of colonies compared with control (vehicle). E1 induced 
similar colony formation as E2 in 17β-HSD 1 positive cells (Ishi-M1-HSD-B and Ishi-M3-HSD-A), 
thus confirming the conversion of E1 into E2 by 17β-HSD 1. This was impaired by FP4643 (500 
nM).  
Using empty vector transfected cells (Ishi-M3-EV-C), E2 significantly increased colony 
formation, while no effect of E1 was seen (supplementary material, Figure S3).  
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17β-HSD type 1 inhibitor impairs the effects of E1 in vivo  
Results were next verified in vivo using the chicken chorioallantoic membrane assay (CAM). 
Tumor grafts were induced using 17β-HSD 1 positive and empty vector Ishi-clones. At the end 
of the experiment (embryonic day 14, corresponding to six days of tumor growth on the CAM), 
harvested lesions were characterized. Tumor morphology was similar between clones, and 
consisted of small nests surrounded by a mucoid stroma with some hyalinization (likely 
remnants of matrigel) and with high cytonuclear atypia. The cells had large, polymorphic, 
hyperchromatic nuclei with large nucleoli placed in a moderate amount of cytoplasm. Several 
mitotic figures and apoptotic cells were visible (Figure 2A). Tumor cells maintained ERα and PR 
expression and 17β-HSD 1 protein was present in the positive clones (Figure 2B).  
The activation of estrogen signaling in these grafts was assessed by immunohistochemical 
quantification of cyclin A, which is a well-known estrogen responsive gene [3, 20, 21]. E2 
treatment resulted in up-regulation of cyclin A expression in 17β-HSD 1 positive clones (Ishi-
M1-HSD-B and Ishi-M3-HSD-A; Figure 2B,C). Similarly, exposure to E1 (0.1 nM) resulted in up-
regulation of cyclin A and the presence of FP4643 impaired such estrogen signaling activation 
(Figure 2C). Using the empty vector transfected clone (Ishi-M3-EV-C; supplementary material, 
Figure S4A), E2 treatment up-regulated cyclin A expression but in contrast, exposure to E1 had 
no effect compared with control (vehicle treatment). 
In these experiments, a high concentration of FP4643 was used (2.5 μM) in order to prevent 
that poor solubility, cell/tissue permeability and pharmacokinetics would hamper the inhibitor 
to reach its target. Nevertheless, in a titration experiment, FP4643 efficiently blocked E1 
induced estrogen activation (i.e. the induction of cyclin A and the proliferation marker Ki67) at 
a concentration as low as 100 nM (supplementary material, Figure S4B). The gender of the 
chick embryo (determined as described in supplementary material, Materials and Methods) 
influenced neither the expression of cyclin A nor that of Ki67. 
108
Chapter 3 
 
 
 
 
Figure 1. 17β-HSD type 1 activity and inhibition in Ishi-M1-HSD-B and M3-HSD-A 
a) Cell-free assay followed by HPLC analyses was used to measure the 17β-HSD reductive activity (formation of 
E2 from E1) in the 17β-HSD 1 positive clones Ishi-M1-HSD-B (closed circles, top) and M3-HSD-A (open circles, 
bottom). Reductive activity showed linearity with cell/protein inputs in both clones. Results were reproduced in 
three independent experiments. 
b) Rate of inhibition of the generation of E2 from E1 in the presence of increasing concentration of FP4643 in 
both Ishi-M1-HSD-B and M3-HSD-A clones. Results were reproduced in three independent experiments. 
c & d) Type 1 17β-HSD positive clones Ishi-M1-HSD-B (c) and M3-HSD-A (d) were seeded in 6-well plates (3000 
cells/plate) and stimulated with E1, E2 (0.1 nM) or E1 plus FP4643 (0.1 nM and 500 nM, respectively) for 12-14 
days until colonies were formed/visible. Total colony area was determined using ImageJ. Data are represented as 
mean  standard deviation. Statistical test: ANOVA, P<0.05 were considered significant, # P<0.05 compared with 
control, * P<0.05 compared with E1 (post-hoc Bonferroni test). Results were reproduced in three independent 
experiments. 
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Figure 2. FP4643 inhibits the up-regulation of cyclin A induced by E1 in vivo using the chicken chorioallantoic 
membrane assay (CAM) 
a. Top image: histology of the induced tumors (hematoxylin & eosin staining). Tumor is indicated by black 
arrowheads (Tu). At the top-right, a macroscopic image of a CAM assay at sacrifice is shown, with the two tumor 
grafts indicated by white arrowheads (Tu). Middle image: enlargement of the black-squared inset. Several blood 
vessels grow in the tumor grafts. Lower image: enlargement of the red-framed region. Red arrowheads indicate 
mitotic figures whereas green arrowheads show apoptotic cells. These are representative images obtained from 
clone Ishi-M1-HSD-B, vehicle treatment. No major histological differences were observed between 
treatments/clones. Scale bar in the middle image: 100 m. 
b. Representative immunohistochemistry images (clone Ishi-M1-HSD-B, vehicle treatment) for ER, PR, 17β-HSD 
type 1 and Cyclin A. Scale bars: 40 m. 
c. Immunohistochemical staining intensity of Cyclin A computed using a modified Allred system (range 0-15; [3]) 
for Ishi-M1-HSD-B and Ishi-M3-HSD-A upon the indicated treatment: control (vehicle); E2 0.1nM; E1 0.1 nM; E1 
0.1 nM plus FP4643 2.5 μM and inhibitor alone. Statistical test: ANOVA, P<0.05 was considered significant, # 
P<0.05 compared with control, * P<0.05 compared with E1 (post-hoc Bonferroni test). Number of samples in this 
experiment is indicated above the X axis (n). The results were reproduced in one independent experiment (not 
shown). 
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Type 1 17β-HSD inhibition impairs the synthesis of E2 in human EC biopsies ex vivo 
To confirm that the inhibition of 17β-HSD 1 as observed in vitro and in vivo is relevant also in 
human tissue, 52 human primary EC biopsies were investigated. Patient characteristics are 
summarized in supplemental material. Table S1 (cohort one).   
Type 1 17β-HSD enzyme activity was measured in 48 samples. Two specimens were excluded 
because histologic evaluation of the tissue used for the assay revealed the presence of normal 
proliferative endometrium and not grade 1 EC (as determined in the resection specimen used 
for patient diagnosis). In these two specimens, 17β-HSD 1 activity was 1.6 and 2.7 nMol E2/mg 
protein, i.e. among the lowest levels measured. The enzyme activity in the remaining 46 tumor 
samples ranged between 2.0 and 72.3 nMol E2/mg protein. The ability of compound FP4643 
to block the synthesis of E2 was determined in these 46 tumor biopsies (Table 1). The mean 
inhibition was over 80% in all kinds of lesions, and compound FP4643 could inhibit the 
synthesis of E2 from E1 by over 90% in 40% to 50% of the patient biopsies (Table 1).  
Type 1 17β-HSD enzyme activity, inhibition and mRNA levels (available from 39 specimens) 
were next explored for any association with the patient clinical features (Table 2 and 
supplementary material, Tables S2 and S3). For these analyses, enzyme activity levels were 
clustered in tertiles (high, medium, low) whereas mRNA levels were clustered in 2-quantiles 
and inhibition in two groups (lower than 95% of E2 formation, higher/equal to 95%). The 
prevalence of specimens with high enzyme activity tended to be greater among tissues with 
high mRNA expression levels (supplementary material, Figure S5), although there was no clear 
correlation between protein (activity) and mRNA, as shown previously [22], and suggestive of 
the presence of post-transcriptional events. As shown previously [22], biopsies of patients with 
advanced stage disease tended to have higher levels of type 1 17β-HSD mRNA (supplementary 
material, Table S2). More frequently than ERα negative specimens, ERα positive samples had 
high type 1 17β-HSD levels (enzyme activity, Table 2; non-significant trend for the mRNA level, 
supplementary material, Table S2). No additional associations between patient characteristics 
and mRNA, activity or 17β-HSD 1 inhibition levels (supplementary material, Table S3) were 
observed.  
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Figure 2. FP4643 inhibits the up-regulation of cyclin A induced by E1 in vivo using the chicken chorioallantoic 
membrane assay (CAM) 
a. Top image: histology of the induced tumors (hematoxylin & eosin staining). Tumor is indicated by black 
arrowheads (Tu). At the top-right, a macroscopic image of a CAM assay at sacrifice is shown, with the two tumor 
grafts indicated by white arrowheads (Tu). Middle image: enlargement of the black-squared inset. Several blood 
vessels grow in the tumor grafts. Lower image: nlargement of th  red-framed region. Red arrowheads indicate 
mitotic figures whereas green arrowheads show apoptotic cells. These are representative images obtained from 
clone Ishi-M1-HSD-B, vehicle treatment. No major histological differences were observed between 
treatments/clones. Scale bar in the middle image: 100 m. 
b. Representative immunohistochemistry images (clone Ishi-M1-HSD-B, vehicle treatment) for ER, PR, 17β-HSD 
type 1 and Cyclin A. Scale bars: 40 m. 
c. Immunohistochemical staining intensity of Cyclin A computed using a modified Allred system (range 0-15; [3]) 
for Ishi-M1-HSD-B and Ishi-M3-HSD-A upon the indicated treatment: control (vehicle); E2 0.1nM; E1 0.1 nM; E1 
0.1 nM pl s FP4643 2.5 μM and inhibitor alone. Statistical test: ANOVA, P<0.05 was considered significant, # 
P<0.05 comp red with c ntrol, * P<0.05 compared with E1 (post-hoc Bonferr ni test). Number of samples in this 
experiment is indicated above the X axis (n). The results were reproduced in one independent experiment (not 
shown). 
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Type 1 17β-HSD inhibition impairs the synthesis of E2 in human EC biopsies ex vivo 
To confirm that the inhibition of 17β-HSD 1 as observed in vitro and in vivo is relevant also in 
human tissue, 52 human primary EC biopsies were investigated. Patient characteristics are 
summarized in supplemental material. Table S1 (cohort one).   
Type 1 17β-HSD enzyme activity was measured in 48 samples. Two specimens were excluded 
because histologic evaluation of the tissue used for the assay revealed the presence of normal 
proliferative endometrium and not grade 1 EC (as determined in the resection specimen used 
for patient diagnosis). In these two specimens, 17β-HSD 1 activity was 1.6 and 2.7 nMol E2/mg 
protein, i.e. among the lowest levels measured. The enzyme activity in the remaining 46 tumor 
samples ranged between 2.0 and 72.3 nMol E2/mg protein. The ability of compound FP4643 
to block the synthesis of E2 was determined in these 46 tumor biopsies (Table 1). The mean 
inhibition was over 80% in all kinds of lesions, and compound FP4643 could inhibit the 
synthesis of E2 from E1 by over 90% in 40% to 50% of the patient biopsies (Table 1).  
Type 1 17β-HSD enzyme activity, inhibition and mRNA levels (available from 39 specimens) 
were next explored for any association with the patient clinical features (Table 2 and 
supplementary material, Tables S2 and S3). For these analyses, enzyme activity levels were 
clustered in tertiles (high, medium, low) whereas mRNA levels were clustered in 2-quantiles 
and inhibition in two groups (lower than 95% of E2 formation, higher/equal to 95%). The 
prevalence of specimens with high enzyme activity tended to be greater among tissues with 
high mRNA expression levels (supplementary material, Figure S5), although there was no clear 
correlation between protein (activity) and mRNA, as shown previously [22], and suggestive of 
the presence of post-transcriptional events. As shown previously [22], biopsies of patients with 
advanced stage disease tended to have higher levels of type 1 17β-HSD mRNA (supplementary 
material, Table S2). More frequently than ERα negative specimens, ERα positive samples had 
high type 1 17β-HSD levels (enzyme activity, Table 2; non-significant trend for the mRNA level, 
supplementary material, Table S2). No additional associations between patient characteristics 
and mRNA, activity or 17β-HSD 1 inhibition levels (supplementary material, Table S3) were 
observed.  
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Figure 2. FP4643 inhibits the up-regulation of cyclin A induced by E1 in vivo using the chicken chorioallantoic 
membrane assay (CAM) 
a. Top image: histology of the induced tumors (hematoxylin & eosin staining). Tumor is indicated by black 
arrowheads (Tu). At the top-right, a macroscopic image of a CAM assay at sacrifice is shown, with the two tumor 
grafts indicated by white arrowheads (Tu). Middle image: enlargement of the black-squared inset. Several blood 
vessels grow in the tumor grafts. Lower image: enlargement of the red-framed region. Red arrowheads indicate 
mitotic figures whereas green arrowheads show apoptotic cells. These are representative images obtained from 
clone Ishi-M1-HSD-B, vehicle treatment. No major histological differences were observed between 
treatments/clones. Scale bar in the middle image: 100 m. 
b. Representative immunohistochemistry images (clone Ishi-M1-HSD-B, vehicle treatment) for ER, PR, 17β-HSD 
type 1 and Cyclin A. Scale bars: 40 m. 
c. Immunohistochemical staining intensity of Cyclin A computed using a modified Allred system (range 0-15; [3]) 
for Ishi-M1-HSD-B and Ishi-M3-HSD-A upon the indicated treatment: control (vehicle); E2 0.1nM; E1 0.1 nM; E1 
0.1 nM pl s FP4643 2.5 μM and inhibitor alone. Statistical test: ANOVA, P<0.05 was considered significant, # 
P<0.05 compared with control, * P<0.05 compared with E1 (post-hoc Bonferroni test). Number of samples in this 
experiment is indicated above the X axis (n). The results were reproduced in one independent experiment (not 
shown). 
114
Chapter 3 
 
 
Table II. Enzyme level of 17βHSD type 1 and clinical characteristics of patients (cohort one). 
 17βHSD type 1 activity level *  
 low medium high ANOVA 
Mean age ^ ± standard deviation 69.9 ± 10.7 70.4 ± 10.9 68.6 ± 11.4 N.S. 
Minimum – Maximum age ^ 49 - 90 55 - 91 45 - 81  
Mean Body Max Index (BMI) 26.6 ± 6.1 32.6 ± 10.8 30.0 ± 7.8 N.S. 
Minimum – Maximum BMI 19.9 – 39.3 21.3 – 55.1 23.3 – 54.1  
Mean CA-125 ^^  147 ± 201 99.4 ± 165 53.4 ± 38.7 N.S. 
Minimum – Maximum CA-125 ^^ 24 - 379 9 - 346 15 - 104  
TOTAL SPECIMENS (n = 46) Number (%)  Number (%)  Number (%)  
Fisher exact test 
** 
 14 (30) 15 (33) 17 (37)  
Menopausal status     
Pre-menopausal 1 (2) 0 2 (4) N.S. 
Post-menopausal 13 (29) 14 (31) 15 (33)  
Unknown - 1 -  
Age at diagnosis     
< 65 years 6 (13) 5 (11) 5 (11) N.S. 
≥ 65 years 8 (18) 9 (20) 12 (27)  
Unknown - 1 -  
Body Mass Index (BMI)     
< 25 5 (13) 3 (8) 2 (5) N.S. 
25 ≤ BMI ≤ 30 3 (8) 5 (13) 8 (21)  
> 30 3 (8) 5 (13) 5 (13)  
Unknown 3 2 2  
ERα expression ##     
Negative 9 (24) 10 (26) 7 (18) 0.02 
Positive 0 4 (11) 8 (21)  
Unknown 5 1 2  
Histology of endometrium     
Hyperplasia 3 (7) 0 1 (2) N.S. 
Endometrioid EC 7 (15) 10 (22) 10 (22)  
Non-endometrioid EC 4 (9) 5 (11) 6 (13)  
     
Grading #     
Grade 1 6 (14) 8 (19) 6 (14) N.S. 
Grade 2 3 (7) 1 (2) 3 (7)  
Grade 3 2 (5) 6 (14) 7 (17)  
     
Staging  #, ***     
FIGO Ia 5 (12) 6 (15) 2 (5) 0.09& 
FIGO Ib 4 (10) 4 (10) 10 (24)  
FIGO II, III or IV 2 (5) 4 (10) 4 (10)  
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Unknown - 1 -  
     
Myometrium invasion #     
None  1 (3) 4 (10) 2 (5) N.S. 
<1/2 4 (10) 4 (10) 7 (18)  
>1/2 4 (10) 4 (10) 7 (18)  
unknown 2 3 1  
Recurrence #      
Negative (or non-applicable)  10 (27) 9 (24) 12 (32) N.S. 
Positive 0 4 (11) 2 (5)  
unknown 1 2 2  
17βHSD type 1 inhibition     
< 95 % 9 (20) 8 (17) 14 (30) N.S. 
≥ 95 % 5 (11) 7 (15) 3 (7)  
     
Parity     
Positive 7 (18) 7 (18) 15 (38) N.S. 
Negative 3 (8) 5 (13) 2 (5)  
unknown 4 3 -  
History of hypertension     
Negative 6 (14) 8 (19) 11 (26) N.S. 
Positive 6 (14) 6 (14) 6 (14)  
unknown 2 1 -  
History of T2 Diabetes      
Negative 12 (28) 10 (23) 14 (33) N.S. 
Positive 0 4 (9) 3 (7)  
unknown 2 1 -  
 
* The 17βHSD type 1 (reductive) activity was clustered in tertiles as described in Materials and Methods. 
^ Age = age at diagnosis. 
^^ Pre-operative level of CA-125 (E / mL). 
** N.S. = non-significant 
## ERα positivity was defined on RT-qPCR data validated on immunohistochemistry as described in Materials and 
Methods. 
# Total specimens considered: 42 (the four hyperplasia cases are not computed).  
*** FIGO stage based on 2009. 
Further characteristics (type of surgery, treatment, nodal staging, lymph-angio invasion, CA-125 level) did not 
show any correlation with 17βHSD type 1 activity. 
& FIGO Ia was compared with the rest (FIGO Ib and higher). 
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Type 1 17β-HSD is expressed in metastatic EC 
Primary EC is normally treated surgically. In case of recurrent or metastatic disease, endocrine 
therapy becomes a treatment option. Hence we wondered whether type 1 17β-HSD as 
potential drug target was also expressed in metastatic lesions. A second cohort of 37 primary 
ECs and 48 corresponding metastatic lesions (cohort two) with available mRNA expression data 
from micro-array analysis [15] was used to investigate the expression of type 1 17β-HSD in 
paired primary (continuous grey line in Figure 3) and metastatic lesions (bars in Figure 3). Type 
1 17β-HSD expression was detected in all metastases and the level was higher than the lowest 
level measured in primary EC (dotted line in Figure 3). In over 50% of the cases (21/37) at least 
one metastasis had higher type 1 17β-HSD expression than the corresponding primary EC 
(Figure 3). There was no correlation between 17β-HSD 1 levels in primary tumor and 
metastases, no association with ERα and with histology or grading (Figure 3 and supplementary 
material, Table S4).  
 
Figure 3. The 17β-HSD type 1 mRNA levels in primary and the corresponding metastases 
The mRNA level of 17β-HSD 1 in 37 primary ECs (grey continuous line) is plotted against the levels observed in 
the corresponding 47 metastatic lesions (black bars; black and grey-striped bars when two metastases from the 
same patient were available). The dotted line indicates the minimum mRNA expression for 17β-HSD 1 seen in 
primary EC. All metastases have levels higher than this minimum. The expression of ERα based on 
immunohistochemistry as described earlier [15] is indicated at the top of the graph. 
The low panel gives the numbers (and percentages) of metastatic lesions having lower or higher/equal 17β-HSD 
1 mRNA levels than the corresponding primary ECs (the mRNA levels in primary EC are clustered in tertiles: 
low/medium/high). 
117
Blocking 17-HSD 1 in endometrial cancer 
 
Additional patient characteristics are shown in supplementary material, Table S4 and were described previously 
[15]. 
* mRNA level for 17β-HSD 1 was derived from microarray analyses performed previously [15] and outlined in 
Material and Methods. 
$ in case more than one metastases corresponded to one primary EC, the metastatic lesion with higher 17β-HSD 
1 mRNA level was considered. 
# mRNA levels between primary and metastasis were considered different when they deviated more than ± 0.03 
arbitrary mRNA units (± 0.5% of the mRNA value). 
^ ERα expression was determined by immunohistochemistry as described previously [15]. 
^^ Five samples were classified as carcinosarcoma, three were clear cell EC, one sample was classified as 
undifferentiated EC. 
 
Discussion 
Local estrogen overexposure in EC, at least in part, is determined by increased level of the 
enzyme 17β-HSD 1 [3]. Hence, blocking 17β-HSD 1 can be a potential novel endocrine 
therapeutic strategy. In the present study, we demonstrated that type 1 17β-HSD inhibition 
efficiently blocks the synthesis of active E2 using models of EC in vitro and in vivo. First we 
genetically modified the well-differentiated endometrioid EC cell line Ishikawa to generate 
lines expressing 17β-HSD 1 at levels that are comparable with those observed in patients. Using 
these cells, we demonstrated that the 17β-HSD 1 inhibitor FP4643 blocks the synthesis of E2 
from E1 in cell-free assays.  Since this assay is devoid of cell membranes and intracellular 
signaling paths, we demonstrated that FP4643 blocks the conversion of E1 to E2 also in a 
complete-cell contest by showing that treatment with FP4643 impairs the E1-induced estrogen 
signaling activation in vitro as assessed by colony formation assay. Next, we confirmed that 
FP4643 blocks the E1-induced estrogen signaling in vivo using the CAM model, demonstrating 
the potential of this compound in a more complex whole organism setting. The relevance of 
the inhibition of 17β-HSD 1 by FP4643 was further demonstrated using lysates of human 
primary EC biopsies (ex vivo) as well as in metastatic disease, a condition that is currently an 
indicator for hormonal treatment.  
Although no compound directed against 17β-HSD 1 has reached the clinical phase yet, good 
results in various in vivo disease models have been demonstrated. These include human 
endometrial hyperplasia [9] and breast cancer [23] models in mice, endometriosis models in 
primates [24] and in human endometriotic lesions ex vivo [8]. 
 
Local synthesis, activation and deactivation of estrogens, but also androgens and progesterone 
occur in the endometrium and in several other peripheral tissues. Such hormone metabolism 
is termed ‘intracrinology’ and is increasingly more considered as part of the endocrine control 
[4]. Imbalances of intracrinological pathways lead to hormone dependent pathologies. 
Increased local estrogen generation caused by de-regulated 17β-HSD 1/17β-HSD-2 balance, 
controlling the interconversions of E1 and E2, is implicated in endometriosis [8, 25-27], 
endometrial cancer [3], and in non-gynecological conditions too [28]. Estrogen overexposure 
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can also be caused by imbalances of other intracrine enzymes, like aromatase, (reported to be 
increased in endometriosis [26, 29, 30], EC [31] or infertile patients [32]) or like the sulfatase 
pathway that controls the cell influx/outflow of sulfated steroids [33, 34].  
Local steroid metabolism and intracrinology offer opportunities for novel drug targets and 
prognosis markers in hormone dependent conditions like EC [15, 22, 35-39]. At the same time, 
however, intracrine networks are complex, can convert adrenal steroid precursors into 
androgens and estrogens, can interconvert androgens, estrogens, active and inactive 
compounds, protective and cancer-promoting compounds. In addition, several intracrine 
enzymes have promiscuous and redundant activities, thus blocking one step can be rescued by 
other compensating reactions. Therefore, it is not surprising that so far, attempts to use 
inhibitors of intracrine enzymes for patient care did not confirm the expectations generated in 
the preclinical phase. For instance, promising STS inhibitors in preclinical EC models [37] 
resulted inferior compared with progestogens (standard endocrine care for EC) in a phase II 
trial on EC patients with advanced stage disease [40]. The use of various aromatase inhibitors 
was attempted in a number of phase II trials on advanced stage EC, with little efficacy [41-43].  
In order to exploit the opportunities offered by the local steroid metabolism and by 
intracrinology, it is fundamental to learn how to predict a therapeutic response of a patient to 
a drug, e.g. by assessing the presence of the drug target and the activation of relevant signaling 
pathway in the tissue intended to be treated (primary or metastatic lesion). This 
recommendation is being made for hormonal drugs in general [44]. Additionally, the 
development of dual/triple inhibitors, able to simultaneously target redundant intracrine 
pathways, is desirable. Several double STS-aromatase inhibitors are under investigations [34] 
and very recently, the first dual 17β-HSD 1/STS inhibitor was developed [45]. 
 
In conclusion, 17β-HSD 1 is a novel potential target for endocrine treatment in EC. Endocrine 
care in EC is currently prescribed in case of advanced stage or recurrent disease and in case of 
fertility preservation. Since the efficacy of current endocrine care is limited due the occurrence 
of drug insensitivity/resistance [1, 46], novel endocrine and intracrine targets may allow 
alternating drug regimen targeting different pathways, thus diminishing the problem of drug 
resistance development. 
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Supplementary Materials and Methods 
Reference numbers refer to the main text. 
 
Creation and characterization of Ishikawa clones expressing type 1 17β-HSD 
To evaluate the therapeutic potential of 17β-HSD type 1 in EC, Ishikawa cells were used. These 
cells are well-differentiated, estrogen-dependent, ERα and PR positive, human endometrial 
adenocarcinoma cells. Ishikawa cells do not express any major enzymes involved in the 
activation and deactivation of E1 and E2 (unpublished data and further characterization 
described below).  
A European Collection of Cell Cultures (ECACC) certified Ishikawa cell line was purchased from 
Sigma-Aldrich (Zwijndrecht, The Netherlands). Cell were cultured in RPMI 1640 (Invitrogen, 
Carlsbad, CA) supplemented with sodium-pyruvate, L-glutamine, penicillin-streptomycin and 
10% fetal bovine serum at 37 °C with 5% CO2 in humidified air.  
To generate Ishikawa clones expressing 17β-HSD type 1, cells were subjected to two rounds of 
genetic modification and clonal selection. First, Ishikawa cells were transduced with a construct 
harboring a firefly luciferase and a green fluorescent protein as described previously [6]. After 
thorough characterization of luciferase-GFP clones with respect to reporter gene expression 
and estrogen sensitivity (not shown), two clones (Ishi-M1 and Ishi-M3) were stably transfected 
with a plasmid containing the cDNA for 17β-HSD type 1 or with empty vector (see Materials 
and Methods). A number of Ishi-M1/M3 derived clones were thoroughly characterized for the 
presence of 17β-HSD-1 activity and the absence of other oxidizing and reducing 17β-HSDs. 
Empty vector clones had no detectable 17β-HSD-1 activity (supplementary material, Figure S1, 
S2). In addition, in Ishi-M1/M3 derived clones containing the 17β-HSD-1 cDNA or the empty 
vector, we confirmed the expression of ERα and the activation of the estrogen signaling 
(supplementary material, Figure S1).  
For the experiments described in the main text, two 17β-HSD-1 positive clones (Ishi-M1-HSD-
B and M3-HSD-A) and one empty vector (Ishi-M3-EV-C) were selected. Authenticity of clones 
Ishi-M1-HSD-B and Ishi-M3-HSD-A was confirmed by short tandem repeat analysis (STR). Ishi-
M3-HSD-A displayed high 17β-HSD-1 reductive activity, comparable to the highest quartile 
observed in patients. Ishi-M1-HSD-B and Ishi-M3-EV-C displayed medium/low and no activity, 
respectively (supplementary material, Figure S2). The estrogen sensitivity/responsiveness of 
these cells was confirmed using tumor xenograft experiments in nude-mice where tumor 
growth was estrogen-dependent (results not shown).  
 
Reverse Transcription - quantitative PCR (RT-qPCR) 
Total RNA of in vitro propagated Ishikawa lines (12-well / 6-well-plates) was extracted using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), then assessed spectrophotometrically for 
quantity and purity (260/280 nm and 260/230 nm ratios). Total RNA of patient tumor 
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specimens was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) from 10 X 10 μM 
cryo-sections. cDNA was synthesized by reverse transcription of total RNA using the iScript 
cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, US) according to manufacturer’s 
protocol. Quantitative PCR followed the protocol described previously [3, 8, 21, 22, 28, 47].  
Gene entries and primer sequences used were the following (*: described earlier in [3]; **: 
described earlier in [28]; #: described earlier in [21]; ##: described earlier in [48]). 
 
a.  Type 1 17β-hydroxysteroid dehydrogenase (17β-HSD-1) * 
 Gene name: HSD17B1 NCBI Gene ID1: 3292 
 Primer Forward: 5’-GTTTATTGCGCCAGCAAGTT-3’ 
 Primer Reverse:  5’-CCCAACACCTTCTCCATGA-3’ 
b.  Estrogen receptor-α (ERα) **  
 Gene name: ERS1 NCBI Gene ID: 2099 
 Primer Forward: 5’-AGCTCCTCCTCATCCTCTCCCA-3’ 
 Primer Reverse:  5’-ACCACGTTCTTGCACTTCATGCTG-3’ 
 
Estrogen responsive genes 
c.  Trefoil factor family 1 # 
 Gene name: TFF1 NCBI Gene ID: 7131 
 Primer Forward: 5’- CATCGACGTCCCTCCAGAAGAG-3’ 
 Primer Reverse:  5’- CTCTGGGACTAATCACCGTGCTG-3’ 
d.  Cyclin A # 
 Gene name: CCNA2 NCBI Gene ID: 890 
 Primer Forward: 5’- ATTGCTGGAGCTGCCTTTCATTTAG-3’ 
 Primer Revers:    5’- CTTTGAGGTAGGTCTGGTGAAGGTCC-3’ 
 
Reference genes 
e.  Cyclophilin A * 
 Gene name: PPIA NCBI Gene ID: 5478 
 Primer Forward: 5’- CCGTGTTCTTCGACATTGCCGT-3’ 
 Primer Revers:    5’- AATCCTTTCTCTCCAGTGCTCAGA-3’ 
f.  -actin * 
 Gene name: ACTB NCBI Gene ID: 60 
 Primer Forward: 5’- GCCAACCGCGAGAAGATGAC-3’ 
 Primer Revers:    5’- GATGGGCACAGTGTGGGTGAC-3’ 
g.  Ribosomal protein S18 ## 
 Gene name: RPS18 NCBI Gene ID: 6222 
 Primer Forward: 5’- TGCGAGTACTCAACACCAACA-3’ 
 Primer Revers:    5’- GCATATCTTCGGCCCACA-3’ 
                                                 
1 NCBI: The National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov) 
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Relative mRNA expression levels were calculated using the delta CT method with the three 
reference genes for normalization and expressed as relative values [3, 21, 28]. 
 
Western blot analysis  
Western blotting was performed as described earlier [3]. In brief, total proteins were extracted 
using radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCL, pH 7.4 1% NP-40, 0.25% 
sodiumdeoxycholate, 150 mM NaCl, 1 mM EDTA) and concentrations were determined using 
a BCA assay protein quantification kit (Uptima-Interchim, Montlucon, France). Equal amounts 
of protein were separated on acrylamide gel (7–9%) and transferred to a nitrocellulose 
membrane by electroblotting. Blotting efficiency was confirmed by Ponceau staining (Sigma-
Aldrich, Zwijndrecht, The Netherlands).  
For ERα and 17-HSD type 1 protein detection, rabbit polyclonal antibody HC-20 (1:500; Santa 
Cruz Biotechnology, Heidelberg, Germany) and rabbit monoclonal antibody EP1682-Y (1:1000; 
Epitomics, CA, USA) were used, respectively. As loading control, mouse monoclonal -actin 
antibody AC-15 (Sigma-Aldrich, Zwijndrecht, The Netherlands) was used. Horseradish 
peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratory, Inc., 
Suffolk, UK) and the SuperSignal West Pico chemiluminescent or SuperSignal West Femto 
chemiluminescent substrate (Pierce Biotechnology, Rockford, IL, USA) were used for 
visualization. Signal intensities were quantified using ImageJ software (National Institutes of 
Health, Bethesda, MD, USA). 
 
Fluorescence-activated Cell Sorting (FACS)  
Cells seeded in 6-well plates were trypsinized and re-suspended in ice cold PBS. For detection 
of GPF in clones constitutively expressing this protein (Inshi-M1, Ishi-M3 and derivative 
subclones), living cells were directly subjected to FACS analyses. For detection of 17-HSD type 
1, re-suspended cells were fixed in cold methanol (-20 °C) following incubation with rabbit 
monoclonal antibody EP1682-Y (1:50; Epitomics, CA, USA) and phycoerythrin-conjugated goat 
anti rabbit secondary antibody (Sigma-Aldrich, Zwijndrecht, The Netherlands). Analyses were 
performed on a FACSCalibur (BD Biosciences, CA, USA) and analyzed using the CellQuest 
software (BD Biosciences, CA, USA). Forward and side-scattered cells were gated to exclude 
cell debris/aggregates and the percentage of positive cells was measured using as cutoff for 
background native Ishikawa cells (for GFP) or cells stained with secondary antibody only (for 
17-HSD type 1 detection). 
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Cell proliferation 
Cells (2,000–10,000) were seeded in 96-well plates and grown as standard or as indicated. 
Viable cells at desired time points were quantified by staining with crystal violet as described 
in Materials and Methods followed by dissolving the stain in equal volumes (150 μl) of acetic 
acid and by measuring the optical density at 590 nm. 
 
Gender determination of chicken embryos   
Genomic DNA was isolated from eight slices (10 μm thick) cut from CAM-FFPE blocks using the 
GenElute Mammalian Genomic DNA miniprepation kit (Sigma-Aldrich, Zwijndrecht, The 
Netherlands). DNA quality and quantity were determined spectrophotometrically. The gender-
polymorphic region of the Gallus gallus sex chromosomes (Chr. Z: 51306275 - 51306677; Chr. 
W: 4999969 - 5000388) was amplified using nested PCR and the following primers: 
External Primer Forward: 5’- GAGGAGGAAAGACAAAAAGAACTTG-3’; 
External Primer Reverse:  5’ - CAYATCTTACCGYCTRATCTCTGCA-3’; 
Nested Primer Forward:   5’- CTCCCAAGGATGAGRAAYTG-3’; 
Nested Primer Reverse:    5’- TCTGCATCGCTAAATCCTTT-3’. 
 
The generated fragments using the nested primers (Z: 345 nucleotides; W: 363 nucleotides) 
were further digested with the restriction endonuclease SpeI, cutting the PCR fragment 
generated from the W chromosome in two fragments of 190 and 173 nucleotides and leaving 
the Z fragment uncut. Data were further confirmed with restriction endonuclease KpnI, cutting 
the PCR fragment generated from the Z chromosome in two fragments of 315 and 30 
nucleotides, whereas leaving the W fragment uncut. Male (ZZ) and female (ZW) were 
distinguished by separating the digested fragment on a 3% agarose gel. 
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Figure S1. Initial characterization of 17β-HSD-1 positive clones derived from the cell line Ishikawa 
A: overview of a number of Ishikawa clones previously transduced with the luciferase-GFP reporter and stably 
transfected with 17β-HSD-1 or empty vector and characterized for: 
- reporter gene expression (luciferase assay as described earlier [3] and GFP expression by FACS); 
- mycoplasma contamination (all negative; MycoAlert, Promega, Madison, USA); 
- expression level of ER and 17β-HSD-1 determined by western blot; 
- 17β-HSD-1 enzyme activity determined by HPLC (see Materials and Methods and previously published [3, 8, 16]);  
- estrogen responsiveness determined by the ability of 17β-estradiol to activate estrogen responsive genes CCNA 
(CCNA2) and TFF1, measured by RT-qPCR.  
- growth rates in presence of culture medium supplemented with complete fetal serum or with hormone-stripped 
fetal serum. This data indicated that selected cells have similar growth rates and that they are growth-factor and 
hormones dependent.  
In bold are indicated the clones selected for further investigation (M3-EV-C, M1-HSD-B and M3-HSD-A). 
# SD: standard deviation; 
^ Mycop: mycoplasma testing 
## Intens: band intensity on western blot evaluated using Image J. 
* Fold-change after 24 hours of E2 treatment versus vehicle. 
** Fold-change in cell number after 24 h of culture. 
n.d.: not determined. 
B. Growth curves of the clones reported in A in presence of culture medium supplemented with complete fetal 
serum (plain lines) or with hormone stripped fetal serum (broken line). Growth was measured by crystal violet for 
three days and each day, the cell number was quantified in triplicate. Charts display mean values ± standard 
deviations. Ishi-clones selected for further investigation (M3-EV-C, M1-HSD-B and M3-HSD-A) are indicated in 
bold. 
C. Western blot analyses for the expression of ER (-actin -act- as loading control) and band intensity 
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quantification (graph below) of the Ishikawa derived clones reported in A. Breast cancer cell line MCF-7 was used 
a positive control. Ishi- clones selected for further investigation (M3-EV-C, M1-HSD-B and M3-HSD-A) are 
indicated in bold. 
 
 
Figure S2.  Characterization of clones Ishi-M1-HSD-B, Ishi-M3-HSD-A and Ishi-M3-EV-C used in the present study 
A. Representative bright-field images of the selected Ishikawa clones: Ishi-M1-HSD-B (left), Ishi-M3-HSD-A 
(middle) (17β-HSD type 1 positive clones) and Ishi-M3-EV-C (empty vector clone). Cells maintain epithelial-like 
cytology similar to the parental line. 
B. Western blot to confirm the expression of 17β-HSD type 1 in lines Ishi-M1-HSD-B and Ishi-M3-HSD-A. Ishi-M3-
HSD-A has higher levels of 17β-HSD type 1 protein compared with Ishi-M1-HSD-B. 
C. Type 1 17β-HSD enzyme activity levels of the lines Ishi-M1-HSD-B and Ishi-M3-HSD-A in comparison with the 
enzyme activity measured in human EC tumor specimens (see main text, patient cohort one; Table I). In line with 
western blot, Ishi-M3-HSD-A has higher enzyme activity than Ishi-M1-HSD-B. Enzyme activity of Ishi-M3-HSD-A 
ranges in the highest quartiles of human specimens, whereas the enzyme activity of Ishi-M1-HSD-B is similar to 
human specimens in the lowest range. The negative control Ishi-M3-EV-C shows no enzyme activity. 
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Figure S3. Absence of 17β-HSD type 1 activity confirmed in Ishi-M3-EV-C colony formation  
Ishi-M3-EV-C (empty vector) was seeded in 6-well plates and stimulated for 12–14 days until colonies were 
formed. Total colony area was determined after crystal violet staining measuring the OD. Results were reproduced 
in three independent experiments and the data are represented as mean  standard deviation. Statistical test: 
ANOVA, P < 0.05 was considered significant, * P < 0.05 compared with control. 
 
 
 
Figure S4. Chicken chorioallantoic membrane (CAM) assay using Ishi-M3-EV-C and titration of FP4643 using Ishi-
M3-HSD-A 
A. Immunohistochemical staining intensity of Cyclin A computed using a modified Allred scoring system (range 0–
15) in tumor grafted on the CAM and derived from the negative control (type 1 17β-HSD negative) Ishi-M3-EV-C. 
Although E2 (1.0 nM) elicits upregulation of Cyclin A, 0.1 nM E1 is not able to do the same and in contrast to the 
type 1 17β-HSD positive clones (Figure 3). 
B. Titration of FP4643 in tumors induced on the CAM using the type 1 17β-HSD positive line Ishi-M3-HSD-A. E1 
was used at 0.1 nM. The graphs show the immunohistochemical staining intensity of the estrogen responsive 
protein Cyclin A and the proliferation marker Ki67 (Allred score). At the top of the graphs, representative images 
showing the expression of Cyclin A and Ki67 are displayed. 
Statistical test: ANOVA, P < 0.05 was considered significant, * P < 0.05 compared with E1 treatment. 
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Figure S5. Relationship between 17β-HSD type 1 activity and mRNA levels in patient specimens 
The level of the type 1 17β-HSD enzyme activity (low, medium, high) was analyzed with respect to the mRNA level 
for the same enzyme (low and high) in 36 patient biopsies from cohort one. 
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Supplementary Tables 
Table S1. Clinical characteristics of patients (cohort one). 
  Endometrial Cancer  
 Hyperplasia Grade 1 Grade 2 Grade 3 
Mean age ^ ± standard deviation$ 58.0 ± 16.7 72.2 ± 10.1 78.4 ± 12.4 70.0 ± 9.9 
Minimum – Maximum age  35 - 79 46 - 90 55 - 91 55 - 91 
Mean Body Max Index (BMI) $ 25.1 ± 2.6 21.1 ± 9.5 26.6 ± 3.9 30.2 ± 8.6 
Minimum – Maximum BMI 22.2 – 26.5 21.3 – 55.1 19.9 – 32.9 21.3 – 54.1 
TOTAL SPECIMENS (n = 52) 
Number 
 (%) 
Number 
 (%) 
Number 
 (%) 
Number 
(%) 
 5 (10) 23 (44) 8 (15) 16 (31) 
Menopausal status     
Pre-menopausal 2 (4) 1 (2) 1 (2) 0 
Post-menopausal 3 (6) 22 (42) 7 (13) 15 (29) 
Unknown - - - 1 
Histology of endometrium     
Hyperplasia 5 (10) - - - 
Endometriod EC - 23 (44) 4 (8) 4 (8) 
Mixed (endometrioid/serous) - 0 0 8 (16) 
Serous EC - 0 0 6 (12) 
Carcinosarcoma - 0 0 2 (4) 
     
Staging *     
Not applicable # 5 (10) - - - 
FIGO Ia - 10 (19) 1 (2) 3 (6) 
FIGO Ib - 8 (15) 5 (10) 7 (13) 
FIGO II, III or IV - 5 (10) 2 (4) 4 (8) 
Unknown - - - 2 
Nodal staging     
Negative (or non-applicable) # 5 (10) 23 (44) 5 (10) 13 (25) 
Positive - 0 2(4) 2 (4) 
Unknown - - 1 1 
Lymph-angio invasion     
Negative (or non-applicable) # 5 (10) 22 (42) 6 (12) 13 (25) 
Positive - 1 (2) 2 (4) 2 (4) 
Unknown - - - 1 
Myometrium invasion     
None (or non-applicable) # 5 (10) 5 (10) 1 (2) 4 (8) 
<1/2 - 7 (13) 3 (6) 7 (13) 
>1/2 - 9 (17) 4 (8) 4 (8) 
Unknown 
 
- 2 - 1 
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Table S1 continued 
 Endometrial Cancer  
 Hyperplasia Grade 1 Grade 2 Grade 3 
TOTAL SPECIMENS (n = 52) 
Number 
 (%) 
Number 
 (%) 
Number 
 (%) 
Number 
(%) 
Recurrence **      
Negative (or non-applicable) # 5 (10) 20 (38) 5 (10) 6 (12) 
Positive - 1 (2) 1 (2) 4 (8) 
Unknown - 2 2 6 
ERα expression ##     
Negative 1 (2) 3 (6) 3 (6) 8 (15) 
Positive 4 (8) 16 (31) 1 (2) 5 (10) 
Unknown - 4 4 3 
Type hysterectomy     
Laparoscopy 2 (4) 6 (12) 1 (2) 0 
Laparotomy 2 (4) 9 (17) 3 (6) 1 (2) 
Vaginal Hysterectomy 1 (2) 2 (4) 0 3 (6) 
Debulking – nodal staging - 4 (8) 4 (8) ### 11 (21) 
Unknown - 2 - 1 
Type of treatment ***     
Surgery 5 (10) 13 (25) 3 (6) 2 (4) ^ 
Surgery + RT - 8 (15) 2 (4) 8 (15) 
Surgery + RT + CT - 0 2 (4) 2 (2) 
Surgery + CT - 0 1 (2) 3 (6) 
Unknown - 2 - 1 
History of hypertension     
Negative 3 (6) 7 (13) 3 (6) 8 (15) 
Positive 2 (4) 14 (27) 5 (10) 7 (13) 
Unknown - 2 - 1 
History of T2 Diabetes $$      
Negative 5 (10) 15 (29) 8 (15) 13 (25) 
Positive 0 6 (12) 0 2 (4) 
Unknown - 2 - 1 
 
$ Mean age and BMI levels did not vary between groups (ANOVA). 
* FIGO stage based on 2009. 
# Non-applicable: hyperplasia cases. 
** Recurrences were local or regional. 
## ERα positivity was defined on RT-qPCR data validated by immunohistochemistry as described in Materials and 
Methods. 
*** RT: radiotherapy; CT: chemotherapy. 
### One patient underwent Wertheim-Meigs operation 
$$ No patient had Type 1 diabetes. 
^ Adjuvant treatment was discussed with the patient, and in some cases was not applied even in presence of an 
indication for it.  
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Table S2. Type 1 17-HSD mRNA level (clustered as low – high as described in Materials and Methods) in relation 
with patient clinical features (cohort one). 
 
 mRNA level of 17β-HSD-1  
 
total 
number 
LOW HIGH 
Fisher exact 
test # 
 
 number % number %  
 
39 21 53.8 18 46.2  
Menopausal status       
pre-menopausal 4 3 75 1 25 N.S. 
post-menopausal 34 18 53 16 47  
unknown    1   
Age at diagnosis       
< 65 13 6 46 7 54 N.S. 
≥ 65 25 15 60 10 40  
unknown    1   
Body Mass Index        
< 25 8 5 63 3 38 N.S. 
25 ≤ MBI ≤ 30 12 8 67 4 33  
> 30 14 8 57 6 43  
unknown    5   
ERα expression        
Positive 15 11 73 4 27 0.054 
Negative 24 10 42 14 58  
unknown       
Histology       
Hyperplasia 3 2 67 1 33 N.S. 
Endometrioid EC 24 14 58 10 42  
Non-endometrioid EC 12 5 42 7 58  
 
      
Grading (n = 36)       
Grade 1 19 11 58 8 42 N.S. 
Grade 2 4 3 75 1 25  
Grade 3 13 5 38 8 62  
unknown       
Staging (n = 36)       
FIGO Ia 13 10 77 3 23 0.042* 
IB 14 5 36 9 64  
II-III-IV 8 4 50 4 50  
unknown    1   
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Table S2 continued 
mRNA level of 17β-HSD-1  
 
total 
number 
LOW HIGH 
Fisher exact 
test # 
 
 number % number %  
Myometrial invasion (n = 36)       
no 7 5 71 2 29 N.S. 
<1/2 13 7 54 6 46  
>1/2 11 4 36 7 64  
unknown  3  2   
Recurrence (n = 36)       
Negative 27 15 56 12 44 N.S. 
Positive 5 3 60 2 40  
unknown  1  3   
Parity       
Positive 27 15 56 12 44 N.S. 
Negative 8 3 38 5 63  
unknown  3  1   
History of hypertension       
Positive 20 8 40 12 60 N.S. 
Negative 16 11 69 5 31  
unknown  2  1   
History of T2 diabetes       
Positive 28 16 57 12 43 N.S. 
Negative 8 3 38 5 63  
unknown  2  1   
 
# N.S. = non-significant; 
* FIGO Ia patients were compared with FIGO Ib and higher.  
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Table S3. Level of type 1 17-HSD inhibition (clustered as ≥ 95% or < 95%) in relation with patient clinical features 
(cohort one). 
 
 Level of 17β-HSD-1 inhibition  
 
total number < 95 % ≥ 95 % 
Fisher exact 
test # 
 
 number % number %  
 46 31 67.4 15 32.6 
 
Menopausal status       
pre-menopausal 3 1 33 2 67 N.S. 
post-menopausal 42 30 71 12 29  
unknown    1   
Age at diagnosis       
< 65 16 9 56 7 44 N.S. 
≥ 65 29 22 76 7 24  
unknown    1   
Body Mass Index        
 <25 10 6 60 4 40 N.S. 
25 ≤ MBI ≤ 30 16 13 81 3 19  
>30 13 8 62 5 38  
unknown  4  3   
ERα expression        
Positive 26 14 54 12 46 N.S. 
Negative 12 9 75 3 25  
unknown  8     
Histology       
Hyperplasia 4 2 50 2 50 N.S. 
Endometrioid EC 26 17 65 9 35  
Non-endometrioid EC 16 12 75 4 25  
 
      
Grading (n = 42)       
Grade 1 20 14 70 6 30 N.S. 
Grade 2 7 6 86 1 14  
Grade 3 15 9 60 6 40  
Staging (n = 42)       
FIGO Ia 13 9 69 4 31 N.S. 
IB 18 14 78 4 22  
II-III-IV 10 6 60 4 40  
unknown    1   
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Table S3 continued 
Level of 17β-HSD-1 inhibition  
 
total number < 95 % ≥ 95 % 
Fisher exact 
test # 
 
 number % number %  
Myometrial invasion (n = 42)       
no 7 5 71 2 29 N.S. 
<1/2 15 9 60 6 40  
>1/2 15 12 80 3 20  
unknown    2   
Recurrence (n = 42)       
Negative 31 20 65 11 35 N.S. 
Positive 6 4 67 2 33  
unknown  5     
Parity       
Positive 29 17 59 12 41 N.S. 
Negative 10 8 80 2 20  
unknown  6  1   
History of hypertension       
Positive 25 18 72 7 28 N.S. 
Negative 18 11 61 7 39  
unknown  2  1   
History of T2 diabetes       
diabetes T2 no 36 24 67 12 33 N.S. 
diabetes T2 yes 7 5 71 2 29  
unknown  2  1   
 
# N.S. = non-significant
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Abstract  
Endometrial cancer (EC) is the most common gynaecological malignancy in the Western society 
and the majority of the cases are estrogen dependent. Although endocrine drugs proved of 
insufficient therapeutic value in the past, recent clinical research shows promising results by 
using combinational regimens and pre-clinical studies identified potential novel endocrine 
targets. Relevant pre-clinical models can accelerate research in this area. In the present study 
we describe an orthotopic and estrogen dependent xenograft mouse model of EC. Tumours 
were induced in one uterine horn of female athymic nude mice using the well-differentiated 
human endometrial adenocarcinoma Ishikawa cell line modified to express the luciferase gene 
for bioluminescence imaging (BLI). BLI and contrast-enhanced CT (CE-CT) were used to 
measure non-invasively tumour growth. Controlled estrogen exposure was achieved by the 
use of MedRod implants releasing 1.5 μg/d of 17β-estradiol (E2) in ovariectomised mice. Stable 
E2 serum concentration was demonstrated by LC-MS/MS. Induced tumours were E2 
responsive as increased tumour growth was observed in presence of E2 but not placebo, 
assessed by BLI, CE-CT and tumour weight at sacrifice. Metastatic spread was assessed 
macroscopically, by BLI and histology and was seen in the peritoneal cavity, in the 
lymphovascular space and in the thoracic cavity. In conclusion, we developed an orthotopic 
xenograft mouse model of EC that exhibits the most relevant features of the human disease, 
regarding metastatic spread and estrogen dependency. This model offers easy to manipulate 
estrogen dosage (by simply adjusting the MedRod implant length), image-guided monitoring 
of tumour growth, and offers objectively measurable endpoints (including tumour weight). 
This is an excellent in vivo tool to further explore endocrine drug regimen and novel endocrine 
drug targets for EC. 
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Introduction 
Endometrial cancer (EC) is the most common gynaecological malignancy in the Western world 
with over 60.000 new cases estimated in 2017 (U.S.; https://seer.cancer.gov). About 70% of 
ECs are diagnosed at an early stage and are treated with surgery, with selected cases also 
receiving adjuvant chemo/radio therapy. Nevertheless, about 25% of EC patients will develop 
recurrent disease. In patients with recurrent EC and in EC cases with primary advanced stage 
and distant metastatic disease, treatment options are limited. They consist of aggressive 
chemotherapy, which however yield low efficacy, poor patient prognosis and are accompanied 
by significant side effects [1, 2]. Hence, there is need for additional treatment possibilities. 
EC is an estrogen dependent disease, but in contrast to other hormone-dependent conditions 
like prostate or breast cancer where endocrine therapy is successfully used, treatment of EC 
with hormonal drugs showed little efficacy [3-6]. However, recent clinical trials indicate that 
the efficacy of hormonal drugs is improved if combined with other targeted treatments (see 
discussion) [7]. Since ongoing pre-clinical research has already identified a number of 
additional novel endocrine targets [8-10], it can be envisaged that in the near future several 
endocrine targets and novel drugs will be available for various combinational regimens in EC 
clinical trials. 
To accelerate the research in this field, relevant pre-clinical models need to be developed that 
better mimic the human situation than the current models. In case of EC, pre-clinical models 
are based on in vitro 2D monolayer cell cultures, 3D spheroid cell cultures and in vivo models 
using the chorioallantoic membrane assay (CAM) or by subcutaneous injection of human EC 
cell lines in athymic mice. However, these models are suboptimal and often lack estrogen 
dependency and clear estrogen responses (see discussion) [10-12]. 
Orthotopic xenografts models are relevant pre-clinical tools because the tumour is induced at 
the same location and similar microenvironment where it occurs in humans. Recently, different 
research groups reported successful orthotopic EC xenografts in mice that mimicked the 
human condition including the metastatic spread [13-16]. In particular, Haldorsen and co-
workers optimised the orthotopic EC xenograft using the estrogen dependent Ishikawa cell 
line. However, tumours were grown in the presence of the natural endogenous source of 
estrogens, the ovaries, and the authors did not explore the possibility to control estrogen 
exposure [14]. To be able to control and modulate steroidal exposure and mimic conditions 
like post menopause, in collaboration with the same authors, here we further advanced this 
orthotopic EC xenograft model to control steroid exposure and induce estrogen dependent 
tumour growth, as is the case in the majority of ECs in humans. This model offers the possibility 
to manipulate estrogen (and other steroid) dosage, image-guided monitoring of tumour 
growth and easily determined and objective endpoints to measure estrogen response. 
Moreover, it exhibits clinical features similar to human EC like metastatic spread and presence 
of lymphovascular invasion (LVI), thus being a highly relevant model of the disease. We believe, 
this is an excellent in vivo tool to further explore endocrine drug regimen and novel endocrine 
drug targets for EC. 
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Results 
Orthotopic EC xenograft: cell titre optimisation 
We first determined the optimal number of Ishikawa-derived cells required for tumour 
induction using three different titres (1x106, 3x106 and 5x106 cells/mouse; Table 1) that were 
injected in gonad-intact mice with no further steroid supplementation (see scheme in Figure 
1a). Ishikawa clone 1 was used in this optimisation. The lowest dose (1x106 cells) gave a weak 
bioluminescence (BLI) signal and tumour engraftment did not occur in one out of three injected 
mice. Although all mice receiving 5x106 cells developed a tumour, it was technically challenging 
to inject such a large number of cells into the uterus. Orthotopic injection of 3x106 cells 
appeared the optimal dose since no technical difficulties were experienced and all mice 
developed a tumour. 
 
Table 1. Optimisation of cell titre for tumour induction. 
Injected cells 
(number) 
Number of mice 
Mice with 
tumour (%) 
Peritoneal 
metastases* 
Distant 
metastases# 
1×106 3 2 (67%) I 0 
3×106 3 3 (100%) I, L, K, S, St 1 (T + LVI) 
5×106 3 3 (100%) I, L, K, S, St 0 
* All mice developed peritoneal spread as assessed by ex-vivo BLI. # number of mice with metastases. 
I=intestine, L=liver, K=kidney, S=spleen, St=Stomach, T=thoracic cavity; LVI= lymphovascular invasion. 
 
Ovariectomy and estrogen supplementation (MedRod implants) 
In order to control the levels of circulating E2 and measure estrogen dependent EC growth, 
the ovaries, which are the main endogenous sources of female sex steroids, were removed by 
ovariectomy (OVX) and E2 was provided exogenously by E2 releasing MedRod implants. 
MedRods consisted of 1-4 mm diameter cylinder-shaped elastic rods containing E2, and were 
implanted subcutaneously on the back of the mice, in between the scapulae. The serum E2 
concentrations in mice with E2 MedRods with daily release of 1.5 μg/day (5.5 nmol/day) 
resulted in constant average serum concentrations of E2 between 338-443 pM (Figure 1b). 
Accordingly, implants releasing another kind of estrogen (estrone) had similar performance, 
i.e., constant serum levels of the test compound at different doses (Supplementary figure 1). 
 
Estrogen responsiveness of the orthotopic EC xenograft 
To assess estrogen dependency of tumour growth, cancer cells (3×106) were injected, mice 
were ovariectomised and E2 or placebo releasing MedRods were implanted (Figure 1a and 
Table 2). Three Ishikawa derived clones (clone 1, clone 2 and clone 3) were used. These clones 
were obtained through genetic modification and clonal expansion of the parental Ishikawa cells 
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(see material and methods) and behave similarly in terms of E2 responsiveness based on 
previous characterisation [10]. Three clones were nevertheless used to avoid that any clonal 
effect would bias the results. 
Previous studies on estrogen dependent cancer models showed that estrogens are required 
for initial tumour engraftment (lag phase) [17-19]. Therefore, complete OVX was performed 
approximately two weeks after tumour cell injection, i.e., when tumours were successfully 
engrafted, as assessed by positive BLI signals. However, at the time of tumour cell injection the 
ovary at the same horn-side of the injection was removed (ipsilateral OVX) to avoid that, after 
the lag phase (two weeks later), tumour overgrowth would impede the complete removal of 
the ovary or that part of the tumour would be removed together with the ovary. Following 
complete OVX, MedRod implants releasing either placebo or 1.5 μg E2/day were implanted 
(see timeline in Figure 1a and the procedure in Supplemental Figure 2).  
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Figure 1. Experimental design and bioluminescence (BLI) results. (a) Timeline of the mouse model. Tumours were 
induced by orthotopic cell injection in one horn of the uterus (week −2). At the same time, ipsilateral OVX was 
performed. Two weeks later (i.e., at the end of the lag phase; week 0) OVX was performed at the other uterine 
horn as well, and the MedRod delivery system for E2 or placebo supplementation was implanted subcutaneously. 
Tumour growth was monitored weekly by BLI until the humane endpoint was reached. Before euthanasia CE-CT 
was performed. # Ipsilateral OVX. & OVX was not performed in the first experiment testing the cell titer. * Humane 
endpoint: signs of discomfort due to large-sized tumours. (b) Serum E2 concentration (LC-MS/MS) in mice 
implanted with MedRod devices releasing 1,5 μg/day of E2. Boxplots indicate the median and the lower and upper 
quartiles. Blots represent data from 9 (5 weeks) and 12 mice (6 weeks) per time point. (c) Body weight. Mean 
values and standard deviations are shown (placebo: 8 mice; E2: 8 mice). (d) Representative images of in vivo 
sequential BLI. Note that the BLI signal from the location of primary tumour induction tends to decrease at late 
time points due to necrosis of the tumour tissue (as assessed histologically). (e) BLI fold change during the 
experiment. Shown data refer to the experiments with the Ishikawa clone 3. Similar data were obtained with the 
other cell clones (data not shown). Mean values and standard deviations are shown (placebo: 3 mice; E2: 2 mice). 
Asterisk (*) indicates a p-value < 0.05 (t-test). 
 
Tumours were grown for additional six weeks (eight weeks in total; i.e., two weeks for tumour 
engraftment -lag phase- and six weeks for E2-stimulated tumour growth) and growth was 
monitored weekly by BLI. Tumours developed in all sixteen mice (Table 2). Three weeks after 
OVX and E2/placebo supplementation, weight loss started to be observed in all mice, most 
likely because of the side effects and initial cachexia due to tumour growth, and this was more 
pronounced in the E2 group (Figure 1c). At week 6 after OVX and E2/placebo supplementation, 
mice presented signs of discomfort due to large-sized tumours, and mice were euthanized 
(humane endpoint). During the six weeks following OVX and E2/placebo supplementation, 
tumour growth (assessed by BLI) was clearly E2 responsive and in the E2 arm, BLI signal was 
not limited to the tumour induction area (as in the placebo group), but it spread to other 
locations in the abdomen (Figures 1d and 1e). As expected, within the same treatment group 
(E2 or placebo), no differences were observed in the growth of tumours induced with different 
Ishikawa clones. 
 
Table 2. Overview of the experimental animals used to develop the E2-dependent endometrial cancer model. 
Ishikawa 
(3×103 cells) 
OVX 
Placebo 
/E2 
Number of 
mice 
Mice with 
tumour 
CE-
CT 
Peritoneal 
metastases* 
LVI#  
(no.) 
Clone 1 
+ Placebo 3 3 (100%) 3 I, L, K, S (P, A) 0 
+ E2 3 3 (100%) 2 I, L, K, S, St (P, A) 3 
Clone 2 
+ Placebo 2 2 (100%) 2 I, L, K, St (A) 1 
+ E2 3 3 (100%) 3 I, L, K, S, St (P, A) 2 
Clone 3 
+ Placebo 3 3 (100%) 0 (A, P) 0 
+ E2 2 2 (100%) 0 (A) 2 
* All mice developed peritoneal spread as assessed by ex vivo BLI. Location is indicated as follow: I=intestine, 
L=liver, K=kidney, S=spleen, St=stomach, P=psoas, A= adipose tissue (by brackets, histologically confirmed); # LVI= 
lymphovascular invasion; number of mice with metastases. 
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Table 3. Overview of the CE-CT scan data. 
Ishikawa 
Placebo 
/E2 
x 
(cm)1 
y 
 
(cm)2 
z 
(cm)3 
Tumour volume (ml)4 Tumour density ± SD5 
Tumour  
Weight* 
Clone 1 placebo n.d. n.d. n.d. n.d. n.d. n.d. 
Clone 1 placebo 0.27 0.23 0.27 0.01 131.7 ± 15.6 20 
Clone 1 placebo 0.63 0.53 0.41 0.07  -9.3 ± 4.9 118 
Clone 2 placebo 0.14 0.14 0.23 0.002 137.3 ± 25.9 18 
Clone 2 placebo 1.18 0.9 1.47 0.78 107.8 ± 4.5 568 
Clone 2 E2 0.68 0.74 0.93 0.23 24.8 ± 4.7 333 
Clone 1 E2 
0.57+ 
0.80+ 
1.0 
0.51+ 
0.94+ 
0.76 
0.63+ 
0.95+ 
0.85 
0.77 57.3 ± 8.0 1123 
Clone 1 E2 0.78 0.98 0.97 0.37 31.2 ± 3.2 353 
Clone 2 E2 n.d. n.d. n.d. n.d. n.d. 2147 
Clone 2 E2 1.25 1.04 1.58 1.03 47.8 ± 15.2 1347 
Clone 2 E2 0.49 0.45 0.43 0.05 -6.3 ± 10.4 81(6) 
 
(1) x: Maximum transverse tumour diameter at the axial image depicting the largest tumour diameter. (2) y: 
Maximum anterioposterior tumour diameter at the axial image depicting the largest tumour diameter. (3) z: 
Maximum sagittal tumour diameter at the sagittal image depicting the longest sagittal tumour diameter. (4) 
Tumour volume (ml): = x×y×z/2. * tumour weight: real wet-weight (in mg) of surgically removed tumour after 
sacrifice. n.d.: non detectable/determinable. (5) Tumour density is indicated as mean values ± standard deviation 
(SD). (6) This mouse (indicated by the red dot in Figure 2) belongs to the E2 treated group but initially there was 
no tumour engraftment (i.e., no BLI signal at the moment of E2 supplementation, week 0, probably due to sub-
optimal cell injection). This mouse was nevertheless kept in the experiment and showed BLI signals, though 
strongly delayed, during next measurements. 
 
CE-CT, endpoint and tumour characteristics 
Prior to sacrifice (six weeks after OVX and E2/placebo supplementation), 11 animals were 
investigated by CE-CT scan (Table 3 and Figure 2a). Tumour volume estimation confirmed a 
more sustained tumour growth in the E2 group (mean volume 0.5 ml) compared to the placebo 
group (mean volume 0.2 ml). Tumour density was very variable between mice (Table 3) and 
was not significantly different between the groups (E2 group: 28±26 vs. placebo group: 92±67). 
Mice were euthanized and uteri, tumours and other organs were isolated and examined. As 
expected, uteri of the E2 group were substantially larger compared with the placebo, due to 
estrogen stimulation (Supplemental Figure 2). Both uterine wet-weight as well as tumour wet-
weight were significantly higher in the E2 treated group compared with placebo (Figure 2b). 
The weight of surgically removed tumours correlated with the tumour volume estimated by 
CE-CT (Figure 2c). Histologic evaluation of uteri confirmed the presence of epithelial gland 
proliferation in the E2 treated group and the absence of growth in the placebo group 
(Supplemental Figure 2). Tumours grew throughout the whole uterine wall and expanded 
locally beyond the uterus. Histologic evaluation confirmed the orthotopic localisation of EC, 
embedded in the endometrium/myometrium (Figure 3a). As tentative discrimination between 
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mouse and human (i.e. induced tumours) tissues, we used immunohistochemistry and 
antibodies able to recognise predominantly the mouse ERα (MC-20), or both human and 
mouse ERα (HC-20; Figure 3b). Although some cross reactivity between species of these 
antibodies is present, they indicate that tumour is most likely of human origin. Tumour 
histology showed no clear glandular organisation, but still it recapitulated the human situation 
and nested or trabecular histology structures, with hypochromatic nuclei and several mitotic 
figures were seen (Figure 3c and 3d). Large tumours showed signs of necrosis (Figure 3d). No 
major histologic differences were seen between the used clones (not shown). 
 
 
 
Figure 2. Tumour growth determined by CE-CT and wet-weight at sacrifice. (a) Representative CE-CT scan images 
centred by the blue cross at the centre of the tumour (indicated by the red dotted line). The yellow-bordered 
inset shows the size of the uterus and the tumour surgically removed at sacrifice. (b) Uterine and tumour wet-
weight in the E2 treated and placebo groups. The colour codes indicate the different cell clones used. The red dot 
in the right panel shows the tumour weight of an E2 treated mouse from clone 1 with not proper tumour 
engraftment (no BLI signal at the moment of E2/placebo supplementation, week 0) probably due to sub-optimal 
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cell injection (see also Table 3). p values are computed using t-test (outlier included). (c) Correlation between 
tumour volume estimated by CE-CT and the wet-weight of surgically removed tumours at sacrifice. 
 
Figure 3. Tumour histology and estrogen receptor expression. (a) Representative histology showing the orthotopic 
location of the induced tumour. The mouse shown is from a placebo treated mouse, where tumour growth 
remained confined inside the uterus until the end of the experiment. The thickness of the endometrium (endom.), 
myometrium (m) (and the tumour, in the right image only) is indicated by the double-headed arrow. Bar scale: 
200 μM. (b) Analysis of ER-α expression using antisera directed against human receptor but cross reacting with 
the mouse ER-α (left, HC-20), where both tumour (most likely of human origin) and mouse endometrial tissues 
have nuclear staining, and using antisera directed against mouse ER-α (right, MC-20), with nuclear staining only 
in mouse tissues and showing cytoplasmic background in the tumour. Bar scale: 200 μM. (c) Representative image 
of the tumour histology (E2 treated sample), with nest and trabecular structures (indicated by the dotted white 
line on the enlargement, right image). Mitotic figures (green arrowheads) and blood vessels (yellow arrowheads) 
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are visible. Bar scale: 200 μM. (d) Representative image of a large tumour with a large necrotic core. Yellow 
arrowheads: blood vessels. Bar scale: 200 μM. 
Metastases 
Metastatic spread was assessed post-mortem by ex-vivo BLI, and it was observed in all mice 
(Tables 1, 2 and Figure 4a), the extent being related to the tumour size. Metastatic spread was 
also assessed histologically in all peritoneal organs (see Tables 1, 2 and Figure 4b). Slides were 
prepared for histology every 200 μM of thickness in order to cover the complete depth of the 
tissue. In most cases, metastatic peritoneal lesions were superficial on various organs in the 
abdomen and, with some exceptions, did not infiltrate the organs (Figure 4b). Careful histologic 
assessment was performed by an experienced pathologist (LK; blinded for other characteristics 
and origin of the samples), for the presence of lymphovascular invasion (LVI) in the tissue 
surrounding the uterus and in the tumour. Seven out of eight E2 treated animals (87%) 
developed LVI, whereas only 1/8 (12%) developed LVI in the placebo group (Tables 1 and 2). 
Representative sections depicting metastases at different sites are displayed in Figure 4b. 
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Figure 4. Ex-vivo BLI and histologically confirmed metastases. (a) Representative images of post mortem ex-vivo 
BLI used to assess the metastatic spread to different peritoneal and extra peritoneal organs. Left: example of 
spread restricted to peritoneal organs. Right: example of spread to the heart/lungs (thoracic cavity). Strong BLI 
signal was associated with fat tissue adjacent to peritoneal organs (spleen, kidneys). (b) Representative images 
and histologic confirmation of tumour spread to the psoas muscle, intestine, stomach/oesophagus, LVI and 
infiltrating tumour cells in the (anatomic location/organs are indicated in the images). Bar scale: 300 μM. 
 
Discussion 
In this study we describe the development of an orthotopic endometrial cancer (EC) mouse 
model where estrogen exposure was controlled and estrogen dependent tumour growth 
measured. Tumours were induced using the well-differentiated human endometrial 
adenocarcinoma Ishikawa cell line, modified to express a luciferase reporter gene [10] for 
bioluminescence imaging (BLI). Moreover, a novel MedRod delivery system was used in which 
subcutaneous implants provided a constant release of 17β-estradiol (E2) after ovariectomy 
(OVX).  
Various in vitro and in vivo models of EC exist. A few EC cell lines are available, and those 
authenticated and deposited in cell banks are the estrogen sensitive Ishikawa, and the less 
estrogen sensitive Hec1A, Hec1b, RL95.2, KLE and An3CA (www.atcc.org). These cells can be 
grown in vitro as monolayers or as spheroids [20]. It is however challenging to measure direct 
cell proliferation (e.g. increased cell number, BrdU incorporation) in response to E2 stimulation 
using these cells (own experience and [21]) and it is frequently necessary to assess cell growth 
using immunohistochemical markers like Ki-67 or cyclin expression. One of the simplest in vivo 
models is based on EC cells xenografted on the chorioallantoic membrane (CAM) of fertilised 
eggs [10]. This model is very suitable to test drugs with strong cytotoxic effects thus allowing 
measuring differences in tumour volumes/wet-weight as endpoints [22], but due to the short 
time of xenograft growth (approximately 5 days), long-term experiments (such as the E2-
dependent growth) need to rely on immunohistochemical markers as endpoints [10]. EC 
models based on rodents are also available in which tumours develop in mice because of 
genetic manipulation or chemical exposure, or tumours are induced via xenotransplantation 
of tumour cells subcutaneously or in the fat pad [21]. 
A subcutaneous EC xenograft model in OVX mice receiving estrogen supplementation was also 
developed and showed estrogen dependency [17]. The induction of tumours orthotopically, 
however, represents an important advancement in oncology research, and orthotopic EC 
models were recently developed using Hec1a and Ishikawa cells [13-15]. The orthotopic model 
is a biologically more relevant model than the subcutaneous or fat pad models since tumours 
are grown in the same microenvironment and the same physiologic conditions as these occur 
in humans. In addition, as shown in the present study and in previous publications [13, 14], the 
orthotopic model has clinical relevance because tumour cells infiltrate the myometrium and 
invade the peritoneal cavity and the vascular and lymphatic systems as well, thus mimicking 
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the progression of human disease. In our study, we advance this orthotopic mouse model of 
EC to optimise and control its estrogen dependency upon OVX. Since most EC are diagnosed 
and treated after menopause, when the ovaries no longer produce estrogens, dosing correctly 
the levels of these steroids is of extreme importance to best mimic the human EC.  
In order to exogenously dose and control estrogen levels, we used a recently optimised 
delivery system consisting of subcutaneous implants called MedRods. This release system 
provides cost effectiveness and constant dosage of the immobilised compound by diffusion in 
the body for a long period (minimum 10 weeks), therefore, in most cases, only one 
implantation for the whole duration of the experiment is required. Different delivery systems 
for exogenous administration of steroids and other compounds exist, which include oral 
administration via drinking water, regular injections, subcutaneous pellets or osmotic mini 
pumps [23-25]. These different delivery systems have obvious advantages and disadvantages 
with lab-to-lab preferences. Administration via drinking water is cost effective but dosing is 
difficult to control. Injections require continuity in the application, result in concentration 
peaks and cause discomfort to the animals. Subcutaneous pellets are easy to apply but often 
the delivery rate is not constant, whereas osmotic minipumps are efficient in terms of delivery 
rates, full customisation of the compound to deliver is feasible (minipumps are assembled by 
the investigators themselves) but are relatively expensive, large in size and have a limited 
elapse time, which may require pump replacement in the course of the experiment. Using the 
MedRod implants, our model proved to be E2 dependent with clear differences in tumour 
growth and wet-weight between the E2 and placebo groups. Thus MedRod implants provide a 
valid alternative over other existing delivery systems. In our experiments we used a relatively 
high level of E2, i.e., 300-400 pM, which is about 10 times more concentrated compared with 
the peak E2 levels in cycling female mice (proestrus, E2 level is about 40 pM). This E2 dose was 
chosen on the one hand because it was used in previous studies [16, 17, 19, 26], on the other 
hand to secure both fast tumour growth and clear and measurable differences between 
placebo and E2 groups. Nevertheless, lower estrogenic doses (e.g. the low active E1 at 
concentrations lower that 100 pM, comparable or lower than 40 pM of E2 - Supplemental 
Figure 3 -, but also the experiment on cell titre performed in gonad intact mice, Table I) elicited 
tumour growth and uterine responses that were indistinguishable from those induced by the 
positive control E2. 
Since most EC in humans are estrogen dependent, it is extremely relevant that the present 
orthotopic EC xenograft model exhibits this feature of the human disease. The estrogen 
dependency of EC is currently not exploited in the clinic as is in breast or prostate cancer 
treatment, due to the reported low efficacy of endocrine drugs for EC patients [3-6]. Although 
single-endocrine drug treatments have failed to show good efficacy, a recent trial of dual 
regimen including an aromatase inhibitor (AI) and an mTOR inhibitor yielded promising results 
with good efficacy [7]. It is generally agreed upon that there is room for improvement of the 
current use of hormonal drugs in EC, and that endocrine treatment may represent an 
important approach in EC in the future [27]. This is demonstrated by the numerous currently 
ongoing phase II trials that are testing various combinational treatments, e.g., mTOR inhibitor 
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in combination with AI and metformin (NCT01797523: www.clinicaltrial.gov); AI and ribociclib 
(NCT03008408); dual mTORC1/mTORC2 inhibitor and AI (NCT02730923); mTOR and AI 
inhibitors compared with progestogens and tamoxifen (NCT02228681); ribociclib and AI 
(NCT02657928); sodium cridanimod in conjunction with progestin (NCT03077698); AI 
combined with palbociclib (NCT02730429). 
In addition, a number of novel potential endocrine drug targets are being discovered [8-10, 28] 
and, therefore, the establishment of proper tools for pre-clinical testing of these novel 
endocrine targets is of foremost importance. 
The protocols and methods described in this study can help future research in endocrine drug 
discovery and accelerate the translation from bench to bedside. We use E2 stimulation as 
reference of positive tumour growth, but the model is amenable to mimic different clinical 
situations, like post menopause (over 90% of all EC cases), recapitulated by OVX and ad-hoc 
steroid supplementation, or pre-menopausal EC, using gonad intact mice with cycling E2 and 
progesterone. We used BLI for tumour growth monitoring, but we also demonstrated a good 
correlation between BLI and CE-CT findings, making our method also suitable for systems 
lacking an endogenous reporter gene (e.g., luciferase/BLI), such as patient derived EC tumour 
xenografts (PDX), the most relevant animal model in cancer research available today [29]. 
In conclusion, we present here an orthotopic xenograft mouse model of EC, which mimics the 
human condition in terms of tumour localisation, estrogen dependency and metastatic spread. 
This model will be useful for future pre-clinical studies testing the efficacy of novel drugs and 
of combinational regimens of novel and existing treatments. 
 
Materials and Methods  
Ethics statement 
All animal procedures were approved by The Netherlands National Committee for the 
protection of animals used for scientific purposes and the Central Authority for Scientific 
Procedures on Animals or by the National Animal Experiment Board of Finland. All procedures 
were performed according to the European Convention for the Protection of Vertebrates Used 
for Scientific Purposes.  
 
Cell lines and tumour graft preparation 
The human endometrial adenocarcinoma cell line Ishikawa (ECACC, Sigma-Aldrich, 
Zwijndrecht, The Netherlands) was previously modified in our laboratory to express firefly 
luciferase fused with green fluorescent protein (GFP) for non-invasive bioluminescence 
imaging (BLI). The established Ishikawa clones were thoroughly characterised for the 
maintenance of markers of the parental Ishikawa cell line and were authenticated by Short 
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Tandem Repeat (STR) profiling [10]. Since different cell lines/clones may behave differently 
(clonal effects), three different Ishikawa clones (Ishi-M3-HSDA, Ishi-M1-HSDB and Ishi-M3-EVC, 
from now on, referred to as clone 1, clone 2 and clone 3) were used in the present animal 
experiments. Cells were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented 
with sodium-pyruvate, L-glutamine, penicillin-streptomycin and 10% foetal bovine serum at 
37°C with 5% CO2 in humidified air, and were tested negative for mycoplasma (MycoAlert, 
Promega, Madison, USA). For orthotopic injections, cells at no more than 70% confluency were 
detached with Accutase (Invitrogen, Carlsbad, CA), pelleted and resuspended in 30 µl ice-cold 
Matrigel (Basement Membrane Matrix; Becton Dickinson, Vianen, The Netherlands).  
 
Optimisation of the MedRod steroid delivery system 
To control estrogen exposure (for estrogen dependent tumour growth), the endogenous 
source of estrogens (ovaries) was removed and an exogenous estrogen supply was provided 
(estrogen supplementation) by using the recently optimised MedRod implants (PreclinApps 
Ltd, Raisio, Finland). MedRods are polydimethylsiloxane cylinders covered by a silicone 
membrane that have constant release of matrix embedded 17β-estradiol (E2) for at least 10 
weeks. The serum estrogen levels in MedRod bearing mice were determined by LC-MS/MS as 
previously described using approximately 1 ml of blood collected at sacrifice by heart puncture 
[30].  
 
Orthotopic estrogen dependent endometrial cancer mouse model (scheme in 
Figure 1a) 
Eight-week-old female athymic nude mice (Crl:NU(NCr)-Foxn1nu) were purchased from 
Charles River ('s-Hertogenbosch, The Netherlands) and housed in groups of 3-4 animals in 
individually ventilated cages and under specified pathogen-free conditions. Food and water 
were both sterilised and provided ad libitum. Complete diet with moderate energy density and 
very low nitrosamine content (Mouse maintenance diet, V1534-703, ssniff Spezialdiäten 
GmbH, Soest, DE) was used. 
For tumour cell injections, mice were anaesthetised with isoflurane (Forane, Abbott 
laboratories Ltd., UK) using 4-5% isoflurane in pressured air for induction of sedation and 1.5% 
isoflurane in pressured air for maintenance. Mice were placed on a heating pad in ventral 
decubitus. The skin was disinfected, an incision was made laterally at the lower dorsum and 
one uterine horn was exteriorized (in most cases, the left uterine horn was operated). If 
ovariectomy (OVX) was performed (see text), ipsilateral OVX was first performed at the uterine 
horn side of tumour induction. To this end, a ligature was placed in the fallopian tube and the 
ovary was removed above the ligature. The uterine horn was clamped at the two edges, just 
before the fallopian tube at the top and just before the uterus body at the bottom, in order to 
prevent leakage. Resuspended cells (30 µl of ice-cold Matrigel; 1-5 million cells as indicated in 
155
Development of an image-guided orthotopic xenograft mouse model of EC 
 
the text) were slowly injected into the endometrial cavity with a 25G needle. The needle was 
retracted after waiting for a few seconds, to allow the polymerisation of the Matrigel cell-
suspension and prevent leakage in the abdominal cavity. Muscle and skin incisions were 
sutured with 6-0 absorbable sutures (Supplemental Figure 2). The un-resected ovary was 
removed approximately two weeks after tumour cell injection, when the tumours had 
successfully engrafted (determined by BLI; next paragraph). 
For the implantation of the MedRod implants containing either placebo or E2 (releasing 1.5 μg 
E2/day; 5.5 nmol/day), a small incision was made in the loose skin of the animal neck. A pocket 
was bluntly dissected under the skin and the MedRod was placed using forceps. The incision 
was closed with a 6-0 absorbable sutures. For analgesia, mice received 7.5 mg/kg Carprofen 
(Norbrook Laboratories Ltd, Newry, UK) subcutaneously, pre- and post-operatively and for the 
following two days. The time-line of the orthotopic xenograft model is illustrated in Figure 1a. 
 
Imaging by BLI 
Tumour growth was visualised weekly by sequential BLI using the Andor iXon Ultra 897 camera 
in the X-RAD 225Cx system (Precision X-ray Inc., North Branford, CT). Mice were anaesthetised 
with isoflurane and injected intraperitoneally with 150 mg/kg D-Luciferin (Becton Dickinson, 
Vianen, The Netherlands), approximately 10 minutes prior to imaging. Six planar images were 
obtained at 0°, 45°, 90°, 180°, 270°, 315° angles (angle 0° corresponding to image from the top, 
dorsal side of the mouse). Images obtained from angles 270°-315° were used to compute the 
BLI signal intensity for mice where the tumour was induced on the left uterine horn (45°-90°, 
in case of right horn tumour induction). BLI data was analysed using ImageJ [31], and the total 
photon flux was determined in the Region of Interest (ROI) located in the abdominal area 
corrected for background signal.  
 
Micro Contrast Enhanced-Computed Tomography (CE-CT) 
Prior to euthanasia, micro CE-CT imaging was performed using the small animal micro-IR (X-
RAD 225Cx, Precision X-ray Inc., North Branford, CT). Mice were anaesthetised with isoflurane, 
and to enhance soft tissue contrast, 150 µl of iodinated Omnipaque 350 (GE Healthcare, Little 
Chalfont, UK) were injected in the tail vein immediately prior to imaging. Images were acquired 
as described earlier [32]. In short, an 80kVp, 2.5mA imaging protocol with an acquisition rate 
of 5 frames/sec, a spatial resolution of 100 microns and a gantry rotation of 0.5 revolution/min 
was used to image the abdominal region of all animals. Imaging dose was 39 cGy, spot size was 
approximately 1 mm and imager mode was in low gain (2x2 binning). The beam was filtered 
with 2 mm aluminium to remove the low energy photons that do not contribute to the imaging. 
The micro CE-CT images were analysed using the PMOD v.3.7 software (PMOD Technologies 
LLC, Zürich, Switzerland). The maximum tumour diameter was measured in three orthogonal 
planes (x, y and z) and tumour volume was estimated using the following equation; tumour 
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volume = x×y×z/2. Tumour density was measured in a volume of interest (VOI) placed in a 
representative part of the tumour, avoiding necrotic or haemorrhagic areas if present. The 
volume of the tumour VOIs had a median (range) of 0.02 (0.002-0.39) ml, wide range being 
explained by variable tumour size. 
 
Histological examination and immunohistochemistry 
Tissue biopsies were fixed in 3.7% formaldehyde, embedded in paraffin and processed for 
histological examination. Histology was determined by a pathologist (LK) from 4 µm 
haematoxylin & eosin (Sigma-Aldrich, Zwijndrecht, The Netherlands) stained sections. 
Detection of estrogen receptor-α (ERα) of human origin was performed with 
immunohistochemistry using the antibody HC-20 (Santa Cruz Biotechnologies, Heidelberg, 
Germany), whereas for mouse ERα, antibody MC-20 (Santa Cruz Biotechnologies, Heidelberg, 
Germany) was used. In brief, sections were subjected to deparaffinization followed by 
rehydration. Heat-induced antigen retrieval was performed and slides were blocked in 1% 
BSA/PBST and subsequently incubated overnight at 4°C with 500 times diluted ERα antibody, 
as described earlier [10]. The EnVision detection system was used according to the 
manufacturer’s manual followed by visualization with Diaminobenzidine (DAB). 
 
Statistics 
Statistical analyses were performed using KaleidaGraph version 4.1.3. (Synergy Software, 
http://www.synergy.com). Variance was analysed using parametric Student’s t-test whereas 
the Pearson’s correlation coefficient was used to evaluate the relationship between two 
variables. Differences and correlations were considered statistically significant at p<0.05. 
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Figure S1. Optimisation of the MedRod delivery using estrone as test compound.  
Serum levels of the estrogenic compound estrone (E1) measured by LC-MS/MS in athymic female mice 
implanted subcutaneously (s.c.) with MedRod releasing E1 at different doses, i.e., 0.3 μg/d (squares), 0.6 μg/d 
(triangles) or 1.8 μg/d (circles). Each line represents data from 5 mice. Data is expressed as mean ± SEM. 
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Figure S2. Overview of the tumour induction and characterisation.  
(a). Procedure of orthotopic tumour induction. One uterine horn is exteriorized and ipsilateral OVX was 
performed prior to cell injection. Cells resuspended in 30 μl ice-cold Matrigel are then slowly injected through 
the myometrium, into the endometrial cavity with a 25G needle syringe.  
(b). Macroscopic appearance of mice, abdominal cavity at laparotomy and surgically resected uterus with 
tumour at the time of sacrifice.  
(c). Macroscopic appearance of uterus with tumour and histology (haematoxylin & eosin, H&E) of mouse 
endometrium receiving either placebo (no growth/atrophic endometrium) or E2 (with evident glandular 
growth). 
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Figure S3. Uterine and tumour weight using less-sustained estrogen signalling. 
Since experiments were conducted with high E2 doses, uterine and tumour growth were tested using pellets 
(MedRods) releasing the low active E1 at a dose as low as of 0.3 μg/day corresponding to approximately 80nM 
of circulating E1 (see supplemental Figure 1). E1 requires concentrations of at least 1-2 magnitudes higher than 
E2 to elicit similar responses [33]. Data shown in figure refers to the wet weights at humane endpoint (animal 
sacrifice, six weeks after OVX). E1 was not significantly converted to E2 (measured by LC-MS in these mice) but 
it induced strong uterine responses and tumour growth that were not distinguishable from E2 treated mice.
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Abstract 
Introduction: Steroid hormones are involved in lung development, pulmonary inflammation, and 
lung cancer. Estrogen signaling and exposure may play a role in pulmonary disorders, including 
COPD. In both genders, estrogens can be generated locally in the lungs and this contributes 
importantly to the tissue exposure to these steroids. 
Objective: To characterize and assess differences in localization of estrogen receptors and 
enzymes involved in the local generation of estrogens in COPD. 
Methods: Estrogen Receptor alpha (ERα/ESR1), Estrogen Receptor beta (ERβ/ESR2) and G-protein-
coupled estrogen receptor 1 (GPER) were explored by real-time (RT)-PCR analysis (mRNA 
expression), immunohistochemistry and western blotting in controls and COPD patients. 
mRNA expression of the enzymes involved in the local estrogen generation – i.e. aromatase 
(CYP19A1), 17beta-hydroxysteroid dehydrogenases (17β-HSDs) 1, 2, 4, 5, 7 and 12, steroid 
sulfatase (STS) and sulfotransferase (SULT1E1) - were analyzed by RT-PCR.  
Results: ERα, ERβ and GPER were expressed in lung tissue, but no differences were observed 
between patients and controls. The main enzymes involved in local estrogen generation were also 
present in both normal and COPD lung tissue. In lungs of COPD patients compared with controls, 
we observed increased expression of the enzymes 17β-HSD type 1 and aromatase (positive 
association), both involved in the local synthesis of active estrogens. 
Conclusion: All ER subtypes are present in the lung. The shift in local mRNA level of estrogen 
metabolic enzymes suggests that exposure to estrogens is involved in the pathogenesis of COPD.  
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a common and debilitating chronic health 
condition characterized by progressive and persistent airflow limitation, associated with an 
enhanced chronic pulmonary inflammatory response. The major risk factor for disease 
development is exposure to inhaled noxious particles or gases, such as tobacco smoke [1-3]. The 
prevalence of COPD is nearly equal among men and women, but the incidence of the disease is 
increasing more rapidly in women than in men. Gender disparities amongst various lung diseases 
are commonly reported and biological and clinical evidence suggests a contribution of the female 
hormones estrogens in disease development [4-8].  
The final cellular and tissue effects exerted by estrogens depend on the presence of the ligand-
activated estrogen receptors (ERs, namely ERα, ERβ and G Protein-coupled estrogen receptor, 
GPER) and the intracellular availability of estrogens, i.e. the ligand for the receptors [9, 10]. ERα 
and ERβ activate the classical genomic and non-genomic estrogen signaling mechanisms, i.e., they 
directly or indirectly (via interaction with other transcription factors) control the transcription of 
target-genes. The more recently characterized transmembrane GPER mediates rapid non-genomic 
signaling [11-15] and was recently implicated in genomic signaling as well [15]. 
Before menopause, the major sources of estrogens are the ovaries, which contribute largely to 
the circulating levels of these hormones. However, in postmenopausal women and in men, 
estrogens are generated locally in various reproductive and non-reproductive tissues using as 
precursors serum androgens and adrenal-cortex steroids. This extra-ovarian source of estrogens 
controls the final intracellular availability of the ligand for the ERs [16-18]. Such local generation 
of estrogens is controlled by enzymatic conversions [19], among which, one of the most important 
is the formation of estradiol (E2), the natural and most potent estrogen, from estrone (E1), a 
precursor of E2 with little biological activity. The enzymes 17-beta-hydroxysteroid dehydrogenases 
(17β-HSDs) control the interconversion between E1 and E2. Type 1 17β-HSD catalyzes the 
reduction of E1 to E2, whereas type 2 17β-HSD catalyzes the oxidation of E2 to E1 [20]. A number 
of additional reductive (types 5, 7 and 12) and oxidizing (type 4) 17β-HSDs have been suggested 
to activate and deactivate estrogens. Although a potential role of 17β-HSD types 7 and 12 to 
convert E1 into E2 is not fully excluded [21], recent investigations disregard that the remaining 
enzymes can use these steroids as substrates in vivo [22-24]. 
Beside the redox balance between E1 and E2 controlled by types 1 and 2 17β-HSDs, steroid 
sulfatase (STS) and estrogen sulfotransferase (SULT1E1) are involved in local estrogen production. 
E1 conjugated with a sulfate group (E1-sulfate) is the estrogenic compound with the highest 
concentration in the blood due to its high water solubility and long half-life. E1-sulfate is 
completely inactive and is not able to pass the cell membrane. STS is a membrane-associated 
microsomal enzyme localized on the endoplasmic reticulum [25] and converts E1-sulfate to free 
intracellular E1, while SULT1E1 catalyzes the reverse reaction. A final extra-ovarian source of 
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estrogens is represented by the aromatization of the androgens androstenedione (A) and 
testosterone (T) to E1 and E2, respectively, catalyzed by the enzyme CYP19A1 aromatase [22-24]. 
Recent investigations underscore the role of these local metabolic conversions in causing local 
estrogen overexposure. A shift in the estrogen metabolism favoring the generation of E2 has been 
observed in several benign and malignant gynecological disorders [18, 24, 26], and also in lung 
diseases [27-29]. In non-small cell lung cancer both aromatase [29] and 17β-HSD type 1 [27, 30] 
contribute to an increased intratumoral generation of E2. Furthermore, in interstitial pneumonia, 
local E2 concentrations in alveolar epithelial cells are increased due to elevated levels and activity 
of aromatase [31]. 
The contribution of local E2 in COPD has not been explored to date. However, women have a 
higher predisposition to develop the disease [28], and, although controversial, epidemiological 
studies have shown that hormone replacement therapy containing estrogens exacerbates COPD 
[32]. 
In this study we examined whether the estrogen signaling and the intracellular pathways 
controlling the generation of E2 are associated with COPD. We examined the level of expression 
and cellular localization of ER subtypes and of the major estrogen metabolizing enzymes in COPD 
affected and control lung tissue. Men and women (in most cases after menopause) were analysed 
together because it is known that the serum level of estrogens and their main precursors show 
only small differences between men and postmenopausal women (http://www.glowm.com), and 
the generation of these steroids locally from serum substrates represents the major estrogen 
source. 
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Material and methods 
Ethical statement 
The present study was conducted in compliance with the Helsinki Declaration. Protocols to use 
human materials for research were approved by the competent medical ethical authorities as 
stated below.  
 
Study population 1 (Table 1) 
Lung tissue for quantitative Real-Time PCR (RT-PCR) and western blot analyses was obtained from 
50 patients diagnosed with solitary pulmonary tumors at the Ghent University Hospital, Belgium. 
The subjects of study population 1 consisted of 24 COPD patients and 26 subjects without COPD 
(controls). Tissue specimens were obtained from the subpleural area of the upper lobe distant 
from the tumor. This study population was previously described [33]. All subjects provided written 
informed consent, according to protocols approved by the medical ethical committee of the Ghent 
University Hospital. 
 
Study population 2 (Table 1) 
In a second group of patients, lung tissue for immunohistochemistry with a cross-sectional surface 
of approximately 2 cm2 was obtained at the University hospital Maastricht, the Netherlands. The 
lung resection specimens for immunohistochemistry were obtained from tumor-free lung tissue 
in the subpleural area from 49 COPD patients, and from 22 subjects without COPD who underwent 
resection for a solitary peripheral tumor. Signs of a respiratory tract infection during four weeks 
preceding the study and a history of respiratory diseases, other than lung cancer were considered 
exclusion criteria. Anonymized archival lung tissue was obtained from the Maastricht Pathology 
Tissue Collection (MPTC). Collection, storage and use of tissue and patient data were performed 
in agreement with the “Code for Proper Secondary Use of Human Tissue in the Netherlands”. The 
scientific board of the MPTC approved the use of materials for this study under MPTC 2009-22.  
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Table 1. Clinical characteristics of study subjects  
 
Data are represented as mean ± standard deviation (SD), or as median (interquartile range (IQR) unless otherwise 
indicated. BMI, body mass index; FEV1, forced expiratory volume; FEV1/FVC, ratio of forced expiratory volume to 
forced vital capacity, DLCO, diffusion capacity. In study population 1 p-value <0.05 between never smokers and 
asymptomatic smoking controls are indicated as A, between COPD patients and never smoking controls is noted as N, 
and between COPD and asymptomatic smoking controls as C. In study population 2 p-value <0.05 control and GOLD 
2 are indicated as M, between control and GOLD 4 is noted as S, and between GOLD 2 and GOLD 4 is noted at G. 
 
Clinical characteristics of study populations 
The clinical characteristics of study population 1 and 2 were collected from hospital records and 
are summarized in Table 1. Both men and women were included: 36 men and 14 women were 
present in population 1 (two women were below the age of 55 and likely peri/premenopausal); 38 
men and 33 women were present in population 2 (eight women were below 55, and likely 
peri/premenopausal). Analyses were corrected for both gender and menopausal status, as 
described below. The number of pack-years and the smoking status were recorded. All subjects 
had smoked at least 10 pack-years. Subjects who stopped smoking at least one year prior to 
recruitment were considered ex-smokers. Lung function was determined by spirometry. Post-
bronchodilator forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were 
calculated from the flow-volume curve, and FEV1/FVC was calculated. 
The subjects of study population 1 were classified into three groups: never smokers, asymptomatic 
smokers and patients with COPD. The patients of study population 2 were classified into three 
groups: control, moderate COPD (GOLD 2; FEV1/FVC <0.70 and FEV1 between 50 and 80% 
predicted) and very severe COPD (GOLD 4; FEV1/FVC <0.70 and FEV1 lower than 30% predicted) 
[1, 2]. 
Population 1 
Never smoker 
n=9 
Asymptomatic 
smoker 
n=17 
COPD 
n=24 
Population  2 
control 
n=22 
GOLD 2 
n=24 
(Moderate) 
GOLD 4 
n=25 
(Severe) 
Age 61±10 61±11 67±8 Age 64±6 66±7 58±10 S,G 
Sex, m/f 2/7 11/6 A 23/1 N,C Sex, m/f 10/12 14/10 14/11 
Pack-year 0 33±18 A 46±25 N Pack-year 34±18 42±18 42±27 
Smoking status, 
N/C/E 
9/0/0 0/11/6 A 0/17/7 N,C 
Smoking status, 
N/C/E 
0/8/13 0/17/7 0/0/25 S,G 
BMI 22.8±3.2 26.4±6.1 24.6±4.5 BMI 25.8±3.6 26.2±4.9 23.9±3.3 
FEV1% predicted 98(86-104) 106(93-114) 68(57-77) N,C FEV1% predicted 101(89-116) 64(56-76) M 
23(19-24) 
S,G 
FEV1/FVC % 76(74-83) 76(71-81) 56(43-59) N,C FEV1/FVC % 78(75-84) 61(51-65) M 
25(23-29) 
S,G 
DLCO % 86(79-101) 91(77-109) 78(56-87) C DLCO % 82(69-106) 80(62-92) 
39(26-47) 
S,G 
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All patients were prescribed combination therapy of inhaled corticosteroids and long-acting β2-
agonists,  on demand.  
 
Quantitative Real-Time PCR 
Total RNA of snap frozen lung tissue was extracted using the RNeasy Mini kit (Qiagen, Hilden, 
Germany) and cDNA was synthesized by reverse transcription of total RNA using the Transcriptor 
First Strand cDNA synthesis kit (Roche, Basel, Switzerland) according to manufacturer’s 
instructions. Expression of the genes of interest ESR1, ESR2, GPER, 17β-HSD types 1, 2, 4, 7, 12, 
AKR1C3 (also known as 17β-HSD type 5), CYP19A1, STS, SULT1E1 and reference genes Homo 
sapiens hypoxanthine phosphoribosyltransferase (HPRT), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and ribosomal protein L13a (RPL13A) were analyzed using an iCycler iQ 
RT-PCR Detection System (Bio-Rad, Veenendaal, The Netherlands). Relative mRNA expression was 
calculated using the delta delta CT method with HPRT, GAPDH and RPL13A as reference genes for 
normalization. Oligonucleotide sequences of primers are provided as Supplementary Table 1.  
 
Western blot analysis 
Total protein extraction was performed using radioimmunoprecipitation assay (RIPA) buffer (Cell 
Signaling). For western blot analyses, 5 µg of protein per sample was separated on a Criterion XT 
4-12% Bis-Tris gel (Bio-RAD) and transferred to a PVDF membrane (Millipore) by electroblotting. 
The membrane was blocked in 5% (w/v) non-fat dry milk diluted in TBS/tween-20 (0.1%), followed 
by overnight incubation at 4°C with ERα (1:500; HC-20, Santa Cruz biotechnology), ERβ (1:200; H-
150, Santa Cruz biotechnology) and GPER (1:250; Sigma-Aldrich), all diluted in blocking buffer. 
After washing, the blots were probed with a peroxidase-conjugated secondary antibody (Vector 
Laboratories, Burlingame, CA, USA) and visualized using SuperSignal West Pico chemiluminescent 
or SuperSignal West Femto chemiluminescent substrate (Pierce Biotechnology, Rockford, IL, USA) 
according to the manufacturer’s instructions. 
 
Immunohistochemical analysis 
Four µm sections of formalin-fixed paraffin-embedded (FFPE) tissue were cut for 
immunohistochemical analyses of ERα (clone 1D5, Dako), ERβ (clone MCA1974ST, Serotec), GPER 
(clone HPA027052, Sigma-Aldrich), 17β-HSD type 1 (clone EP1682Y, GeneTex) and aromatase 
(clone MCA2077, Serotec), using a peroxidase-conjugated polymer backbone system (Dako, 
EnVision™ Detection Systems). Briefly, sections were subjected to deparaffinization followed by 
rehydration. Heat-induced antigen retrieval was performed for ERβ, GPER, 17β-HSD type 1 and 
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aromatase. Slides were immersed in 1% BSA/PBST blocking solution and subsequently incubated 
overnight at 4°C with ERβ (1:250), GPER (1:50), 17β-HSD type 1 (1:100) or aromatase (1:100) 
antibody. The envision detection system was used according to the manufacturer’s protocol 
followed by visualization with HRP-green for staining intensity quantification of ERβ and with 
Diaminobenzidin (DAB) for staining intensity and representative images (Figure 3) of GPER, 17β-
HSD type 1 and aromatase. Representative images for ERβ in Figure 3 were generated using DAB. 
ERα detection was performed with a ready-to-use antibody according to manufacturer’s 
recommendations and visualized with DAB. Sections were counterstained with haematoxylin 
(Merck-Millipore). The Allred method with slight modifications [24] was used to quantify the 
immunoreactivity by two independent observers (GFJK, BD) who were blinded to the clinical 
characteristics of the subjects and each other’s results. 
 
Statistical analysis   
SPSS (version 23, IBM Chicago, IL, USA) was used for data analysis. Comparison of characteristics 
and study variables between groups was performed by ANOVA and Bonferroni or Chi-square tests, 
for continuous or categorical data, respectively (as indicated in figure legend). Linear regression 
analysis (after correcting for the possible confounders age, sex, smoking status, pack-years and 
BMI) was used to investigate the association of gene expression with disease state or lung function 
impairment. P < 0.05 were considered significant. 
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Results 
Subject characteristics  
The clinical characteristics of subjects in whom RT-PCR analysis and western blot analysis were 
performed, are summarized in Table 1 as study population 1. In the COPD group, FEV1 (% of 
predicted), FEV1/FVC ratios and DLCO (%) were lower compared with never smokers and 
asymptomatic smokers. The COPD group was similar to never smokers and asymptomatic smokers 
(without COPD) with regard to age and BMI. The COPD and the group of smokers contained 
significantly more males than the never smokers. The COPD group consisted of significantly more 
current smokers compared with the asymptomatic smoker group, whereas the smoking history 
(pack-years) was similar.  
For the immunohistochemical assessment, a second study population was used (population 2; 
Table 1). GOLD 2 patients had decreased FEV1 values and FEV1/FVC ratios compared with control 
subjects, and these values including DLCO were further decreased in GOLD 4 patients. Gender 
distribution, BMI and pack-years were similar in controls and COPD patients. The number and 
prevalence of current and ex-smokers differed between the groups, whereas the smoking history 
did not. The GOLD 4 group consisted of subjects of a younger age.  
 
In the following analyses, we characterized the expression of ERs and of estrogen metabolizing 
enzymes in lung tissues from patients and controls. In total, 36 men and 14 women were included. 
Two women were below the age of 55 and likely peri/premenopausal. As explained earlier, since 
men and postmenopausal women have similar blood steroid levels, results presented here 
describing the local estrogen metabolism refer to both genders analyzed together. Only in case 
gender or menopausal related differences were observed, this is reported.  
 
Estrogen Receptor mRNA expression in human lung tissue  
To confirm the presence of ERs and measure their expression levels, RT-PCR analysis was 
performed on total lung tissue (population 1). In both males and females, ESR1 and ESR2 (encoding 
for ERα and ERβ, respectively) as well as GPER were expressed in lung tissue obtained from 
controls and patients with COPD (Figure 1). The presence of the translated proteins, ERα, ERβ and 
GPER, was confirmed in lung tissue by western blot analysis (Figure 1a) as well as by 
immunohistochemistry (see next paragraph).  
Linear regression analysis showed that the mRNA expression levels of the receptors did not differ 
between COPD patients and controls. Results were adjusted for possible confounders including 
age, sex, smoking status, pack-years and BMI (Table 2). However, the expression of ESR2 showed 
a negative association with lung function (FEV1; Figure 2a and Supplementary Table 2).  
202
Chapter 6 
Since smoking is the main risk factor for COPD, analyses were repeated by dividing the subjects in 
three groups: never smoker controls, asymptomatic smoker controls and COPD patients (Figure 
1b, 1c and 1d). Although the analysis of the whole population showed a decreased ESR2 mRNA 
expression in the AS group, this finding did not remain significant when the analyses was restricted 
to male only. No other association could be seen.  
 
Figure 1. Expression of ESR1 (ERα), ESR2 (ERβ) and GPER in control and COPD lungs 
a) ERα, ERβ and GPER protein expression in total lung tissue using western blot analysis. Equal amount of proteins 
were loaded per lane. GOLD 2: moderate COPD; GOLD 4: very severe COPD.  
b, c and d) mRNA levels of ESR1 (encoding for ERα; b), ESR2 (ERβ; c) and GPER (d) in never smoking controls (NS), 
asymptomatic smoking controls (AS) and COPD patients. mRNA levels were normalized with the reference genes and 
are shown as fold change compared to the NS controls. NS controls are set to one. Statistic test was based on ANOVA. 
‘A’ indicates that a p<0.05 in the total population did not remain significant when the analyses was restricted to male 
only. 
 
Table 2. Association of gene expression with disease state  
  
Association of disease state with 
gene expression 
  Β 95% CI R p-value p# P## 
Receptors 
ESR1 (ERα) 0.053 -0.251 to 0.360 0.603 0.719 Ns Ns 
ESR2 (ERβ) 0.191 -0.144 to 0.574 0.598 0.231 Ns Ns 
GPER 0.178 -0.056 to 0.233 0.622 0.223 Ns Ns 
Metabolic 
enzymes 
HSD17B1 (E1E2) 0.324 0.001 to 0.018 0.656 0.023 0.025 0.033 
HSD17B2 (E2E1) -0.031 -0.239 to 0.194 0.602 0.837 Ns Ns 
HSD17B5 (AT) -0.085 -0.397 to 0.208 0.607 0.529 Ns Ns 
CYP19A1 (A/T  E1/E2) 0.307 0.025 to 0.279 0.670 0.020 0.023 Ns (0.072) 
Ratio HSD17B1:HSD17B2 0.430 0.002 to 0.011 0.683 0.006 0.008 0.015 
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Association of mRNA levels of ERs and metabolic enzymes in COPD patients and controls. Association was assessed by 
linear regression after correction for age, sex, smoking status, pack-years and BMI.  p#: p-value after excluding women 
below the age of 55 (putative peri/premenopausal). p##:  p-value when only men were analysed. 
 
 
Figure 2. Association of ESR2 (ERβ) and CYP19A1 mRNA levels and lung function 
Negative association of the mRNA levels of ESR2 (ERβ; a) and the mRNA levels of CYP19A1 (b) with FEV1 (% of 
predicted) was computed by linear regression after correction for possible confounders. mRNA levels were normalized 
with the reference genes (see materials and methods). 
 
 
Protein localization of ERα, ERβ and GPER in human lung tissue  
Next, we used immunohistochemistry to characterize the localization of ERs in lung tissue and the 
level of expression in distinct lung compartments.  
ERα was detectable in bronchial epithelial cells (BEC) and alveolar macrophages (AM), whereas 
the expression level in the alveolar region was weak. ERα was significantly decreased in BEC of 
GOLD 4 patients compared with controls and GOLD 2 patients (significance between GOLD 2 and 
4 was lost after correction for menopausal status; Figure 3a).  
ERβ was highly detectable in all regions examined, and significantly increased in GOLD 4 patients 
versus GOLD 2 patients, specifically in the alveolar region (Figure 3b). ERα and ERβ 
immunoreactivity was associated with the cytoplasm and nucleus respectively. 
GPER detection was high in all regions examined. The level of this receptor was increased in AM 
of GOLD 4 patients compared with GOLD 2 patients. However, this difference did not remain 
significant after correction for menopausal status (Figure 3c).  
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Figure 3. Immunohistochemical characterization ERα, ERβ and GPER in control and COPD lungs 
Representative immunohistochemical images of ERα (a), ERβ (b) and GPER (c) in control lungs, COPD GOLD 2 and 
COPD GOLD 4 tissues. Images of bronchial epithelial cells (BEC), alveolar compartment with macrophages (AM, 
arrowheads) and further enlargements of AM (shown in the enlarged islets) are shown. Scale bars: 20 m. 
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Graphs at the right show the immunohistochemical staining intensity calculated using a modified Allred system (range 
0-15) as described earlier [24]. Statistic test: Anova, asterisks indicate p<0.05, ‘A’ indicates that a p<0.05 in the total 
population did not remain significant after correction for menopausal status. 
 
Estrogen metabolism of COPD patients favors the generation of E2 
The local metabolism of estrogens in the lungs of COPD patients and controls was examined by 
assessing the mRNA levels (RT-PCR) of reducing 17β-HSDs (types 1, 5, 7 and 12), oxidizing 17β-
HSDs (types 2 and 4), CYP19A1, STS and SULT1E1. Association with disease was assessed in order 
to correct for possible confounders. The mRNA expression of the E2 generating enzyme 17β-HSD 
type 1 was positively associated with COPD (Table 2). Since 17β-HSD type 1 and type 2 control 
opposite reactions (i.e. activation of E1 to E2 and deactivation of E2 to E1, respectively) their 
balance in each subject may reflect the net local formation of E2. Therefore, we determined the 
balance of estrogen reducing and oxidizing 17β-HSDs in each subject by computing the 17β-HSD 
type 1:2 ratio. We confirmed that 17β-HSD type 1:2 ratio was positively associated with COPD 
state (Table 2).  
Next, never smoker controls were compared with asymptomatic smoker controls and COPD 
patients. The mRNA level of 17β-HSD type 1 and the ratio 17β-HSD type 1:2 was significantly 
upregulated in COPD patients compared with asymptomatic smokers (Figure 4a and 4c). More 
thorough analyses of the COPD patients showed that subjects clustered in two groups, one with 
high 17β-HSD type 1 level, one with levels comparable to the controls. This increased mRNA 
expression of 17β-HSD type 1 in COPD patients was restriched to ex-smokers. Results did not 
change when analyses were restricted to men or when women younger than 55 
(peri/premenopausal) were removed from the analyses. No differences were observed in the 
expression level of 17β-HSD type 2 when considered alone (Table 2 and Figure 4b). 
Although we confirmed that the 17β-HSDs type 5, 7, 12 and 4 were highly expressed in lung tissue 
(Supplementary Table 4), none was associated with either COPD status or differed between never 
smokers and asymptomatic smokers (Table 2; Figure 4d shows the levels of 17β-HSD type 5 that, 
due to its action in androgen metabolism, may be relevant in men).  
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Figure 4. mRNA levels of the major enzymes involved in the local estrogen generation 
Gene expression of the HSD17B1 (17β-HSD type 1; a), HSD17B2 (17β-HSD type 2; b), 17β-HSD type 1:2 ratio (c), 
HSD17B5 (17β-HSD type 5; d), and CYP19A1 (e) in never smokers (NS), asymptomatic smokers (AS) and COPD patients. 
mRNA levels were normalized with the reference genes and are expressed as fold change compared to the NS 
controls. NS controls are set to one. Statistic test: ANOVA, asterisks indicate p<0.05. 
 
The aromatase and sulfatase pathways were examined subsequently. CYP19A1 mRNA expression, 
responsible for converting androgens into estrogens, was significantly associated with COPD 
(Table 2) but when men only were considered, only a non-significant trend was observed 
(p=0.072). CYP19A1 was also negatively associated with lung function (Figure 2b and 
Supplementary Table 2). No further association was observed when never smokers, 
asympomating smokers and COPD patients were compared (Figure 4e). The expression levels of 
STS were higher than those of SULT1E1, but no differences were observed in the mRNA expression 
levels within the study groups (Supplementary Table 4).  
Since 17β-HSD type 1 and aromatase were found to be associated with disease state, these 
enzymes were further explored by immunohistochemistry to assess their location. Both proteins 
were expressed at very low levels in BEC and alveolar compartment (barely detectable), whereas 
strong expression was observed in the AM (Supplementary Figure 1). 
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Discussion  
In the present study we confirmed that ERα, ERβ and GPER are expressed in lung tissue of COPD 
patients and control subjects. We also demonstrated the presence of all main enzymes involved 
in the local generation and degradation of estrogens in lung tissue indicating that the lungs, like 
many other tissues, are able to generate their own steroids intracellularly. These enzymes include 
aromatase (CYP19A1), 17β-HSDs, SULT1E1 and STS. In addition, in lungs of COPD patients, the 
metabolic balance controlled by these enzymes potentially favors the generation of active 
estrogens.  
 
Similar to previous studies [10, 34-37], in our investigation ERα and ERβ immunoreactivity was 
associated with the cytoplasm and nucleus respectively. Additionally, we observed high pulmonary 
expression levels of GPER, indicating an important role of the estrogen rapid signaling in lung 
tissue. No significant differences in the distribution of the receptors between men and women 
were observed (data not shown).  
Regarding the intracellular generation of the ligands for the ERs [16-18, 23, 38] our data show an 
increased level of 17β-HSD type 1 in COPD patients compared with controls, and an increased ratio 
17β-HSD type 1:2, which suggests a potential increase generation of the biological active E2 in the 
COPD group. Nevertheless, to confirm or disregard such conclusion, a steroid profile by mass-
spectrometry is necessary.  
The STS-pathway also contributes to estrogen synthesis and we observed STS expression in the 
lungs. In lung cancer STS was found to be expressed and correlated with patient prognosis (Iida et 
al. 2013). 
In addition, CYP19A1, involved in the generation of estrogens from androgens, was associated 
with COPD disease state and decreased lung function. These data confirm previous evidences 
obtained from tissues other than the lung, where 17β-HSD type 1 and aromatase are the most 
relevant enzymes in controlling the local generation of E2 [18, 24, 26, 39].  
  
Chronic inflammation is a major hallmark of COPD. The inflammatory process involves both lung 
cells (BEC, alveolar cells) as well as alveolar macrophages (AM). AM, together with other immune 
cells, progressively infiltrate the lungs, lead to chronic inflammation [40, 41], to tissue injury and 
disturbed repair mechanisms [3]. Interestingly, all ERs as well as the metabolic enzymes 17β-HSD 
type 1 and aromatase were expressed in AM, suggesting that estrogen signaling can affect 
inflammatory status within the macrophages. In the BEC of COPD patients, the protein level of ERα 
was lower than in controls. In mouse studies, estrogens have a protective action against 
inflammation of the lungs and such effect is mediated by ERα and not ERβ [42]. In other tissues as 
well, including brain and endothelium, the protective and beneficial effects of estrogens are lost 
when ERα is abolished, whereas the absence of ERβ has no influence [43, 44]. We also observed 
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that, although this data was not confirmed after correction for menopausal status, GPER was 
increased in AM of very severe versus mild COPD patients (GOLD 4 versus GOLD 2), suggesting a 
pro-inflammatory role of this receptor. Increased levels of GPER have been shown in other 
inflammatory disorders like endometriosis [45, 46]. 
Taken together, our data indicate that increased levels of active estrogens in the lungs together 
with a diminished protective effect mediated by ERα (BEC) and probably an increased 
inflammatory action of GPER could be associated with the increased inflammatory status observed 
in COPD development. We do not have data on inflammation to further support this hypothesis 
and to dissect whether estrogens influence the inflammatory status only or exert additional effects 
underlying the pathogenesis of COPD. These associations should be explored in future studies. 
 
The biggest risk factor for COPD development is the inhalation of noxious particles like those 
present in tobacco smoke (TS), followed by aging and gender. Therefore smoking status was also 
analyzed in our study. The levels of 17β-HSD type 1 and the ratio 17β-HSD type 1:2 were increased 
in COPD versus asymptomatic smokers. TS is a complex mixture of compounds, which include 
environmental estrogens, specifically metallo-estrogens. It is therefore plausible that, like other 
endogenous and exogenous ligands, the metallo-estrogens present in smoke affect the estrogen 
signaling in lungs, similar to what reported for breast cancer cells where TS decreases the 
expression of the ER [47].  
 
In conclusion, the association of aromatase with disease state and a shift in balance of reducing 
and oxidizing 17β-HSDs towards the reducing enzyme 17β-HSD 1 suggest an increased production 
of the biological active E2 in COPD patients.  
The efficacy of anti-estrogen treatments (aromatase inhibitors) in lung disease like lung cancer is 
well demonstrated in preclinical studies [48, 49]. Similar approaches could have potential benefits 
in COPD as well and the utility of novel therapeutic targets like aromatase or 17β-HSD type 1 
should be further explored. Several aromatase inhibitors are approved for clinical use and potent 
and specific 17β-HSD type 1 inhibitors have been developed and thoroughly evaluated in 
preclinical settings [18].  
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Supplementary Table 1. Oligonucleotide sequences of primers used for real-time PCR 
Gene name Gene ID Sequences 
ESR1 2099 
Forward: 5’-AGCTCCTCCTCATCCTCTCCCA-3’ 
Reverse: 5’-ACCACGTTCTTGCACTTCATGCTG-3’ 
ESR2 2100 Hs00230957_m1 (Applied Biosystems) 
GPER 2852 
Forward: 5’-ACGAGACTGTGAAATCCGCAA-3’ 
Reverse: 5’-GGTACCTGCCGTCCAGATGTT-3’ 
HSD17B1* 3292 
Forward: 5’-GTTTATTGCGCCAGCAAGTT-3’ 
Reverse: 5’-CCCAACACCTTCTCCATGA-3’ 
HSD17B2* 3294 
Forward: 5’-TCAAAACTCCGGCAAATACC-3’ 
Reverse: 5’-ACCTGTGGATCAGAAGGCAG-3’ 
HSD17B4*  
 
3295 
Forward: 5’-GAAGTCCCCTCCCAAATCAT-3’ 
Reverse: 5’-GTGGTACTGGTCACCGGA-3’ 
HSD17B5*  
(AKR1C3) 
8644 
Forward: 5’-AATGAGCAGCGCATCAGAC-3’ 
Reverse: 5’-GGGTGGCTAGCAAAACTATCA-3’ 
HSD17B7* 51478 
Forward: 5’-ACCACTGGCTTTGGAAGAAAT-3’ 
Reverse: 5’-TGACCCTAATGTGCTTTTCCA-3’ 
HSD17B12* 51144 
Forward: 5’-GTCTGGGGAGTGGGGAAT-3’ 
Reverse: 5’-CCTTCATTCCATGCTTTGCT-3’ 
CYP19A1* 1588 
Forward: 5’-ATGCGAGTCTGGATCTCTGG-3’ 
Reverse: 5’-GCCTTTCTCATGCATACC-3’ 
STS 412 Hs00165853_m1 (Applied Biosystems) 
SULT1E1 6783 
Forward: 5’-CTGCCTCATTTTGGGAAAAG-3’ 
Reverse: 5’-ATCCAGGATTTGGATGACCA-3’ 
HPRT 3251 
Forward: 5’-AGAATGTCTTGATTGTGGAAGA-3’ 
Reverse: 5’-ACCTTGACCATCTTTGGATTA-3’ 
GAPDH 2597 
Forward: 5’-CGTCTTCACCATCAT-3’ 
Reverse: 5’-CGGCCATCACGCCACAGTTT-3’ 
RP13A 23521 
Forward: 5’-CCTGGAGGAGAAGAGGAAAGAGA-3’ 
Reverse: 5’-TTGAGGACCTCTGTGTATTTGTCAA-3’ 
 
ESR, estrogen receptor; GPER, G protein-coupled estrogen receptor 1; HSD17B, 17-beta-hydroxysteroid 
dehydrogenase; CYP191A1, Cytochrome P450, family 19, subfamily A, polypeptide 1; SULT1E1, sulfotransferase 
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family 1E member 1; HPRT, Homo sapiens hypoxanthine phosphoribosyltransferase; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; RPL13A, ribosomal protein L13a. 
*: All published (Cornel et. al, J Clin Endocrinol Metab 97 E591-601) 
 
Supplementary Table 2. Association of gene expression with lung function (FEV1)  
  
Association of lung function with 
gene expression 
  β 95% CI R p-value 
ESR1 -0.084 -18.737 to 11.138 0.446 0.609 
ESR2 -0.346 -32.496 to -0.765 0.556 0.041* 
GPER 0.033 -6.505   to  7.928 0.441 0.843 
HSD17B1 -0.245 -0.760   to  0.106 0.468 0.134 
HSD17B5 0.003 -14.751 to  15.045 0.440 0.984 
HSD17B2 -0.040 -11.877  to  9.347 0.441 0.811 
CYP19A1 -0.355 -13.867  to -1.467 0.557 0.017* 
Ratio HSD17B1:HSD17B2 -0.338 -0.448   to  0.012 0.496 0.062 
 
Association was assessed by linear regression after correction for age, sex, smoking status, pack-years and BMI. The 
p-values of ESR2 and CYP19A1 remain significant after considering men only or after removing peri/premenopausal 
women from the analyses.  
Asterisks indicate p<0.05 
 
 
Supplementary Table 3 Association of ER protein expression with lung function (FEV1)  
  
Association of lung function with 
protein expression 
  β 95% CI R p-value  
ERα BEC  0.230 -0.537 to 5.508 0.603 0.104  
ERα alveolar  0.018 -5.954 to 6.792 0.566 0.895  
ERα AM  0.174 -1.295 to 4.084 0.581 0.301  
ERβ BEC -0.041 -2.074 to 1.527 0.557 0.761  
ERβ alveolar -0.061 -3.191 to 2.115 0.560 0.684  
ERβ AM  0.248 -0.104 to 3.528 0.605 0.064  
GPER BEC  0.090 -1.379 to 2.599 0.561 0.538  
GPER alveolar  0.011 -2.157 to 2.334 0.535 0.937  
GPER AM -0.088 -3.576 to 1.895 0.542 0.537  
 
Association was assessed by linear regression after correction for age, sex, smoking status, pack-years and BMI.  
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Supplementary Table 4. Average gene expression levels 
    NS AS COPD 
    CT-value 
fold 
change 
CT-value 
fold 
change 
CT-value 
fold 
change 
Receptors 
ESR1 (ERα) 30.85 1.00 31.16 0.70 31.24 0.74 
ESR2 (ERβ) 33.66 1.00 34.38 0.46 34.66 0.65 
GPER 31.69 1.00 31.74 1.12 31.30 1.60 
Metabolic 
enzymes 
HSD17B1 (E1E2) 40.32 1.00 40.84 0.72 38.67 13.80 
HSD17B5 (A T/E1E2) 24.73 1.00 24.57 1.25 24.97 0.99 
HSD17B7 (E1 E2) 27.37 1.00 27.12 1.20 27.13 1.39 
HSD17B12 (E1 E2) 25.32 1.00 25.49 0.94 25.76 0.83 
HSD17B2 (E2 E1) 31.67 1.00 31.34 1.27 31.93 1.00 
HSD17B4 (E2 E1) 25.66 1.00 25.62 1.08 25.62 1.12 
CYP19A1 (A/T  E1/E2) 34.50 1.00 34.19 1.11 33.78 1.71 
STS (E1S  E1) 29.08 1.00 29.36 0.87 29.74 0.69 
SULT1E1 (E1  E1S) 32.73 1.00 32.95 0.90 33.01 1.04 
 
Data are shown as mean values. CT (cycle Treshold)-value 
mRNA levels were normalized with the reference genes and are shown as fold change compared to the NS controls. 
The NS controls are set to one. 
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Supplementary Figures 
 
 
Supplementary Figure 1. Immunohistochemical staining of 17β-HSD type 1 and CYP19A1 aromatase in Alveolar 
Macrophages 
Representative immunohistochemical images of 17β-HSD type 1 (a), and aromatase (b) in the alveolar compartment 
with macrophages (AM, arrowheads). No differences in the staining intensities were seen between controls and COPD. 
Immunohistochemistry was performed as described in materials and methods. Heat-induced antigen retrieval was 
performed, followed by  detection of 17β-HSD type 1 with antibody clone EP1682Y (GeneTex) and aromatase with 
antibody clone MCA2077 (Serotec). Dako, EnVision™ Detection Systems and DAB were used for visualization of 
antibody binding. 
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Estrogens exert pleiotropic effects in the body throughout our lifetime. They are responsible 
for maintaining a healthy physiology. Disruption or unbalances in the estrogen signalling play 
an important role in disease development and progression.  
In this thesis, the local estrogen metabolism is explored (and to a limited extent that of other 
steroids), in the endometrium and in the lung. First, a systemic search of the local steroid and 
estrogen metabolism in endometrium and the lung was performed, as described in chapter 2. 
In both tissues estrogens have an important role and the analysis showed that the intracrine 
(local) metabolism is important to maintain the proper tissue steroid levels. Several pathways 
are involved in the production and deactivation of estrogens and other steroids, which make 
the intracrine networks in peripheral tissues extremely complex.  
 
Intracrinology 
Intracrinology (local steroid metabolism) is the complex network that consists of alternative 
and redundant pathways to generate, deactivate and interconvert steroids in peripheral 
tissues [1, 2]. Recent studies on intracrinology clearly demonstrated that estrogen responsive 
tissues and organs are not passive receivers of the pool of steroids present in the blood. 
Although these responsive tissues, including endometrium and the lungs (see below), do not 
possess the machinery to produce steroids from cholesterol, most peripheral sites are able to 
use DHEA for estrogen and androgen generation [1-7]. Additional reactions compared with 
those present in the classic endocrine glands, like the reactions catalysed by 5α-reductases 
(SRDAs) or aldo-ketoreducases (AKRs), can generate a plethora of additional compounds, with 
various biological activities. In this context, a number of non-estrogenic compounds also 
possess estrogenic activity, as they are able to bind and activate the estrogen receptors (Figure 
1). For instance, 5α-reductases catalyse the conversion of T into the more potent AR agonist 
DHT (best known in prostate biology), but also progestogens into neurosteroids and A4 into 
androstanedione, which will be further reduced by AKRs to the androgenic and neuroactive 
AN and to other androgens like 3α-DIOL and 3β-DIOL which are molecules with estrogenic 
actions [8]. Noteworthy is the high affinity of 3β-DIOL for ERβ. DHEA can be converted to A5, 
which next to weak androgenic action, it also possesses estrogenic activity, and the ability to 
stimulate the immune system. Its 17α-isomer (17α-A5) has androgenic, antitumor and 
neuroactivity. 17α-A5 is further converted by 3β-HSD 1 (or 2) into Epitestosterone (EpiT, the 
17α-isomer of T). EpiT has a weak affinity for AR, and acts as an anti-androgenic activity by its 
strong endogenous inhibition of SRD5As [9]. The endogenous occurrence of 17α-A5 is 
demonstrated in humans [10] but its route of synthesis is unclear [11].  A 17α-HSD able to 
convert A4 to EpiT and DHEA to 17α-A5 is characterised in mice [12] but no human homologous 
is described yet. 
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Yellow Background: Ovarian classic steroidogenesis. 
Red circles: 3β-sulphated hydroxyl groups. 
Orange circles: 3α-sulphated hydroxyl groups. 
 
progesterone receptor activation (PRA/B) 
androgen receptor activation (AR) 
estrogen receptor activation (ERα/β) 
GABAA receptor allosteric modulator 
 
Figure 1. Intracrine networks (adapted from Konings et al. [7]) 
Major intracrine networks metabolising steroids. In this figure, each reaction reports the catalysing enzymes 
whose role in that specific reaction is established based on robust evidences (in vitro, ex vivo, in vivo).  
Colour codes: 
 
 
 
 
 
 
OV ovarian specific; ---- dotted arrows indicate reactions that are not fully demonstrated to occur or for which the 
responsible enzyme is not identified yet; (enzyme) enzymes indicated by brackets are supposed to catalyse the 
reaction based on the theoretical assumptions, no experimental proof is yet available; & these compounds (THP, 
3αDHP and allopregnandiol) exists as various hydroxyl α/β isomers (3, 5, 17) with no activity, classic action or 
neuroactivity; * the role of DHRS11 in steroid metabolism is reported only recently by one publication [13]. 
   Biological activity 
   weak                  strong 
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Endometrium and the role of intracrinology 
In endometrium, the hormonal network plays an important role throughout life. In 
premenopausal women, the endometrium undergoes cyclic changes of proliferation and 
secretion followed by menstruation, which is all controlled by E2 and progesterone. E2 
overexposure, especially in case it is unopposed by progestogens, can lead to endometrial 
disorders including endometrial cancer (EC, in particular the type I endometrioid disease, that 
represents the majority of the cases). Although most ECs are diagnosed at an early stage and 
are treated with surgery (with adjuvant care, if needed), about 20-30% of EC-patients develop 
recurrent disease and/or are diagnosed with primary advanced stage EC. These patients are 
often treated with chemotherapy that, however, has important debilitating side-effects 
leading to compromised Quality of Life (QoL) and have overall poor efficacy. As an alternative, 
endocrine drugs are also prescribed in these EC cases, but therapeutic efficacy is currently 
limited and tumours may quickly become insensitive [14, 15]. There is however consensus 
about the idea that there exists room for improvement in the existing endocrine treatment for 
EC. This is also indicated by recent trials on combinational regimen based on endocrine and 
other targeted treatments [16, 17].  
 
A fundamental aspect to improve our use of endocrine drugs is to understand the mechanisms 
leading to estrogen overexposure in EC, and the mechanisms leading to the development of 
drug insensitivity. In this respect, the new paradigmatic model of intracrinology, where tissue 
exposure to steroids is not controlled by serum levels (classic endocrinology) but by the local 
intracellular generation of hormones from low-active/inactive serum precursors can explain 
the underlying cause of estrogen overexposure in, at least, a subset of the patients [3, 18]. This 
interpretation offers new perspectives and can open new future scenarios for endocrine 
treatment in EC.  
Since most EC are diagnosed after menopause, when the ovaries ceased their actions, the 
major source of E2 is represented by the local metabolism. A recent systematic review of our 
group on the local estrogen metabolism present in the endometrium discussed the most 
important pathways in EC, that include the sulfatase pathway, aromatase pathway, and the 
17β-HSD1/17β-HSD2 redox balance (Figure 2) [19]. 
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Figure 2. Estrogen metabolism in endometrium  
DHEA(-S) = Dehydroepiandrosterone(-Sulfate); 3β-HSD = 3β-hydroxysteroid dehydrogenase; 17β-HSD 1= 
17β-hydroxysteroid dehydrogenase type 1; 17β-HSD 2= 17β-hydroxysteroid dehydrogenase type 2; 
CYP19A1 = aromatase; DHT = dihydrotestosterone; SULT1E1 = estrogen sulfotransferase; STS = steroid 
sulfatase. 
 
The enzyme 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) generates highly-active 
17β-estradiol (E2) from low-active estrone (E1). The enzyme 17β-HSD2 catalyses the reverse 
reaction, by inactivating E2 into E1 (Figure 2). In this thesis, the balance between these two 
enzymes in normal endometrium and EC was studied extensively. Our research group already 
showed that in estrogen-dependent EC, the enzyme 17β-HSD1 is overexpressed, and the 
disruption of 17β-HSD1/17β-HSD2 enzyme balance implicates an increased intra-tissue 
generation of E2, leading to the maintenance of the disease [20]. Therefore, the enzyme 17β-
HSD1 represent a potential therapeutic target for EC treatment. Since drug treatment in EC is 
generally indicated for metastatic and recurrent disease and not for treatment of the primary 
tumour, the mRNA expression of this potential drug target 17β-HSD1 was confirmed in 
metastatic lesions using a cohort of 37 EC patients (chapter 3). Although there was no 
correlation between 17β-HSD-1 levels in primary tumor and metastases, in over 50% of the 
cases, at least one metastases had higher 17β-HSD-1 expression than the corresponding 
primary EC. 
Although some studies question the significance of 17β-HSD1, the presence of mRNA, protein 
and activity is demonstrated and the use of specific 17β-HSD1 inhibitors are able to inhibit the 
reductive activity and impair the generation of E2 in preclinical models of EC. Even though the 
17β-HSD1 enzyme activity is low (f-nMol/mg protein/hour), even lower than the activity of 
17β-HSD2, the reductive metabolism in favour of E2 synthesis is predominant in the 17β-
HSD1/17β-HSD2 redox balance in vivo, this occurs due to the fact that the cofactor availability 
is in favour of the enzyme 17β-HSD1 [21]. 
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In normal endometrium and in EC, the sulfatase pathway also represents a major route of 
estrogen supply and estrogen deactivation. This pathway consists of the combined action of 
the enzymes estrogen sulfatase (STS) and estrogen sulfotransferase (SULT)1E1 (Figure 2). STS 
activates by hydrolysis DHEAS and E1-S into DHEA and E1, respectively, whereas, SULT1E1 
inactivates the estrogen E1, and to minor extent E2, into the inactive sufated forms. In normal 
endometrium versus EC, the literature shows discrepancy in STS and SULT1E1 expression 
levels, but all data confirm higher mRNA and protein levels for STS. Also the STS activity appears 
much higher, its activity is in the range of nMol/mg protein per hour, while the activity of 
SULT1E1 only reaches pMol/mg/hour [22-24]. This together indicates that the sulfatase 
pathway is shifted towards the formation of free estrone in EC.  
 
The activity of the aromatase pathway in EC is suggested to be of importance by several studies 
[25, 26]. The enzyme aromatase (CYP19A1) plays the key role by conversion of 
androstenedione and T into E1 and E2, respectively (Figure 2). Nevertheless, mRNA and protein 
were not detected in the endometrium by all authors and the activity of the enzyme is only 
ranging in the fMOL/mg protein/hour. The aromatase pathway therefore shows to be of less 
importance in producing estrogens in the endometrium. Despite these findings, intracrine 
aromatase may be relevant in a subset of patients showing overexpression of this enzyme, as 
it is of interest in obese patients were the adipose tissue synthesise and secrete estrogens into 
the blood circulation [19].  
 
The intracrine network represented by STS/SULT1E1, aromatase and 17β-HSD1/17β-HSD2 
comprise those enzymes that are ultimately involved in direct E2 generation (Figure 2). 
However, intracrine networks can be more complex and include enzymes for progestogen, 
androgen and corticosteroid metabolism, leading to the formation of various compounds with 
neuro, estrogenic or androgenic activity. In case of the endometrium, androgens and 
progestogens can be metabolised via the enzymes AKR1Cs and SRD5As to produce a wide 
range of compounds, including estrogens (see Figure 1). Nevertheless, the ability of the 
endometrium to synthesize steroids and DHEA from cholesterol needs confirmation. 
 
Intracrinology and prognostic markers in EC 
Current valuable prognostic markers like immunohistochemical loss of ER and PR are 
established markers of poor prognosis. Another promising prognostic marker is L1 cell 
adhesion molecule (L1CAM) which is a predictor of poor survival in EC [27-29]. 
In our recent study (ENITEC1 collaboration) we focussed on the level of estrogen and other 
steroids in the blood, as potential prognostic biomarkers [30]. In this study, plasma of 38 
postmenopausal EC patients of which 19 with a long survival and 19 who died of the disease 
within a short time, was used to investigate the relation between specific abdominal fat 
                                                             
ENITEC: European Network of Individual Treatment in Endometrial Cancer;   
https://www.esgo.org/network/enitec/ 
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distribution patterns and estradiol levels. Therefore, 19 circulating levels of steroid were 
examined using liquid-chromatography tandem mass-spectrometry. DHEA, DHEAS, 
progesterone, 21-OH progesterone and E1-S were significantly increased in patients with long 
survival as compared to the short survival patients. A positive correlation of circulating 
estradiol with visceral fat percentage was found, including the increased expression of genes 
involved in the intra-tumoural estrogen signalling in these patients with high circulating 
estradiol levels. This study is promising for the identification of novel prognostic biomarkers in 
EC patients. 
Our group has examined the prognostic value of genes involved in the intracrine metabolism, 
and found that high levels of the enzyme 17β-HSD1 in EC correlated with unfavorable 
prognosis in patients, whereas STS, SULT1E1 and CYP19A1 did not show any significant 
correlation [31]. This study was performed on a cohort of EC specimens with long time follow 
up information, and the results were confirmed only using RNA of patient biopsies. The use of 
immunohistochemistry in the same patient cohort, however, gave insufficient sensitivity. In 
the clinical setting, tumour histology is used for diagnostics. Therefore the use of molecular 
histological markers would be a more appropriate prognostic model [31, 32].  
 
Intracrinology and drugs in EC 
The use of endocrine treatment for EC, usually progestins, is associated with low response 
rates varing between 15-46%. Patients with well-differentiated tumours and a progesterone 
receptor positive status benefit most [33-36]. Also tamoxifen or aromatase inhibitors can be 
used, with similar response rates as progestins. Endocrine therapy is better accepted due to 
low toxicity levels, as compared with chemotherapy, therefore, options for improvement in 
treatment efficacy should be further explored. 
 
It is generally accepted that there is room for improvements in hormonal treatment, starting 
with the preselection of responsive patients [17, 37]. A relevant opening for future 
improvement of endocrine treatment is targeting intracrine enzymes to pursue a cell 
environment devoid from local estrogens.  
Aromatase Inhibitors (AIs) have been tested in various trials for advanced or recurrent EC, with 
low therapeutic response rates when used as single agent treatment. Since aromatase is 
abundantly present in adipose tissue, it may not only affect the intra-tumoural environment 
but also the systemic estrogen levels. This makes it impossible to discriminate between the 
intra-tumoural and systemic effects of AI. 
The use of STS inhibitors directly reduces the intracellular estrogen levels. So far, potent STS 
inhibitors have only been tested in phase I and II clinical trials for endometriosis, which is like 
EC an estrogen dependent condition of the endometrium [38]. Preclinical data on the use of 
STS in EC are promising, nevertheless, the use of the STS inhibitor Irosustat in a recent phase 
II clinical trial on advanced stage EC was stopped early due to no additional benefit compared 
with standard Progestin treatment [39, 40]. However, as also indicated by novel studies on 
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breast cancer research, patient preselection to improve the therapeutic efficacy is a 
prerequisite [41, 42]. 
 
In the present thesis, we have focussed on the use of 17β-HSD1 inhibitors to block estrogen 
dependent tumour growth in EC. For this purpose we used ex vivo studies and in vitro systems 
(preclinical models, chapter 3). Such studies and models are of foremost importance to 
progress oncology research; dissect mechanism of action, mechanisms of resistance and to 
test drugs prior to their release in human treatment. 
Ex vivo studies are based on patient materials, therefore they are relevant because they show 
the engagement of a specific protein/drug target in human samples. Ex vivo approaches to 
measure the 17β-HSD1 enzyme activity were initially based on cell-free assays. Cell free assays 
lack the complexity of cellular systems, taking into account the transport of a drug in and out 
the cell through the plasma membrane. They do not consider the cell compartmentation of a 
protein and have unphysiologic concentrations of substrates and cofactors.  
In vitro systems are simplified cellular systems, with active membrane transport and 
physiologic concentrations of substrates and cofactors. We used EC-cell lines derived from the 
well-differentiated endometrial adenocarcinoma Ishikawa cells which were genetically 
manipulated to express levels of 17β-HSD1 similar to human EC-tissue levels. High-
performance-liquid-chromatography (HPLC) was used to measure the 17β-HSD1 activity of 
these cells in a cell free assay. The successful inhibition of the 17β-HSD1 activity by the specific 
17β-HSD1 inhibitor FP4643 resulted in reduced E2 production. Furthermore, in an in vitro 
colony formation assay, E1 supplementation elicited colony formation similar to E2, but such 
E1 dependent colony formation was impaired by 17β-HSD1 inhibition.  
Cell cultures lack the real tissue environment, O2 and CO2 concentration are unphysiological, 
as is the culture media. The use of the CAM (ChorioAllantoic Membrane of fertilized chicken 
eggs) assay as a model of EC complements the use of in vitro assays, and has several 
advantages. The CAM is a 3D-model that, with the presence of extracellular matrix proteins, 
mimics the physiological cancer cell microenvironment. It is a cost-effective and easy-to-
handle model, the tumours engraft on the CAM and can be treated topically. An additional 
advantage is the vascularised network of the CAM, which is supporting the tumour viability. 
Due to this vascularisation, the model might as well be interesting to investigate metastatic 
growth [43]. We grafted EC tumours on the CAM. In this in-ovo model, E1 demonstrated 
upregulated expression of the estrogen responsive cyclin A in a similar way as E2, which could 
be impaired by FP4643.  
The CAM assay also holds certain limitations including, the short treatment-window of 6 days, 
the results in estrogen-dependent cancers may be influenced by exposure of endogenous sex 
steroids due to the gender of the developing chicken. CAM is a half-isolated system, and 
therefore the half-life of the drugs is much longer compared to mouse models, which might be 
both an advantage (less drug needed) as a disadvantage (cytoxicity), therefore careful titration 
of the drug might be mandatory. Since tumours on the CAM are unable to grow for a long 
period, the only reliable endpoint measurement consists of is immunohistochemical markers 
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and investigating mRNA expression levels by qPCR – the tumour size cannot sufficiently be 
explored during the short period of hormonal treatment.  
To further progress in this research, mouse models to prove the preclinical validity of the 
therapeutic approach may be more useful and represent the final step before the clinical trials 
may be performed. When this work was initiated, few mouse models were available, and in 
most of these available models the tumours were injected subcutaneously which does not 
mimic the human situation. These models also lack the estrogen dependent characteristic of 
EC. An orthotopic xenograft model is of more relevance since the tumour is induced at the 
same location and with a comparable microenvironment, as the tumour in humans. Such 
model was designed by Haldorsen using the estrogen dependent Ishikawa cell line and other 
endometrial cancer cell lines [44]. However, the estrogen dependency of this model was not 
explored, the tumours were grown in gonad intact mice, with the endogenous estrogens 
present. Therefore, we designed an orthotopic estrogen-dependent EC mouse model (chapter 
4), with controlled exposure of steroids and thus amenable to test several steroidal drugs. For 
that reason, we engrafted orthotopic -in uterus- tumour grafts using the well-differentiated 
human endometrial adenocarcinoma Ishikawa cell line, modified to express a luciferase 
reporter gene for bioluminescence imaging (BLI) [45]. After the confirmation of tumour 
establishment using BLI imaging, mice were ovariectomised to remove the endogenous source 
of estrogens and next subcutaneously implanted with a novel MedRod delivery system. These 
MedRod implants are polydimethylsiloxane cylinders covered by a silicone membrane that 
provides a constant release of E2. This novel MedRod system has advantages over the more 
commonly used osmotic minipumps and pellets, or oral administration via drinking water and 
injections. They can be used for longer periods (minimum of 10 weeks) with a guaranteed 
stable compound diffusion into the body, therefore in many cases only one implantation for 
the entire duration of the experiment is required. This amendable dosing of steroids is of great 
importance, since most EC cases are diagnosed after menopause, when the ovaries have 
ceased their estrogen production, but mimicking other clinical situations are also optional. BLI 
was used for monitoring tumour growth, but also a good correlation between BLI imaging and 
contrast enhanced computed tomography (CE-CT) was demonstrated. This makes our model 
also suitable for systems lacking an endogenous reporter gene (e.g. luciferase/BLI) such as 
patient derived EC tumour xenografts (PDTX). The latter is currently the most relevant 
preclinical model available in cancer research [46]. 
In addition, tumours showed E2-dependency as determined by bioluminescence imaging (BLI) 
and CT-scan, and by the determination of the weight of the surgically resected tumours at 
sacrifice. Thorough macroscopic and microscopic examination of the mice showed metastatic 
spread and lymph vessel invasion. Thus, this model mimics the human disease, and is therefore 
a relevant estrogen-dependent model to explore further endocrine drugs possibilities. 
Possibilities to further explore endocrine drug opportunities are not limited to monotherapies. 
Recently, drugs with dual action targeting both 17β-HSD1 and STS, and also, aromatase and 
STS have been developed [47]. Our model would be a perfect candidate to test the in vivo 
efficacy of these novel drugs prior their use in clinical trials. Multimodal therapeutic 
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approaches, like targeting endocrine therapy in combination with chemotherapy are also 
promising to be further explored in our novel preclinical EC model. 
 
At the moment, we are performing experiments with this novel designed orthotopic mouse 
model, to test the feasibility of blocking 17β-HSD1 and consequently tumour growth by a 
specific 17β-HSD1 inhibitor. In this experiment, we use Ishikawa cell lines with 3 different 
expression levels of 17β-HSD1 to mimic more accurately the divergent expression levels of this 
target as also observed in EC patients [20]. The preliminary results, followed up by BLI imaging 
are promising for targeting 17β-HSD1 in EC treatment, and at mice sacrifice we observed a 
significant reduction in tumour growth upon treatment with the 17β-HSD1 inhibitor, compared 
with untreated mice (data not published). 
 
Beside the orthotopic xenograft model, we further developed in a pilot experiment this mouse 
model and designed a metastatic mouse model of estrogen dependent EC. This is induced via 
intraperitoneal-injection of cells. The preliminary results of this model showed metastatic 
spread to liver and lungs, resembling the human situation. Therefore, this experimental design 
recapitulates the current clinical situation encountered in case of recurrent disease or in case 
of unresectable metastatic spreading after primary surgery from advanced stage EC.  
 
Conclusions endometrial cancer 
In future patient care, it is recommended to take interpatient variability into account, and map 
in each patient the mechanism(s) leading to the estrogen-overexposure and consequently the 
tumour growth. It is of major importance to determine if estrogen signalling is present, and via 
which pathways estrogens are being provided to the tissue. These pathways (STS/SULT, 
aromatase, 17β-HSD1/17β-HSD2) could be used to block estrogen-overexposure and prevent 
further tumour progression.  
Multimodal therapeutic approaches, like combination of multiple drugs (e.g. chemotherapy, 
inhibitors of PR and ER or endocrine therapy) should diminish the development of drug 
resistance, and hopefully will transform metastatic EC from a currently incurable disease to a 
chronic disease.  
In august 2018, Forendo Pharma started a phase-1a trial for their specific 17β-HSD1 inhibitor 
(FOR-6219), to investigate the safety, tolerability and pharmacokinetics in healthy 
postmenopausal women [48]. To our knowledge, this is the first clinical trial using a 17β-HSD1 
inhibitor, results are promising as underscored by preclinical studies as studied and described 
in this thesis. Efficacy data are awaited with interest.  
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Intracrinology in the pulmonary compartment  
In this paragraph, intracrinology of the adult lung is discussed in order to understand the ability 
of this organ system to generate and deactivate estrogens and evaluate the impact of an 
unbalanced estrogen exposure on lung disease.  
The sex hormone receptors are expressed throughout the pulmonary compartment 
(conducting airways and lung parenchyma) and sex hormones have been shown to play an 
important role in pulmonary physiology and disturbances [49-54]. In accordance with other 
studies, we have provided evidence that the lungs express STS, SULT1E1, aromatase and most 
17β-HSDs (types 1, 2, 4, 5, 7, 8, 11, and 12), and thus are capable of metabolizing sex hormones 
locally [54-57] (chapter 6).  
Next to the endogenous estrogens, also exogenous estrogens may play an important role in 
disease development, expecially in lungs, which are directly exposed to pollutants and 
compunds present in the air. Among these, several compounds present in the environment 
can exert estrogenic actions. Cigarette smoke (CS), which is the major risk-factor for COPD 
development, contains metallo-estrogens which are able to activate the estrogen receptors 
[58-60]. 
 
Currently, the increased COPD morbidity and mortality rates are largely driven by the female 
population.  The increasing tobacco consumption amongst women during the past several 
decades is linked to the rising prevalence of COPD in women, although the relationship may 
be more complex. Multiple studies have suggested that females are biologically more 
susceptible to cigarette smoke associated diseases as compared with males [61-64]. However, 
the degree to which this represents a biological or physiological difference is largely unknown. 
For the same level of tobacco exposure, women experience a greater risk of smoking-induced 
lung function impairment, more severe dyspnea, and poorer health status as compared to 
male smokers [65, 66]. Due to the diffenences in men and women in expression and activity of 
cytochrome P450 enzymes, the metabolism of CS may be different, resulting in a different 
susceptibility to CS [67]. Additional factors such as greater exposure to environmental 
pollution, anatomic and hormonal differences, as well as behavioural differences in response 
to available therapeutic regimens may also contribute to the increased prevalence of COPD in 
women [68-72]. Both the endocrine and immune systems may contribute to the sexual 
dimorphism in the pathogenesis of COPD.  
Moreover, it is not yet understood wether sex hormones and their receptors are protective or 
detrimental in COPD development. Estrogens can promote proliferation and thereby 
potentiate CS-effects on airway and alveolar epithelial cells leading to small airway disease, 
which is the more common hallmark of COPD in women. The development of increased small 
airway remodelling and peripheral airway obstruction in female as compared with male mice, 
was shown recently in a chronic CS-exposure model. The male mice were more prone to 
develop emphesyma [62]. As suggested by other authors, testosterone may potentiate 
alveolar destruction and therewith contribute to emphysema in the male lung [51].  
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To better understand the role of ERα in COPD, the CS-induced pulmonary inflammatory 
responses were explored in a smoking mouse-model using female ERα knock-out (ERαKO) mice 
and wild-type (WT) littermates. Mice were exposed to air or CS for 4 weeks (subacute 
exposure; chapter 5).  
Pulmonary inflammation was increased upon CS exposure and ERα deficiency resulted in a 
higher numbers of neutrophils, dendritic cells and activated T-lymphocytes compared with ERα 
intact WT mice, in which this increase was mainly driven by the macrophages. A lower presence 
of macrophages may explain the increased accumulation of neutrophils in bronchoalveolar 
lavage fluid of ERαKO mice, since macrophages play a role in the removal of apoptotic 
neutrophils by efferocytosis [73]. It has also been suggested that neutrophil apoptosis is 
delayed in females due to increased estradiol and progesterone levels, mediated via ERα and 
ERβ present on the surface of the neutrophils [74]. Moreover, Couse et al. reported that 
circulating estradiol levels in female ERαKO mice are 10-fold higher than those in WT mice [75], 
therefore, another possible explanation for the neutrophil survival could be explained by a 
sustained signalling initiated by ERβ on the surface of the neutrophils.  
Interestingly, in human lung tissue, all ERs as well as the metabolic enzymes 17β-HSD type 1 
and aromatase, which promote local estrogen production, are expressed in alveolar 
macrophages, suggesting that estrogen signalling can affect inflammatory status within the 
macrophages (chapter 6). 
 
As macrophages were the most prominent cells present in the BALF of WT mice -but not in 
ERαKO mice-, the presence of interstitial macrophages in lung tissue was evaluated. ERα 
deficiency resulted in a higher number of tissue macrophages in the lungs as compared to ERα 
intact mice. Interestingly, the number of macrophages in ERαKO mice decreased after CS 
exposure and this effect was not present in the WT mice. This observation suggests a deficiency 
in interstitial macrophage proliferation or a defect in the formation of interstitial macrophages 
from the circulating monocyte supply. In response to CS exposure, macrophage chemotactic 
proteins were elevated in both WT as ERαKO mice, indicating that alterations in chemotactic 
cytokines are not responsible for the lower presence of interstitial macrophages in the lungs 
of ERαKO mice. Together, this suggests that a defect in proliferation is the most likely 
explanation. 
Macrophage phenotype was also explored. In the lung, the macrophages are typically non-
polarized under physiological normal conditions. Depending on the signals exerted in their 
microenvironment, macrophages are known to adopt different polarisation states [76]. The 
classical M1-macrophage, supports inflammation via the production of proinflammatory 
mediators and drives oxidative stress. The alternatively activated anti-inflammatory M2-
macrophages may contribute to lung remodelling via production of excessive proteases, 
including MMP12 [77]. In COPD, alveolar macrophages from BALF and sputum of patients, 
show a mixed M1/M2-phenotype, whereas data from interstitial macrophages is less clear 
[78]. Our observation in murine BALF is in line with both clinical data of COPD patients and 
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animal data showing that cigarette smoking reprograms macrophages towards an M2-
phenotype [78, 79]. Interstitial macrophages of the ERαKO mice showed, at baseline, an 
increase in the M2-marker YM1, as compared with WT mice. However, there was no further 
increase in ERαKO mice upon smoke exposure, as there was in WT mice. These data imply that 
ERα deficiency in mice may contribute to macrophage reprograming into a M2-phenotype.  
 
In the same mouse model, we further explored the CS-induced activation of estrogen-
regulated genes, which was present in both ERα deficient as in ERα intact mice upon CS 
exposure, most likely because of the presence of ERβ and GPER. We also observed that ERβ 
expression was unchanged after CS exposure, but GPER protein levels were increased by CS 
exposure. Therefore, ERβ and GPER might be involved in estrogen signalling in response to CS, 
and may be responsible for the estrogen-signalling which is still present in the lungs of ERαKO 
mice. Supporting evidence of a promoting role for GPER in COPD progression was observed in 
our study investigating human alveolar macrophages in chapter 6. GPER was increased in 
alveolar macrophages of very severe versus mild COPD patients, suggesting a pro-
inflammatory role for this receptor. Increased levels of GPER have been shown in other 
inflammatory disorders like endometriosis [80, 81]. 
As mentioned before, circulating estradiol levels in female ERαKO mice are 10-fold higher than 
those in WT mice [75], therefore, due to the presence of estrogen receptor subtypes, this 
might partly contribute to the observed differences between WT and ERα deficient mice. In 
conclusion, our study showed a modulatory effect of ERα on the inflammatory response in the 
lung after subacute CS exposure.  
 
Next, the role of endogenous (in particular intracrinally generated) estrogens in COPD through 
an observational study of human specimens was further explored (chapter 6). In this study, 
ERα and ERβ immunoreactivity was associated with the cytoplasm and nucleus respectively, 
which is in line with other studies [82-86]. Additionally, we observed high pulmonary 
expression levels of GPER, indicating an important role of the estrogen rapid signalling in lung 
tissue. No significant differences in the distribution of the receptors between men and women 
were observed.  
The mRNA expression of the all main enzymes involved in estrogen generation was also 
detected, namely from the aromatase pathway (CYP19A1), the redox balance of the 17β-HSDs 
(17β-HSD 1, 2, 4, 5, 7 and 12) and the sulfatase pathway (STS and SULT1E1). 
Our data showed an increased level of 17β-HSD type 1 in COPD patients compared with 
controls, and an increased ratio 17β-HSD1/17β-HSD2. This suggests an increased net 
generation of the biological active E2 in the COPD group. A limitation of this study is the use of 
RNA to determine the ratio 17β-HSD1/17β-HSD2, the highly-sensitive HPLC-mass spectrometry 
should be used to confirm the formation of E2. 
In addition, our study showed, as observed in NSCLC patients [87], a higher STS expression level 
compared to SULT1E1. This observation might suggest a favourable pathway for the E1 
formation through E1S-desulfation, as seen in other tissues [23, 24, 88].  
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In addition, CYP19A1, involved in the generation of estrogens from androgens, was associated 
with COPD disease state and with decreased lung function. These data confirm previous 
evidences obtained from tissues other than the lung, where 17β-HSD type 1 and aromatase 
are the most relevant enzymes in controlling the local generation of E2 [20, 21, 89, 90]. Further 
research is necessary to provide more insights in the opportunities to target the estrogen 
receptors and the key enzymes involved in the intracrine estrogen production in the disease 
pathogenesis. Even though there still exist controversy, our knowledge of estrogen signalling 
in the lung is slowly improving and should be used to consider the possibility of developing 
novel endocrine therapeutic treatment, in either a sex-specific way, or even in both sexes. 
 
Potential novel treatment 
Promising preclinical results in animal models of lung cancer were observed by blocking the 
estrogen signalling [91]. In humans, antiestrogen treatments (estrogen receptor antagonists, 
gonadotropin-releasing hormone, oophorectomy, progesterone) have been used in 
lymphangioleiomyomatosis (LAM) [92] and lung cancer patients [91, 93]. A phase II study on 
advanced non-small cell lung carcinoma (NSCLC) patients non-responsive to platinum-based 
drugs tested the dual-regimen mTOR/CYP19A1 inhibitors. Unfortunately, this study was 
prematurely terminated due to high toxicity [94]. One additional trial using an estrogen 
receptor antagonist plus aromatase inhibitor (fulvestrant and anastrozole) as consolidation 
therapy in postmenopausal women with advanced NSCLC (NCT00932152) was terminated due 
to poor recruitment. 
Better results were obtained using the AI letrozole as single agent or in combination with 
rapamycin in a phase II trial on 17 postmenopausal women with LAM (NCT01353209). AI 
treatment was safe and well tolerated also in the dual drug regimen [95].  
Steroids are involved in lung maturation, development and in susceptibility to diseases. Most 
17β-HSDs, STS/SULT1E1, CYP19A1 are expressed indicating the lung ability to metabolise 
androgens, estrogens and progestogens. Therefore, antiestrogenic approaches may offer 
future novel drug regimen in a multitude of pulmonary disease, including COPD. 
 
Conclusions COPD 
In both genders, sex steroids play a role in lung maturation, development and in the 
susceptibility to disease development. The ability of the lungs to metabolise androgens, 
estrogen and progestogens is indicated by the presence of most 17β-HSDs, STS/SULT1E1 and 
aromatase, and contributes importantly to the tissue exposure to these steroids.  
In this thesis, an increased net generation of the biological active E2 in COPD patients is shown, 
therefore further exploration for the possibility to use anti-estrogen treatment is 
recommended. So far, the efficacy of anti-estrogen treatments (aromatase inhibitors) in lung 
disease, such as lung cancer, is well demonstrated in preclinical studies [96, 97]. Similar 
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approaches could have potential benefits in COPD, and the utility of novel therapeutic targets 
like aromatase and 17β-HSD type 1 should be further explored. To date, several aromatase 
inhibitors are already approved for clinical use, and promissing specific 17β-HSD 1 inhibitors 
have been developed and thoroughly evaluated in preclinical settings [18, 89, 95]].  
 
General conclusions 
In this thesis, we clearly demonstrated that intracrinology is an important mechanism to 
control the intracellular steroid mileu in both endometrium and the lungs. In addition, 
endocrine treatments are potential approaches for those conditions of the endometrium and 
the lungs that are associated with unbalanced steroid exposure. However, the studies 
presented in this thesis (chapter 2 and Konings et al. [7]) also highlighted that intracrinology 
involves complex pathways that generate and deactivate steroids in several peripheral tissues 
other than endometrium and lungs. This implies that targeting intracrine enzymes as a 
treatment can cause unpredicted effects on other estrogen-responsive tissues. Even though 
current standard endocrine treatment is considered as well tolerated, significant side-effects 
including bone loss, thrombosis and several non-sufficienlty recognised central nervous system 
effects (like cognitive impairments, depression, memory impairment) adversely affect the 
general health and Quality of Life. These side-effects are arising from the significant reduction 
of systemic and peripheral estrogen levels.  
Side-effects play an important role in the choice of treatment and their occurrence is often the 
cause of endocrine treatment discontinuation. Therefore, an area that needs attention is the 
occurrence of these unwanted side-effects upon use of targeting intracrine enzymes. In the 
current era of precision medicine, the classic drug-development pipelines assessing 
pharmacokinetics, dynamics and general toxicity, should be paralleled by evaluation of 
unpredicted effects of a drug in tissues other than the primary target tissue.  
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Samenvatting 
 
Estrogenen zijn de belangrijkste vrouwelijke geslachtshormonen en zijn verantwoordelijk voor 
de ontwikkeling van de vrouwelijke voortplantingsorganen, de regulatie van de 
voortplantingsfuncties, de menstruatiecyclus, de ontvankelijkheid van het endometrium 
(baarmoederslijmvlies), de totstandkoming en handhaving van de zwangerschap. Naast hun 
rol in de vrouwelijke voortplantingsfuncties spelen ze ook een regulerende rol in 
uiteenlopende fysiologische processen van verschillende organen en weefsels in gezondheid 
en ziekte bij zowel man als vrouw.  
 
In het begin van dit proefschrift hebben wij een grondige verkenning uitgevoerd om de 
relevantie van estrogeen-signalering en de bijdrage van intracrinologie in verschillende 
humane weefsels te bepalen. Intracrinologie is de lokale intracellulaire generatie van 
hormonen uit precursors. Hiertoe werd in hoofdstuk 2 een systematisch literatuuronderzoek 
uitgevoerd naar de expressie van de verschillende enzymen die betrokken zijn bij het 
metabolisme van estrogenen en in beperkte mate van de geslachtshormonen progestagenen 
en androgenen, in humane weefsels. Beter inzicht in de moleculaire controle van 
intracrinologie is een noodzaak, evenals de manier waarop regulatie naast endocriene 
behandeling uiteindelijk kan resulteren in verbeterde uitkomsten voor patiënten van een groot 
aantal klinische aandoeningen. Daarom is tevens een overzicht weergegeven van de 
intracriene vorming en inactivatie van intracriene enzymen in perifere weefsels en in 
pathologische aandoeningen. 
 
Dit proefschrift gaat verder met de experimentele exploratie van de estrogeen-signalering en 
intracrinologie in twee humane weefsels: het klassieke en estrogeen-afhankelijke 
endometrium met de aandoening endometriumkanker (hoofdstuk 3 en 4) en het, niet-klassiek 
estrogeen-afhankelijke longweefsel, met de aandoening COPD (chronische obstructieve 
longziekte; hoofdstuk 5 en 6). 
De estrogeen-afhankelijke groei van endometriumkanker is goed erkend en eerdere studies 
van onze onderzoeksgroep hebben aangetoond dat het enzym 17β-hydroxysteroid 
dehydrogenase 1 (17β-HSD 1) in hoge mate tot expressie komt in endometriumkanker cellen. 
Dit enzym zorgt ervoor dat lokaal in de cel, de in het bloed circulerende laag-actieve precursor 
estrone wordt omgezet naar het actieve estradiol, die als gevolg de tumorgroei stimuleert. In 
hoofdstuk 3 hebben we de klinische relevantie aangetoond van 17β-HSD 1 in vitro 
(endometrium adenocarcinoom “Ishikawa” cellijn ) en in ovo (tumor grafts van Ishikiawa cellen 
gegroeid op het chorioallantoic membraan van bevruchte kippeneieren). Met dit onderzoek 
werd bevestigd dat zowel in vitro als in ovo de precursor estrone wordt omgezet naar het 
actieve estradiol. Dit proces kan worden geremd door een 17β-HSD 1-remmer. Ook hebben 
we gebruik gemaakt van een endometriumkanker patiëntencohort. We hebben de 
aanwezigheid van 17β-HSD 1 enzymactiviteit aangetoond in primair tumorweefsel van deze 
endometriumkanker patiënten, en in 45% van de tumorweefsels kon de enzymactiviteit met 
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meer dan 90% geremd worden met behulp van de 17β-HSD 1-remmer. Medicamenteuze 
behandeling wordt over het algemeen alleen voorgeschreven bij patiënten met metastasen 
(uitzaaiingen) en recidiverende tumoren, en niet als primaire behandeling. Daarom hebben we 
tevens de mRNA-expressie van het potentiële therapeutische doelwit, 17β-HSD 1, in 
metastatische laesies aangetoond in een tweede cohort van endometriumkanker patiënten. 
Concluderend, de 17β-HSD 1-remmer remt de generatie van het actieve estradiol uit het laag 
actieve estrone in meerdere endometriumkanker modellen. 
 
Om de klinische validiteit van dit ‘proof-of-concept’ verder te verifiëren, is in hoofdstuk 4 de 
ontwikkeling van een orthotoop xenograft muismodel beschreven (humane 
endometriumkanker cellen die getransplanteerd worden in de baarmoeder van de muis). Dit 
model weerspiegelt de meest relevante kenmerken van de menselijke ziekte, met betrekking 
tot metastasen en estrogeen-afhankelijkheid. De voordelen van dit model zijn de estrogeen-
afhankelijke kankergroei, die gemakkelijk te regelen is met behulp van een estrogeen-
afgiftesysteem, monitoren van tumorgroei met behulp van bioluminescente 
beeldvormingstechnieken, computertomografie (CT-scan) en objectief meetbare eindpunten 
(zoals tumor gewicht). Dit is een uitstekende in vivo methode om endocriene medicijnen en 
nieuwe endocriene doelwitten voor endometrium kanker verder te onderzoeken. Tevens kan 
dit model gebruikt worden voor onderzoek naar andere estrogeen-afhankelijke ziekten. 
 
De longen worden niet beschouwd als klassiek estrogeen-afhankelijke weefsels, maar zowel 
estrogenen als intracrinologie lijken ook een cruciale rol te spelen in dit orgaan. We gebruikten 
COPD als een model om estrogeen-signalering en intracrinologie in de longen te bestuderen. 
Vrouwen zijn biologisch meer vatbaar voor door sigarettenrook (CS) geïnduceerde 
longaandoeningen in vergelijking met mannen. Aangezien endogene circulerende niveaus van 
het vrouwelijke geslachtshormoon estradiol bij vrouwen hoger zijn dan bij mannen, kan 
estradiol worden gekoppeld aan geslachtsverschillen in CS-geïnduceerde pulmonaire 
ontstekingsreacties. We veronderstelden dat Estrogeen Receptor-α (ERα) door CS 
geïnduceerde pulmonaire ontstekingsreacties in vrouwelijke muizen moduleert. 
Hiertoe onderzochten we in hoofdstuk 5 muizen met intacte ERα (WT muizen) en muizen 
zonder intacte ERα (ERαKO muizen) in het "rokende muis-model". Het totale aantal 
ontstekingscellen in de broncho-alveolaire vloeistof in WT en ERαKO muizen was verhoogd na 
CS-blootstelling. In WT muizen was deze toename het gevolg van de opeenhoping van 
alveolaire macrofagen, terwijl ERα deficiënte-muizen een veranderd ontstekingsprofiel 
vertoonden met een toename van neutrofielen, dendritische cellen en geactiveerde T-
lymfocyten. Verder hebben we aangetoond dat ERα-deficiëntie kan zorgen voor 
herprogrammering van de interstitiële macrofagen naar een ontstekingsremmend M2-
fenotype. De expressie van meerdere varianten van estrogeen receptoren (ER) werden 
aangetoond (ERβ en GPER) in het longweefsel; daarom kunnen deze ER's een aanvullende rol 
spelen bij de activering van estrogeen-signalering door de blootstelling aan sigarettenrook in 
de longen van muizen. Toekomstige studies zijn nodig om een beter inzicht te krijgen in de 
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onderliggende mechanismen en de effecten van CS-blootstelling op ER's binnen de 
ontstekingsreactie van de longen. In hoofdstuk 6 hebben we het intracriene netwerk in de 
longen en in de aandoening COPD verder in kaart gebracht. Op het moment dat we aan deze 
studie begonnen, was er weinig bekend over het estrogeen-metabolisme in de longen van 
COPD-patiënten. Daarom is er zowel de estrogeen-signalering alsook de intracriene 
mechanismen in longweefsel onderzocht. Hierbij werd aangetoond dat alle enzymen die nodig 
zijn voor het intracriene estrogeen-metabolisme aanwezig zijn in de humane longen van zowel 
controle personen als COPD-patiënten. De expressie van 17β-HSD 1 en aromatase werden bij 
COPD-patiënten in verhoogde mate teruggevonden. Dit geeft aan dat er mogelijk in de longen 
van COPD-patiënten meer estrogenen gevormd worden dan in controle personen. Deze 
resultaten suggereren dat estrogenen betrokken zijn bij de ontwikkeling van de aandoening 
COPD.  
 
In hoofdstuk 7 werden de implicaties van het onderzoek in dit proefschrift besproken en 
aanbevelingen voor toekomstig onderzoek benadrukt. 
 
Aan de hand van dit proefschrift kunnen de volgende conclusies getrokken worden: 
- Het remmen van het enzym 17β-HSD 1 in preklinische endometriumkanker experimenten 
lijkt effectief om de lokale omzetting van estrogeen naar het actieve estradiol tegen te gaan. 
Daarom is 17β-HSD 1 een belangrijk therapeutisch doelwit bij de mogelijke behandeling van 
vooraf geselecteerde endometriumkanker patiënten.  
- Een verhoogde generatie van estradiol werd aangetoond bij COPD-patiënten, daarom wordt 
verder onderzoek naar de mogelijkheid om anti-estrogeen behandeling te gebruiken 
aanbevolen. 
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The potential impact of this thesis and the societal impact will be considered in this 
valorisation paragraph.  
 
Valorisation Endometrial Cancer 
 
Relevance 
Endometrial Cancer (EC) is the most common gynaecological malignancy in the Western 
World, with an incidence rate of 25.7 new diagnosed cases per 100.000 women each year, and 
4.6 per 100.000 related deaths in the period of 2010 to 2014. EC comes with a large personal 
burden of disease and an economic burden for our society. Its prevalence is steadily increasing 
due to increases in life expectancy and a high body-mass-index, leading to estrogen 
overexposure which is the main driver of EC-tumour growth.  
The research presented in this thesis addresses the unmet medical need for treatment of 
women with recurrent or metastatic EC. These patients have poor prognosis, with a 5-year 
survival rate of 16-66%. Only aggressive chemotherapeutic treatment regimens have shown 
some improvement in survival, but this comes with debilitating side-effects which results in 
important reduction of the Quality of Life (QoL).  
 
Endocrine drugs (currently tamoxifen, aromatase inhibitors and progestogens) are generally 
well-tolerated and have therapeutic-effects similar to chemotherapy, however, overtime drug-
resistance occurs. Therefore, it is of importance to identify novel endocrine drug-targets that, 
in the future, will allow us to alternate drugs with distinct mechanisms of action. Multimodal 
therapeutic strategies are well known for preventing/diminishing the development of drug 
resistance and likely will render a currently incurable condition, a chronic disease. 
 
Target groups 
Patients with recurrent or metastatic EC may benefit from this research. Future potential 
target patients who can have advantages from the use of endocrine care and novel endocrine 
drugs may be 1) EC patients with advanced stage or recurrent disease which are not willing to 
take chemotherapy, 2)patients for whom surgery is contra-indicated or 3) women who want 
to preserve their fertility.  
 
Activities and innovation 
The results presented in this thesis are published in international scientific research journals 
and were discussed at several international conferences. A collaboration between co-workers 
on this topic and the ENITEC network (European Network or Individualised Treatment of 
Endometrial Cancer) resulted in a strong collaboration between our group, the University of 
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Bergen in Norway, Universities of Turku and Koupio in Finland, and the pharmaceutical 
company Forendo Pharma (Finland). Continuation of this research, based on the results in this 
thesis, will provide important insights for health care providers. Furthermore, the ongoing 
research as well as new study setups, will be discussed within the patient organisations for 
gynaecological cancers; “Stichting Olijf” and “Ruby and Rose”. This will lead to better 
understanding of what is important in the patient perspective and to improve their QoL.  
New studies will focus on both the development of new drugs as well as the use of new 
treatment regimens in pre-clinical and clinical models.  
 The developed image-guided models can be used also for pre-clinical research of other 
estrogen-dependent conditions including the commonly diagnosed breast and 
prostate cancers. Since the models are based on non-invasive imaging of tumour 
growth, and controlled with a validated ready-to-use delivery system, it is easy to use 
and low in discomfort for the animals (3R-strategy in animal-experimentation; 
reduction, refinement, replacement). 
 A collaboration with the pharmaceutical company Forendo Pharma is set up to discuss 
future study plans related to the research presented in this thesis. This company 
started a Phase I clinical trial to use 17β-HSD 1 inhibition as a therapeutic treatment in 
endometriosis (another estrogen-dependent condition of the endometrium) in august 
2018. The overall aim of our ongoing research is to test the therapeutic efficacy of 17β-
HSD 1 inhibition in two novel relevant pre-clinical mouse models of EC: an orthotopic 
EC-xenograft model and a metastatic EC-xenograft model. First, the efficacy of 17β-
HSD 1 inhibition will be determined in the developed orthotopic-EC model. This 
experimental design is proof-of-concept oriented to demonstrate the feasibility of 17β-
HSD 1 inhibition in a model which represents the primary tumour as present in the 
clinical situation. And secondly, the therapeutic efficacy of 17β-HSD 1 inhibition alone 
or in combination with chemotherapy will be assessed in a metastatic-EC mouse model. 
This experimental design recapitulates the current clinical situation encountered in 
case of recurrent disease or in case of unresectable metastatic spreading after primary 
surgery from advanced-stage EC. These conditions are indicated for chemotherapy or 
endocrine therapy and therefore of clinical relevance. 
 As an innovative and exciting next step, patient-derived tumour xenograft (PDTX) 
models - which have unique human-like characteristics and are highly predictive of 
clinical outcome - provides an excellent pre-clinical platform to further explore 
endocrine drugs and novel endocrine drug targets. Our research team has already 
strong collaboration with the PDTX platform in Leuven (Belgium), for implementation 
of the PDTX model in Maastricht. Leuven has over 20 EC-PDTX available, ready to be 
transplanted in mice.  
 Since intracrinology consists of complex pathways that generate and deactivate 
steroids in peripheral tissues (this thesis, chapter 2), targeting 17β-HSD 1 as a cancer-
treatment can cause unpredicted effects on other estrogen-responsive tissues. Even 
though current standard endocrine treatment is considered well tolerated, significant 
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side-effects including bone loss, thrombosis and cognitive impairments (depression, 
memory impairment) adversely affect the general health and QoL. These side-effects 
are arising from the significant reduction of systemic and peripheral estrogen levels. 
Side-effects play an important role in the choice of treatment and their occurrence is 
often the cause of endocrine treatment discontinuation. Therefore, an area that I am 
committed to explore in my future activities are the occurrence of these unwanted 
side-effects upon use of 17β-HSD 1 (and other endocrine) therapy. In the era of 
precision medicine, the classic drug-development pipelines assessing 
pharmacokinetics, dynamics and general toxicity, should be paralleled by evaluation of 
unpredicted effects of a drug in tissues other than the primary target tissue. Due to the 
particular complexity of the steroid metabolism in the Central Nervous System, there 
will be a special focus on cognitive impairment in collaboration with neuroscience 
researchers. Our novel developed mouse models and the PDTX model will aid in 
mapping potential side-effects by exploring affected brain regions in treated animals. 
This information will be used to design ad hoc pre-clinical studies. This together will 
reliably predict the clinical outcome of 17β-HSD 1 inhibition in patients with 
endometrial cancer. 
If our follow-up pre-clinical research, which is currently either in progress or planned 
for the near future, demonstrates a good therapeutic value of 17β-HSD 1 inhibition in 
our EC-models, and if the clinical phase 1 investigation shows good tolerability and 
good pharmacokinetics of this novel drug, it will be feasible to design a phase 2 human 
clinical trial to test the efficacy of the specific 17β-HSD 1-inhibitor for EC treatment.  
 Improved knowledge of the local estrogen metabolism using a decision tree-model will 
be designed to guide clinicians to provide patients with optimal tailored-treatment. 
Multimodal therapeutic-strategies are well known for preventing/diminishing the 
development of drug resistance, and likely will render a currently incurable condition 
into a chronic disease. 
 
Valorisation COPD 
 
Worldwide 251 million people suffered from COPD and caused over three million deaths in the 
year 2016. Formerly, the incidence and mortality by COPD was greater among men than 
women, but is currently almost equal in both sexes. In the Netherlands, this is demonstrated 
by the diagnoses of 589.400 new cases of which 300.400 men and 297.900 women. The 
increased use of tobacco in women only partly explains this new trend. Several studies suggest 
that women are biologically more susceptibility to the effects of tobacco smoke after the 
consumption of the same number of cigarettes. Gender differences regarding prevalence and 
progression appears common in airway diseases, including asthma and cystic fibrosis, but is 
also commonly demonstrated in other diseases including heart disease. Awareness of gender 
differences is needed, not only among clinicians and researchers, but also grant providers, the 
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media and the general public. The gender disparity has implications for potential diagnostic, 
prognosis and treatment of the disease. Being familiar with disease differences in men and 
women, should improve the effectiveness of disease management, patient outcome and QoL. 
 
Currently there are no therapies available to reduce disease progression in COPD patients. The 
treatment is primarily based on the reduction of symptoms and the prevention of disease 
exacerbations. Stable disease is treated with inhaled long-acting bronchodilators, and 
corticosteroids can be used in patients who have co-existing features of asthma and more 
reversible airway obstruction. Nevertheless, most COPD patients are insensitive to 
corticosteroid therapy. A better understanding of the mechanisms underlying COPD 
development and pathogenesis are a necessity in order to develop therapies that reduce 
disease symptoms and progression.  
 
At the time we started our studies, little was known about the estrogen metabolism in the 
lungs of COPD patients. Therefore, this thesis focused on examining the estrogen signalling 
pathway and intracrinology in COPD. The lungs are influenced by the action of steroid 
hormones, and we demonstrated that local regulation and metabolism of steroids in the lungs 
(intracrinology) are important. Also, an increased generation of estradiol in the lungs of COPD 
patients has been demonstrated.  
Some lung disorders, including lymphangioleiomyomatosis (LAM) and non-small cell lung 
carcinoma (NSCLC) are currently treated (or ameliorated) with endocrine treatments. In the 
case of COPD, new pre-clinical research should be designed that is aimed at gaining a better 
understanding of the role of estrogen on cigarette smoke induced-lung inflammation, and 
determines whether endocrine treatments may represent future therapeutic options for COPD 
patients. Also, the role of the different Estrogen Receptors, and their interaction should be 
elucidated.  
Even though it is still controversial, our knowledge of estrogen signalling in the lung is getting 
more and more solid.  Therefore, further pre-clinical research into the possibility of using anti-
estrogenic treatment in COPD and other lung diseases is recommended.
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Dankwoord 
 
Volgens een Afrikaans gezegde heb je een heel dorp nodig om een kind op te voeden, zo is het 
ook met promoveren, dat doe je niet alleen! Daarom wil ik in dit laatste hoofdstuk iedereen 
bedanken die de afgelopen jaren hebben meegeholpen om dit proefschrift tot stand te laten 
komen. 
 
Ten eerste gaat mijn dank uit naar mijn promotieteam, Roy Kruitwagen, Andrea Romano en 
Juanita Vernooy, bedankt voor jullie waardevolle begeleiding, optimisme, enthousiasme en 
steun. Beste Roy, vanaf onze eerste ontmoeting was ik erg onder de indruk van je 
enthousiasme voor onderzoek. Door dit enthousiasme, wat erg motiverend werkt, was het 
voor mij een plezier om mijn data tijdens onze meetings aan jou te laten zien. Ook in de 
afrondende fase van dit proefschrift ben ik je heel dankbaar voor de fijne begeleiding en de 
manier waarop jij teksten om weet te toveren naar een logisch verhaal. Dear Andrea, where to 
start? Optimistic, enthusiastic, creative, dedicated, patience, are all words that describe you 
very well. In every situation, and every seemingly not so successful experiment, you will find a 
way to turn it into something positive. Thank you very much for your support and guidance, 
which already started during my work at the Pulmonology department. I am very grateful for 
the opportunity you gave me to complete this thesis and introduce me to the interesting world 
of sex steroids and endometrial cancer. Andrea, do you know where your keys are at this 
moment? Juanita, wij hebben elkaar al een lange tijd geleden leren kennen bij de afdeling 
Longziekten. In 2010 zijn we samen met prof. Wouters gestart aan een project dat helaas niet 
rijp genoeg was om te kunnen resulteren in een proefschrift. Desondanks was dit een hele 
leerzame tijd en hebben we de moed niet opgegeven en zijn we samen met Roy en Andrea 
begonnen aan een nieuw avontuur, met een mooi eindresultaat, waar we trots op mogen zijn. 
 
I would like to thank the members of the thesis reviewing committee consisting of prof. dr. 
Dingemans (chairman), prof dr. Lanišnik Rižner, prof dr. Postma, prof dr. Hauptmann and dr. 
Werner for critically reviewing and evaluating this thesis. Furthermore, I would also like to 
thank the members of the corona.  
 
In het bijzonder wil ik mijn collega’s van de afdeling Obstetrie en Gynaecologie bedanken. Bert, 
je deur stond altijd open voor advies of een interessant gesprek. Je enorme kennis en harde 
werk op het lab zijn van grote waarde en hebben een enorme bijdrage geleverd aan dit 
proefschrift. De komende jaren zullen we nog vaak, onder het genot van een kop koffie met 
een enorme portie humor, de relevante en niet zo relevante zaken van de dag kunnen 
bespreken, want Bert.. ik blijf nog eventjes! Sofia, thank you so much for all the help with our 
mice, we managed to fully optiMICE the operations! Without your company, it would be less 
fun at the animal facility. And Sofia, what are you going to cook tonight?  
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Ook de stagiaires hebben een hoop werk uit mijn handen genomen. Kim, wat was het een 
plezier om met jou samen te werken! En wat waren we trots toen we “mama” werden van 
Kiep en Cool! Inmiddels ben jij zelf bezig met jouw promotieonderzoek, en ik wens je daar heel 
veel plezier en succes bij. Janelle en Jella, wat was het leuk om jullie te mogen begeleiden. Ook 
jullie wil ik heel erg graag bedanken voor het harde werk en ik wens jullie veel succes met jullie 
studies. 
 
Dank aan al mijn collega’s van de afdeling Longziekten voor de jarenlange plezierige 
samenwerking. In het begin was ik hier werkzaam als analist en later is hier het zaadje gepland 
voor dit proefschrift. Gedurende deze tijd zijn er veel leuke en interessante mensen 
voorbijgekomen. Dus laat ik bij het begin beginnen. Niki, jij bent altijd zo behulpzaam geweest 
tijdens mijn tijd als analist, maar zeker ook tijdens mijn promotieonderzoek. Ik hoefde je maar 
iets te vragen en jij wist het antwoord. Jouw enorme creativiteit en positieve blik op het 
onderzoek hebben enorm bijgedragen aan dit proefschrift, bedankt! Mieke, jij zal ongetwijfeld 
een paar grijze haren van mij hebben gekregen. Jij wilde graag van ieder experiment een 
verslagje, en van mij kreeg je alleen maar de resultaten. Na wat pogingen van jou om mij over 
te halen toch verslagjes te schrijven, of zelf de verslagjes maar te schrijven, heb je uiteindelijk 
die hoop opgegeven. Gelukkig was dit allemaal niet voor niets Mieke, door al deze pogingen 
weet ik precies hoe ik alles goed moet organiseren en ordenen. Claudia, wij zijn ongeveer gelijk 
gestart als analist bij de longlijn. Wat heb ik een bewondering voor je onvermoeibare pipetteer 
kunsten! En wat hebben wij een plezier gehad op het lab, tijdens de lunch, maar ook tijdens 
onze chocolade-fondue avonden. Marco, jij hebt een enorme kennis aan labtechnieken en 
weet deze ook haarfijn over te dragen aan je collega’s. Ik heb genoten van onze koffiepauzes 
en wekelijkse etentjes. Ine, vanaf het eerste moment dat wij elkaar ontmoette was er een leuke 
klik. Naast het samen schreeuwen in de doka dat we “bandjes” zagen, hebben we samen hele 
mooie reizen gemaakt, die ik nooit zal vergeten! En dankzij jouw waarschuwingen “opstapje!” 
wist ik ook weer iedere keer in één stuk thuis te komen. Céline “roomie”, wat hebben wij samen 
vele late uurtjes doorgebracht op onze kamer. Gelukkig niet alleen om te werken, of in “ons 
boek” te schrijven, maar ook om meesterplannen te smeden om Harry en Ramon een koekje 
van eigen deeg te geven. Harry en Ramon, het was me een waar genoegen om een “practical 
joke oorlog” met jullie te voeren! Ramon, ik wil je bedanken voor de goede adviezen die je mij 
gegeven hebt op momenten dat ik deze even nodig had. Niki, Irene, Renske en Sofie, wat begon 
als een drankje op de bank, groeide uit tot cocktailparty’s en avondjes stappen. Inmiddels 
wonen we verspreid door het binnen- en buitenland, maar nog steeds lukt het ons om 
regelmatig samen te komen. Vrijgezellenfeesten, carnaval, cocktailparty’s zonder alcohol (hoe 
is dit zo ver gekomen?), musical, Europa Park, bezoekjes bij Niki in Lausanne, noem maar op. 
Dankjulliewel voor al deze toffe momenten samen! Ook wil ik graag Pascal, Astrid, Evi, Bram, 
Chiel, Anon, Frank, Valéry, Nicky, Koen, Ilse, Alex, Bettine, Pol en Tim bedanken voor de leuke 
en leerzame tijd. De stagiaires, Jarno, Juul, Bart en Silke, die ik heb mogen begeleiden tijdens 
deze periode wil ik graag bedanken voor de vele lab analyses die ze hebben uitgevoerd.  
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Ook wil ik graag de collega’s van de afdeling Anatomie bedanken voor de gastvrijheid en leuke 
praatjes op het lab. Wout en Leo, jullie wil ik graag bedanken dat er een fijn plekje voor mij vrij 
is gemaakt om rustig te kunnen werken. Leo, jij bent altijd zo behulpzaam en vriendelijk. Wout, 
ik vind het heel mooi om te zien hoeveel kennis en passie jij bezit voor het onderzoek. Jill, wat 
ben ik blij dat wij samen een kamer mogen delen. Er is een mooie balans tussen werk en wat 
afleiding. Dankjewel voor je motiverende woorden en goede tips. Hayelom, it was very nice to 
share the office with you. Nac, I wish you good luck finishing your PhD project. Cindy, wat 
hebben wij laatst een heerlijke taart gebakken, het wordt tijd dat we die proberen te evenaren. 
Ook jou wens ik veel succes toe met je promotieonderzoek. Paul, het is enorm fijn om elkaar 
af en toe van het werk af te houden en een ontspannend gesprek over whisky’s of vakanties 
te hebben, om vervolgens weer verder te kunnen met de orde van de dag. Sandra en Nicolle, 
dankjulliewel voor de gezellige praatjes en heel fijn dat ik bij jullie terecht kan voor mijn 
administratieve vragen. 
 
Clarice en Rik, dankjulliewel voor de hulp bij het proefdierwerk. Ook gaat een grote dank uit 
naar de muizen die bijgedragen hebben aan dit proefschrift!  
 
Dit proefschrift was niet tot stand gekomen zonder hulp van vele vriendelijke mensen uit 
andere laboratoria. Daarom wil ik onderstaande mensen bedanken voor ieders unieke en 
waardevolle wijze waarop ze hebben bijgedragen aan dit proefschrift: Marlies Bongers, Karlijn 
Cornel, Linda Brentjes, Loes Kooreman, Ludwig Dubois, Frank Verhagen, Marc Vooijs, Natasja 
Liewens, Lotte Schyns, Arjan Groot, Ken Bracke, Guy Brusselle, Fien Verhamme, Barbro Melgert 
en Hanny Pijnenborgen. Many thanks for the nice and good collaboration: Camilla Krakstad, 
Ingfrid Haldorsen, Kristine Fasmer, Seppo Auriola, Tero Linnanen, Matti Putanen, Merja 
Hakkinen, Niina Saarinen, Pasi Koskimies, Margaretha Skowron and Amina Zaffagnini. 
 
Dan wil ik heel graag mijn paranymfen Niki en Chantal bedanken, ik ben zo blij dat jullie tijdens 
mijn promotie naast mij willen staan. Lieve Niki, het is me een eer dat jij mijn paranymf wilt 
zijn. Wat heb ik een bewondering voor jouw doorzettingsvermogen, niets lijkt jou te veel. 
Maastricht, Vermont, Lausanne, overal vind jij jouw plekje. Als collega’s bij de afdeling 
Longziekten hebben we veel steun aan elkaar gehad, het was niet altijd even gemakkelijk, maar 
na een babbel met een koffietje erbij konden we er weer tegenaan. Ook bij het afronden van 
dit proefschrift en het schrijven van de Kootstra aanvraag heb je me ontzettend goed 
geholpen. Je maakte altijd wel weer tijd om een document van mij door te lezen en van 
commentaar te voorzien. Ik wil je enorm bedanken voor je kritische kijk naar mijn artikels en 
het meedenken naar oplossingen en verklaringen als ik vastliep. Dankjewel voor je 
motiverende woorden (of een schop onder mijn kont) op de momenten dat ik deze nodig had. 
Naast de enorme hulp en tips die je me gegeven hebt, is er gelukkig ook af en toe tijd over voor 
een gezellig bezoekje. Ik wens jou heel veel goeds toe voor de toekomst. Lieve Chantal, de 
eerste keer dat ik jou ontmoette waren we beide nog student. Ik was mijn poster aan het 
presenteren op Hogeschool Zuyd en jij kwam bij me staan, je was zo geïnteresseerd in het 
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onderzoek, dat was zo ontzettend leuk. Een tijd later kwamen we elkaar weer tegen, nu op de 
universiteit van Maastricht, en onze vriendschap was begonnen. Je hebt vast al een aantal 
keren in mijn dankwoord kunnen lezen dat ik de afgelopen jaren een aantal mensen 
tegengekomen ben die heel enthousiast zijn en een passie bezitten. Jij bent een van deze 
mensen! Het is mooi om te zien hoe enthousiast en vrolijk jij kan zijn en hoe jij met volle 
overtuiging en passie je leven leeft, dit is heel inspirerend. Zoals uit onze eerste ontmoeting al 
bleek, delen wij veel dezelfde interesses, de laatste jaren is gebleken dat dit er alleen maar 
meer zijn geworden, leuk! Ook jou wil ik heel graag bedanken voor je hulp en het opvrolijken 
als het even niet helemaal mee zat. Ik kan enorm van jouw aanwezigheid genieten en vind het 
dan ook een eer dat jij mijn paranymf wilt zijn. 
 
Ook wil ik graag mijn vrienden bedanken voor hun steun, er is meer in het leven dan alleen 
werken. Deborah en Christine, een wintersportvakantie, een duikvakantie, een zomervakantie, 
wat is het volgende wat er op het programma staat? Ik wil jullie bedanken voor de leuke tijd 
die we samen hebben, maar ook zeker voor de motiverende woorden. Christine en Nadja, wij 
leerden elkaar al kennen tijdens onze studie, wat is het leuk dat wij na al die jaren nog steeds 
regelmatig samen gaan lunchen of andere uitstapjes ondernemen. Food & Friends: An & Ben, 
Lisanne & Dennis, Lars, waar moet ik beginnen? Wat maken we veel mee, vakanties, carnaval, 
pretparken, wandelingen, uiteten noem maar op. Dankjulliewel dat jullie mij altijd op gepaste 
wijze weten op te vrolijken als het even moeilijk is. Ruth, our friendship was born from the very 
first moment we met. I feel so lucky that a true friendship continues to grow, even over the 
longest distance. Debbie, thank you very much for designing the cover of my thesis! It makes 
me feel proud to have an original Debbie Bonello on the cover of this book.  
 
Mam en Hans, toen ik net startte met mijn promotieonderzoek vroegen jullie je af waarom ik 
na 4 jaar werken besloten had om te gaan promoveren. Promoveren is studeren, toch? Na alle 
verhalen die ik de afgelopen jaren over mijn onderzoek heb verteld, is jullie inmiddels duidelijk 
wat promoveren inhoudt. Dankjulliewel voor de interesse die jullie getoond hebben en de 
verschillende manieren waarop jullie mij de afgelopen jaren gesteund hebben. Lieve Hans 
(knul), dit is de eerste keer dat ik een “werkstuk” zonder jouw aanwezigheid en helpende hand 
moest afronden. Gelukkig wist je me op een ontzettend fijne en verassende manier toch te 
ondersteunen, net zoals je altijd deed. Dankjewel! Pap en Ine, dankjulliewel voor de interesse 
in mijn onderzoek en voor de steun de afgelopen jaren. Pap, ik hoop dat we binnenkort weer 
de tijd vinden om samen te gaan wandelen. Martine en Sanne, ook jullie wil ik graag bedanken 
voor jullie interesse in mijn werkzaamheden. 
 
Lieve Jochem, wat ben ik blij dat wij elkaar hebben leren kennen. Iedere keer als ik je zie word 
ik helemaal blij, jij maakt mij heel gelukkig! Ik wil je enorm graag bedanken voor de steun die 
je voor mij bent. De afgelopen tijd hebben we toch een paar pittige dingen meegemaakt en 
het betekent heel veel voor me dat we er voor elkaar kunnen zijn. Liefje, ik hou van je, ik kijk 
uit naar een mooie toekomst samen met jou!
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Gonda Konings was born on April 6th 1983 in Geleen, The Netherlands. In 2003 she acquired 
her secondary vocational education diploma (Biological Laboratory Technology) at 
Leeuwenborgh in Sittard, The Netherlands. She graduated her Bachelor’s education in Biology 
and Medical Laboratory Sciences at Hogeschool Zuyd (University of Applied Sciences) in 
Heerlen, The Netherlands in 2006. In the same year, she started working as a research 
technician at the Department of Molecular and Cellular Cardiology at Maastricht University. In 
2008, she joined the Department of Respiratory Medicine to work as a research technician. In 
2010 she started her PhD trajectory at the same department. Her project entitled “Smoking 
and femininity: Hormonal cross-talk in the development of COPD?” did not result in a 
dissertation. In 2015 she started working as a forensic research technician at The Maastricht 
Forensic Institute, The Netherlands. In 2016, she proceeded as a PhD-Candidate at the 
Department of Obstetrics & Gynaecology. Her research focused on exploring the estrogen 
metabolism in endometrial cancer and COPD. The results obtained during this period and the 
PhD trajectory at the Department of Respiratory Medicine are described in this dissertation. 
Gonda presented her work by means of poster and oral presentations at numerous national 
and international meetings, and received a full congress scholarship at the Gynaecological 
Endocrionology 18th World Congress. She is currently working as a post-doctoral fellow at the 
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